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1 ATHEROSCLEROSIS 
1.1 GENERAL 
Cardiovascular disease (CVD) is still the number one cause of death in the Western 
world. There are many different clinical manifestations of cardiovascular disease 
such as angina pectoris, cardiomyopathy, endo-myocarditis and aneurysm.  
Atherosclerosis affects the medium and large sized arteries of the heart and 
blood vessels and is the underlying cause of many clinical symptoms of CVD. 
Major risk factors for CVD, such as smoking, obesity and a high fat diet are well 
recognized. In 2004, 45445 people died of the consequences of CVD, accounting for 
33%1 of all reported deaths in the Netherlands, whereas 28% (38824 people) of all 
reported deaths death were related to cancer.2 This states the importance of 
cardiovascular disease in the Dutch society.  
The current treatment of atherosclerosis is mostly aimed at the reduction of 
risk factors by life style advice (stop smoking, more exercise, and lower cholesterol 
intake) and by subscribing drugs, such as statins, that lower plasma cholesterol 
levels. Additionaly drugs that lower blood coagulation and blood pressure are 
prescribed. However, these interventions cannot prevent that CVD is still the 
leading cause of death in the Western world. Therefore, there is an urge to develop 
new therapies targeting the different molecular pathways and stages of 
atherosclerosis. 
 
1.2 PATHOGENESIS OF ATHEROSCLEROSIS 
1.2.1 Initiation of the lesion 
The first stage of atherosclerosis is fatty-streak formation. Fatty streak formation is 
asymptomatic and is already found during the first decades of life in medium and 
large sized arteries, at predisposed sites. The typical atherosclerotic prone sites are 
characterized by low shear stress and high oscillatory shear stress, which increase 
adhesion of leukocytes and the expression of inflammatory genes.3  
Under normal conditions, healthy endothelium is able to respond to 
physical and chemical signals by the production of a wide range of factors that 
regulate vascular tone, cellular adhesion, thrombus resistance, smooth muscle cell 
proliferation, and vessel wall inflammation.4 It is generally accepted that the 
activation of the endothelial cell layer, as a response to modulated gene expression, 
caused by hyperlipidemia, hypertension, diabetes mellitus and smoking, forms the 
first step in atherosclerosis, the fatty-streak formation.5, 6  
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Circulating lipoproteins, in particularly very low-density lipoproteins 
(VLDL) and low-density lipoproteins (LDL) infiltrate into the arterial intima and 
become modified through processes, such as oxidation, glycation, aggregation, 
association with proteoglycans or incorporation into immune complexes.7-10 The 
modified LDL particles are highly immunogenic and activate the endothelial cells. 
Stimulated endothelial cells undergo a switch from a quiescent phenotype 
towards a phenotype that initiates a defense response. Most cardiovascular risk 
factors, such as smoking and high blood pressure, activate the molecular 
machinery in the endothelium, resulting in the expression of chemokines, 
cytokines and adhesion molecules designed to interact with leukocytes and 
platelets and designed to target inflammatory cells to specific tissues to clear 
invading microorganisms or to respond to vascular injury.11 Activated endothelial 
cells express adhesion molecules, like vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1), P-selectin and E-selectin.3, 12 
Leukocytes (i.e. monocytes and lymphocytes) express counter receptors for these 
adhesion molecules and decelerate via interaction with P- and E-selectin. Once 
slowed down, a more firm adhesion is facilitated via interaction with VCAM-1 and 
ICAM-1 with very late antigen-4 (VLA-4) and lymphocyte function associated 
antigen-1 (LFA-1), respectively, which are expressed on leukocytes.13-15  
 Once a firm adhesion is established, leukocytes migrate through the 
interendothelial junction into the subendothelial space (diapedesis) (Figure 1.2A). 
This process is facilitated by additional adhesion molecules, such as 
platelet/endothelial cell adhesion molecule-1 (PECAM-1) and junctional adhesion 
molecule-1 (JAM-1).16, 17 Furthermore, activated endothelial cells produce several 
chemokines and interleukins (IL), which enhance diapedesis 18 and the recruitment 
of leukocytes into the lesion. CCL2 (MCP-1), produced by vascular endothelial 
cells, is an important chemoattractant for monocytes and T cells. These cells play 
an important role in lesion development.19-22 Activated vascular cells but also 
macrophages within the lesion continue to produce chemokines such as, CCL5 
(RANTES), CXCL10 (IP-10) and CCL11 (eotaxin) to further enhance the immune 
response (Figure 1.2B).23-25 Within the lesion, monocytes differentiate into 
macrophages by stimulation of macrophage-colony-stimulating factor (M-CSF), 
which is produced by endothelial and smooth muscle cells.26 The macrophages 
become activated by the uptake of modified LDL, thereby transforming into lipid 
loaded “foam cells”. This process will be discussed in more detail later on. 
The above-described process will lead to focal fatty streak formation and 
remain asymptomatic for a long time and may even be reversible at this stage. 
However, during the progression of life these fatty streaks may develop into more 
advanced lesions, depending on the exposure to several risk factors. A schematic 
overview of the above-described processes are depicted in figure 1.1A. 
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FIGURE 1.1: DEVELOPMENT OF ATHEROSCLEROSIS.  
A, fatty streak formation: Endothelial cells in lesion prone areas become activated leading to 
permeabilety for lipoproteins, such as LDL. Within the intima, LDL is modified by processes, like 
oxidation and becomes immunogenic. Monocyte derived macrophages migrate into the intima and start 
to phagocytose the modified LDL particles and become activated. Macrophages, trapped in the intima 
and loaded with cholesterol are now called “foam cells”. B, progression of the plaque: vascular smooth 
muscle cells become activated. They migrate and produce extracellular matrix proteins, in particular 
collagen, to form a cap structure to protect the lesion from the blood flow. More leukocytes are recruited 
to the intima, such as T cells and monocytes and these cells enhance the inflammation. To compensate 
for the narrowed lumen, outward remodeling takes place. C, necrotic core and thrombus formation: 
“foam cells” become apoptotic and eventually form a necrotic core, consisting of cellular debris and free 
cholesterol. The necrotic core is highly immunogenic, which results in the recruitment of more 
inflammatory cells to the intima. The fibrous cap formed by the smooth muscle cells protects the lesion 
from the bloodflow, however this may not prevent rupture. When the plaque ruptures, a thrombus will 
form and can cause clinical symptoms, such as acute coronary syndrome. D, obstructive lesion: when 
the plaque does not rupture, the lesion can grow by the ongoing inflammation. When outward 
remodeling is not sufficient, the lesion becomes obstructive and causes clinical symptoms, such as 
angina pectoris. More details are described in the text. (Adapted from Rader and Daugherty).236 
1.2.2 Progression of the lesion  
Atherosclerotic lesion progression is associated with the continuous influx of 
inflammatory cells due to the local production of chemokines in the plaque. T cells 
interact with activated macrophages (“foam cells”), which express class II and class 
I histocompatiblity complexes (MHC II and MHC I) and present antigens to T cells. 
CD4+ and CD8+ T cells are associated with all stages of atherosclerotic lesion 
development and activation of T cells results in a broad range of immune 
responses and the acquisition of many features of a chronic inflammatory state.27 
Activated T cells produce several cytokines such as IFN-γ and TNF-α.28 These 
cytokines activate other cells within the lesion, such as endothelial cells, 
macrophages and smooth muscle cells.  
The next step in atherosclerotic lesion development is the formation of a 
necrotic core. This necrotic core consists of extracellular lipids and cellular debris 
derived from apoptotic cells. This process involves pro- and anti-apoptotic 
proteins, including death receptors, proto-oncogens and tumor suppressor genes. 
Oxidized sterols, present in oxLDL, promote apoptosis and necrosis of foam cells 
in the plaque, thereby releasing oxidized and insoluble lipids within the lesion.29 
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The necrotic core becomes covered by a fibrous cap, which consists of smooth 
muscle cells and extracellular matrix proteins like collagen. The formation of the 
cap structure is facilitated by cytokines and growth factors, which are produced by 
activated macrophages and T cells. The cytokines and growth factors stimulate 
smooth muscle cells to proliferate and migrate to the cap.5, 6Activated smooth 
muscle cells can migrate from the media to the intima, where they are able to 
internalize lipids and transform into smooth muscle cell derived foam cells and can 
produce matrix proteins.30  
In this stage of lesion development, the outward remodeling of the vessel 
takes place to compensate for the increase in lesion size. The process of outward 
remodeling is necessary to prevent severe narrowing of the vessel and to preserve 
blood flow.31 The above-described process is schematically depicted in figure 1.1B 
and C. 
 
 
FIGURE 1.2: THE ROLE OF MACROPHAGES AND T CELLS IN ATHEROSCLEROSIS.  
A, Monocyte and T cells are recruited to the intima of the vessel wall were they become activated via 
different stimuli. Depending on the microenvironment within the intima, the inflammation can be 
enhanced or dampened. B, Within the intima, macrophages take up modified LDL and become 
activated and exert several pro-atherogenic properties. C, Macrophages are able to take up modified 
LDL and present it to T cells, which recognize the antigen and become activated. Depending on the 
microenvironment, T cells can develop into different subtypes of T cells population. B and C, During 
atherosclerosis, T cells and macrophages tightly regulate each others activation and function, which 
make them important immune cells in bridging the innate (macrophages) and adaptive (T cells) 
immune system. 
 General introduction and outline of the thesis 
 
15 
1 
 
1.2.3 Lesion stability and rupture 
When outward remodeling can not compensate for the reduced volume, the 
advanced atherosclerotic lesion leads to insufficient blood flow to distal tissues, 
causing clinical symptoms, such as angina pectoris (Figure 1.1D). However, acute 
cardiovascular events are associated with myocardial infarction and stroke as a 
result of a ruptured plaque and a subsequent thrombotic event (Figure 1.1C).32, 33  
Plaque rupture is the final outcome of plaque destabilization. During 
lesion development activated macrophages, T cells and other immune cells 
accumulate around the necrotic core and in the shoulder regions of the plaque.6, 34 
Furthermore, activated macrophages, T cells, and mast cells have been observed at 
sites of plaque rupture, indicating their potential relation to the rupture process.35-
37 T cells, predominantly of the T helper 1 phenotype, produce high amounts of 
IFN-γ, which inhibit the production of collagen by vascular smooth muscle cells 
and their cell proliferation, thereby negatively influencing plaque stability.28, 38  
Activated macrophages produce several proteases, which destabilize the 
plaque, such as matrix metalloproteinases (MMPs), cysteine proteases, and 
chymases.39-41 Members of these families of enzymes are found in the 
atherosclerotic plaque and can degrade the matrix. Especially MMP-1, MMP-8, 
MMP-9 and MMP-13 may be important.42 In addition, macrophages induce 
apoptosis of vascular smooth muscle cells, thereby negatively influencing the 
collagen production and subsequent plaque stability.43, 44  
Since the weakened cap structure cannot withstand the hemodynamic 
forces, the unstable atherosclerotic lesion may rupture and consequently expose 
thrombogenic plaque material (lipids/necrotic core) to the blood. The subsequent 
aggregation of platelets and coagulation forms a thrombus, which obstructs blood 
flow and results in clinical symptoms such as myocardial infarction and stroke.34 
Plaques that are prone to rupture contain high numbers of activated 
immune cells. Furthermore, patients with acute coronary syndromes (ACS) 
demonstrate signs of inflammation, with elevated levels of circulating cytokines, 
acute phase reactants, and not only activated T cells.45, 46 Therefore the immune 
system and inflammation play an important role throughout atherosclerotic plaque 
development, but are also crucial in the final stage of atherosclerosis.  
 
2 ATHEROSCLEROSIS: AN INFLAMMATORY DISEASE 
During the last years, it has become more clear that atherosclerosis resembles a 
chronic autoimmune-like disease. Inflammation plays a pivotal role in the process 
of atherosclerotic lesion development. As atherosclerosis already starts in early life 
and gradually develops during life, it can be considered a chronic disease. 
Inflammation is tightly regulated by cells involved in the innate and adaptive 
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immune response, both with their specific role in host defense.47,48 This is 
illustrated in different mouse models for atherosclerosis with a specific depletion 
of components of the innate as well as the adaptive immune system.49, 50 For 
example, when LDL receptor deficient mice were cross-bred with lymphocyte-
deficient (RAG1 deficient) mice, a reduction in lesion size was observed.51 
Further evidence supporting the relation between atherosclerosis and 
inflammation is found in gene polymorphisms involved in inflammation, such as 
TLR4 polymorphisms.52-54 There are associations found between an increased risk 
of cardiovascular events and autoimmune diseases, such as rheumatoid arthritis 
and systemic lupus erythematosus.55 However, besides inflammation, 
atherosclerosis is also associated with metabolic and hemodynamic factors, thereby 
placing atherosclerosis as an unique disease. 
Metabolic and hemodynamic factors are likely to play a role in the 
initiation of autoimmunity by activation of endothelial cells and subsequent 
recruitment of immune cells. This process leads to initial atherosclerosis via the 
innate immune system and gradually evolves into a chronic, autoimmune like, 
inflammatory disease via the adaptive immune system. Therefore, the regulation 
and crosstalk between innate and adaptive immune cells is very important in the 
initiation and development of atherosclerosis.  
Although several exogenous stimuli, such as cytomegalovirus (CMV) and 
Chlamydia pneumoniae have been identified in atherosclerosis,56 there is also 
evidence that endogenous stimuli are involved in the process of  
atherosclerosis.57, 58  
 
2.1 INNATE IMMUNE SYSTEM 
The innate immune response is the fist line of defense against pathogenic stimuli 
and is characterized by a natural selection of germline-encoded receptors, which 
focuses on highly conserved motifs in pathogens. It provides the first line of 
defense for the host and is characterized by fast (minutes to hours) and blunt 
(lacking exquisite structural specificity) responses. It is a very conserved system, 
which is already present in many lower organisms. 
Important cells involved in the innate immune response are macrophages, 
neutrophils, mast cells and natural killer (NK) cells. The exact role of neutrophils in 
atherosclerotic lesion initiation is not known yet, but neutrophils are found in 
ruptured or eroded plaques, indicating that they are recruited in a later phase in 
response to injury.59 However, upon endothelial activation, P-selectin and E-
selectin are upregulated, which both bind neutrophils suggesting a non-confirmed 
role in the initial stages of atherosclerosis.60-63 
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Another kind of innate immune cells are mast cells. These cells are present 
in atherosclerotic lesions and are activated at sites of plaque rupture, indicating 
that mast cells are involved in the rupture process of advanced lesions.64 Mast cells 
store granules, which contain growth factors, chymases and pro-inflammatory 
cytokines.65,66 Once stimulated, the mast cells degranulate and exocytose the 
granule-associated effector substances into their microenvironment, thereby 
negatively influencing plaque stability.67, 68 
NK cells are found to play a role in early atherosclerosis.69, 70 Their role 
however, is not yet completely understood. Reduced atherosclerosis was observed 
in LDLr-/- mice after bone marrow transplantation from transgenic mice 
overexpressing the Ly49A receptor, which results in dysfunctional NK cells.70 
Noteworthy, in these transgenic mice, not only NK cells are affected, but also NK T 
cells, CD8+ cytotoxic cells and other lymphocytes expressing granzyme A. 
Therefore, it is difficult to determine the exact role of NK cells in the initiation of 
atherosclerosis.  
The key inflammatory cell during atherosclerotic plaque formation is the 
macrophage. Macrophages are part of the innate immune system and have an 
important “bridge” function between the innate and adaptive immune system by 
presenting innate immune signals to the adaptive immune system. In 
atherosclerosis, macrophages play an important role in the various phases of lesion 
formation and progression.12 Infiltrated monocytes differentiate into macrophages 
and start to express cytokines and receptors71 by stimulation via M-CSF, which is 
produced by endothelial and smooth muscle cells.26 Monocyte-derived 
macrophages express pattern recognition receptors (PRRs), which are involved in 
the innate immune response. PRRs recognize a restricted pattern of ligands called 
pathogen-associated molecular patterns (PAMPs). PAMPS consist of many 
different ligands such as lipopolysaccharides, aldehyde-derivatized proteins, 
bacterial DNAs and denatured DNAs, resulting in endocytoses and lysosomal 
degradation of the ligand72,73 and activation of nuclear factor-κB, resulting in an 
inflammatory response.74 
Two important groups of PRRs are the scavenger receptors (ScRs) and the 
toll-like receptors (TLRs), which are both expressed by macrophages.47, 75 The ScR 
family, which includes CD36, CD68, SR-A and SR-B, mediates the internalization 
of modified lipoproteins (e.g. oxLDL) via endocytosis and contributes to foam cell 
formation, a hallmark of the atherosclerotic lesion.9,76,77 The uptake of modified 
lipoproteins and their constituents via ScRs is important in triggering the 
production of the mediators of innate immunity such as, IL-1β and TNF-α.78 
Additionally, they are important in the activation of the adaptive immune system 
via presentation of internalized material on MHC class II molecules.79  
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The other important pattern recognition receptor family, the TLRs, are 
involved in the activation of macrophages.80 Studies with TLR4 and ApoE double 
knock out mice, demonstrate a reduction in atherosclerotic plaque development, 
thereby further illustrating the importance of the innate immune system in 
atherogenesis.81 Activation of ScRs and TLRs on macrophages within the plaque 
results in a proinflammatory environment capable of activation of other vascular 
and immune cells, thereby enhancing lesion progression.  
 Within the lesion, foam cells contribute to the production of reactive 
oxygen species, cytokines and other molecules, thereby amplifying and sustaining 
the inflammatory response in the plaque.80 Additional cells in the early plaque, 
such as smooth muscle cells and endothelial cells become activated by these 
molecules and start producing interleukins and chemokines, i.e. IL-1β, IL-6, IL-18, 
TNF-α and CCL2.82-84 Besides production of these cytokines, macrophages and 
other vascular cells start to produce T cells attractants, like CCL5, CXCR3, CXCL10 
and CXCL11.24 The pro-atherosclerotic effect of T cells in atherosclerosis is 
demonstrated by blocking for example CCL5 or CXCR3 and thereby attenuating 
atherosclerosis.85,25  
Besides attracting T cells, macrophages also express MHC class II in 
association with a specific epitope. This is a pivotal step in bridging the innate 
immune response to the adaptive immune response. Within the lesion MHC class 
II expressing macrophages (and also dendritic cells, discussed in more detail later 
on) can be detected close to T cells, which suggests that there is an ongoing 
immune activation of the adaptive immune response in the plaque.86-88 
 
2.2 ADAPTIVE IMMUNE SYSTEM 
The adaptive immune system is characterized by a slower response than the innate 
immune system and exerts a high specificity for its target. The high variation of 
antigen specificity of, for example T cell receptors (TCRs) and immunoglobulins, is 
a result of somatic rearrangements in blast cells. When T cells recognize a specific 
antigen, which is presented by an antigen-presenting cell (APC), an adaptive 
immune response against that specific antigen is initiated. Many cells are involved 
in the adaptive immune response, in particular DCs, T cells, B cells and 
macrophages. Upon stimulation, these cells demonstrate versatile effects, for 
instance a helper T cell response, regulatory T cell response, cytotoxic T cell 
response, stimulation of B cells and subsequent antibody production, production 
of chemokines and cytokines, which enhance and regulate the innate and adaptive 
immune cells.  
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The role of the adaptive immune system, especially the T and B cells, is 
nicely demonstrated in studies in which these cells were not functional by for 
example using severe combined immunodeficient (SCID) mice, resulting in 
decreased lesion formation.89  
 
2.3 AUTOANTIGENES 
Many exogenous and endogenous antigens have been suggested to be presented in 
atherosclerosis. As mentioned before, T cells recognize specific antigens presented 
by APCs with their TCR. Upon activation, T cells that recognize a specific antigen 
will start proliferating, resulting in clonal T cell expansion. Clonal T cell expansion 
has been detected in atherosclerotic lesions of mice and humans, suggesting 
specific TCR activation by an (auto) antigen.90-92  
Since inflammation has a prominent role in atherosclerosis, it has been 
suggested that exogenous stimuli may initiate atherosclerotic lesion development. 
Many virus and bacteria related antigens have been identified in atherosclerosis, 
but most extensively studied are the Cytomegalovirus (CMV)93 and Chlamydia 
pneumoniae.94, 95 Both pathogens are associated with aggravating atherosclerosis in 
mice and humans, since antibodies against these pathogens have been correlated 
with the severity of cardiovascular disease in patients.93, 96-98 Furthermore, 
experimental data have shown that infection with Chlamydia pneumoniae enhances 
atherosclerosis.97 However, large clinical trials on the treatment of cardiovascular 
patients with antibiotics directed against Chlamydia pneumoniae did not result in a 
reduction of cardiovascular events in antibiotic treated patients.99, 100 
Another group of antigens is of endogenous origin, but is related to 
exogenous antigens via a process called molecular mimicry.101 An example are the 
heat shock proteins (HSPs), a group of highly conserved proteins. These proteins 
are highly conserved and immune responses induced against bacterial HSP60 may 
cross-react with responses against endogenous hsp60. Endogenous HSP60 is 
induced when cells are exposed to different stress stimuli.102 HSP60 is expressed on 
endothelial cells, vascular smooth muscle cells and mononuclear cells in human 
atherosclerotic plaques.103 Furthermore, circulating antibodies against HSP60 were 
detected in patients with atherosclerosis and HSP60 specific T cells were detected 
within the atherosclerotic plaque.104,105 Therefore an immune response against 
HSP60 may contribute to endothelial damage and subsequent enhancement of 
atherosclerosis.106,107 Interestingly, antibodies against HSP60 and its prokaryote 
homologue HSP65 are also detected in other autoimmune diseases such as 
rheumatoid arthritis.108 In relation to this, patients with rheumatoid arthritis have a 
2- to 5- fold higher risk of cardiovascular morbidity and mortality.109  
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A third group of antigens is derived from endogenous sources. This group 
mainly contains altered self-proteins and the autoimmune response against these 
proteins is directed against the neo-epitopes of the altered proteins. T cells do not 
react with native LDL, as there is immunological tolerance against self-antigens. 
However, modifications of LDL lead to non-self epitopes (neo-epitopes) and 
increased autoreactivity of T cells in mice and human.110, 111 LDL in the 
atherosclerotic lesion can be modified by various processes as described before, 
and are accountable for the development of neo-epitopes.112 An example of a neo-
epitope related to LDL is oxLDL. OxLDL specific T cells are identified in human 
plaques and circulating antibodies against epitopes of oxLDL are detected in 
serum samples of patients with cardiovascular disease.110, 113 Furthermore, lymph 
nodes and spleens of ApoE-deficient mice gave rise to an oxLDL specific T and B 
cell line displaying a strong humoral and cellular immune response against these 
modified lipoproteins, indicating the role of oxLDL in immune activation.114, 115  
 
2.4 DENDRITIC CELLS 
Although activated macrophages effectively present antigens to T cells, dendritic 
cells (DCs) are the most potent APCs of the immune system and are the key 
players in the regulation of the adaptive immune response. 116  
 Immature DCs efficiently take “samples” of their antigenic 
microenvironment through macropinocytoses and receptor mediated endocytosis. 
Depending on the triggered PRRs, DCs present the antigen in context of either 
MHC class I or MHC class II and produce cytokines to evoke an appropriate 
immune response.117 Therefore, DCs are crucial for an adequate clearance of the 
infection, but DCs are also responsible for pathogenic immunological responses. 
Dendritic cells are a component of the vasculature associated lymphoid 
tissue and low numbers are found in the intima of healthy, but susceptible arteries 
before atherosclerotic lesion development is initiated. 118 Furthermore, DCs 
increase in number in the intima during the progression of atherosclerosis.119 This 
indicates a role for DCs in the initiation and regulation of arterial inflammation. 
Immature DCs capture antigens at the site of inflammation and migrate to 
secondary lymphoid organs, such as the spleen and lymph nodes. The migration is 
orchestrated by various chemokines, such as CCR-2, -5, -6, -7 and CXCR1 and 
CXCR2.120, 121 Within the secondary organs the maturated DCs are able to stimulate 
antigen specific T cells, which is further enhanced by the fact that mature DCs 
starts to express co-stimulatory molecules, such as CD40, thereby enabling them to 
interact with CD40L expressing T cells.  
Some macrophages take up antigens in tissues and differentiate into 
migratory cells resembling dendritic cells that emigrate to lymph nodes.122 
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However, in hypercholesterolemic conditions these monocyte derived DCs are 
possibly not able to migrate out of the atherosclerotic lesion to the secondary 
lymph organs, thereby directly activating residential cells in the lesion such as T 
cells, which leads to aggravated atherosclerosis.122-124 
 
2.5 T CELLS  
T cells are activated in the lymphoid organs by APCs by recognizing a specific 
antigen and by costimulatory signals such as CD40L-CD40 and CD80/CD86-CD28 
interactions.125 The microenvironment determines the type of T cell response. For 
example IL-12 production by APCs lead to the development of T helper 1 (Th1) 
cells, which have been shown to aggravate atherosclerosis.126 Activated T cells 
migrate from the lymphoid organs to the site of inflammation e.g. the 
atherosclerotic lesion via chemokine signaling and are reactivated upon 
recognition of the antigen presented by APCs. Interference in T cell migration via 
the inhibition of the CXCR3 and CCL5 pathway, results in reduced Th1 cell influx 
into the lesion and subsequently in reduced atherosclerosis. 85, 127 
Most T cells within the atherosclerotic lesions are CD3+ CD4+ TCR αβ+ 
cells.128, 129 Although CD8+ T cells are also found in atherosclerotic plaques, their 
role in atherosclerosis is not yet clear. Furthermore, CD4- CD8- TCR γδ T cells are 
found in plaques and may play a role in relation to IL-17 production.129 IL-17 will 
be discussed later in more detail.  
In relation to the topic of this thesis, the discussed T cell populations will 
be limited to Th1, T helper 2 (Th2), T helper 17 (Th17) and regulatory T (Treg) cells 
(Figure 1.3). 
 
2.5.1 T helper 1 cells 
Data obtained from patients with CVD illustrated a predominant Th1 pattern 
within atherosclerotic plaques. This is also observed in mouse models for 
atherosclerosis. T cells differentiate into Th1 cells through stimulation of naive T 
cells with Th1 polarizing cytokines, such as IL-12 and IL-18.130, 131 The production 
of interferon (IFN)-γ hallmarks Th1 cells, which has pleiotropic pro-atherosclerotic 
effects. IFN-γ promotes activation of macrophages and endothelial cells to produce 
more adhesion molecules, proinflammtory cytokines and chemokines, which 
results in more T cell recruitment. Furthermore, IFN-γ promotes the production of 
proteases and inhibits collagen production, thereby interfering in plaque 
stability.132 Another Th1 associated cytokine is TNF-α, which also exerts pleiotropic 
pro-atherogenic effects.133 
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The role of Th1 cells in the aggravation of atherosclerosis has already been 
demonstrated. For example, vaccination against IL-12 in LDLr-/- mice results in a 
reduction in IFN-γ expression within the lesion and reduced atherosclerotic lesion 
development.131 Buono et al. demonstrated in LDLr and IFN-γ deficient mice a 75% 
reduction in lesion size, indicating the pro-atherosclerotic nature of Th1 cells.134 
Furthermore, IL-18 deficient ApoE-/- mice also showed reduced atherosclerosis.130 
FIGURE 1.3: DIFFERENTIATION OF T HELPER CELLS.  
Naive T cells differentiate into either Th1, Th2, Th17 or Treg cells upon stimulation with specific 
interleukins. Every Th cell subset has its own specific function in the immune response. However, a 
disproportional proliferation of a Th cell subset may lead to autoimmune diseases or chronic 
inflammation. The role of T helper cells in atherosclerosis is also depicted in this figure. See text for a 
more detailed description of the different Th subsets. (Adapted and modified  from Tato and O´Shea)237 
 
2.5.2 T helper 2 cells 
Traditionally, Th2 cells are considered anti-atherosclerotic due to the production of 
IL-4, IL-5, IL-9, IL-13, IL-10 and IL-3.135 An athero-protective role for these cells is 
suggested since the Th2 interleukins inhibit Th1 cells. Overexpressing IL-10 in 
LDLr-/- mice for example, exerts anti-atherosclerotic effects.136, 137 Furthermore, IL-5 
exerts an indirect anti-atherosclerotic effect by stimulation of B-1 cells. These B-1 
cells produce natural occurring T15/EO6 IgM antibodies directed against oxLDL. 
These natural antibodies can block the uptake of oxLDL by macrophages and 
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thereby attenuate atherosclerosis.138 This effect is nicely illustrated by Binder et al., 
where IL-5 deficient bone marrow is transplanted into a LDLr-/- recipient mice 
leading to aggravated atherosclerosis and a decrease in natural autoantibodies.139  
Conflicting data exist on the role of IL-4 in atherosclerotic plaque 
development. An athero-protective effect on initial plaque development was found 
after injection of IL-4 into mild hypercholesterolemic mice.140 On the other hand IL-
4 deficient ApoE-/- mice demonstrate reduced atherosclerosis, illustrating a pro-
atherosclerotic effect of IL-4.141 Moreover, IL-4 is associated with increasing MMP-1 
production by macrophages and may therefore have negative effects on plaque 
stability.142 
For long, it was thought that a disturbed balance between Th1 and Th2 
cells was causative for many autoimmune diseases, including atherosclerosis. 
However, the aforementioned findings on Th2 cells show that the classical 
Th1/Th2 balance cannot adequately explain the inflammatory process in 
atherosclerosis.  
Recently, two new T cell subsets were identified: the Th17 cell and the Treg 
cell. These cells provide more complexity and may provide an opportunity to 
explain the observed conflicting experimental effects. 
 
2.5.3 Regulatory T cells 
The regulatory T cells (Tregs) are important in maintaining immune homeostasis 
and preventing autoimmunity.143 Tregs develop in the thymus and display a 
diverse TCR repertoire specific for autoantigens. Tregs migrate from the thymus 
into the peripheral tissues and exert their anti-inflammatory response by 
recognition of specific autoantigens.144  
There are various mechanisms of immune suppression by Tregs.182 Firstly, 
the suppression of immune cells by cytolysis, via granzymes and perforins. 
Secondly, suppression by metabolic disruption, via “consuming” IL-2. Thirdly, 
suppression by inhibitory cytokines, such as TGF-β and IL-10. Finally, suppression 
by targeting DCs, via the interference in maturation and function of DCs, for 
example by cell-cell inhibition via CTLA4 (on Tregs) and CD80/CD86 (on 
APCs).146 
Tregs can generally be divided into two groups, the natural occurring Treg 
(nTreg) cells and the inducible T regulatory (iTreg) cells.147, 148 nTreg cells express 
CD4, CD25 (IL-2Rα), cytotoxic T lymphocyte antigen (CTLA)-4 and forkhead box 
P3 (Foxp3).145 nTreg cells exert their immunosupressive action predominantly by 
expressing membrane bound TGF-β, which suppress cells via cell-cell contact in 
paracrine fashion.146, 149 Furthermore, nTreg cells are able to bind to CD80 and/or 
CD86 via CTLA-4, thereby suppressing the immune system.150  
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There are also Foxp3 negative Treg cells leaving the thymus, which can be 
induced in the periphery to become immunosuppressive Treg cells, called 
inducible Tregs (iTregs). Depending on the suppressive action, these cells can be 
divided in Tr1 cells, which predominantly produce IL-10151 and Th3 cells, which 
exert their immunosuppressive function predominantly via TGF-β. Interestingly, 
Th3 cells do transiently express FoxP3.152, 153  
Mallat et al. hypothesized that adaptive or natural regulatory T cells may 
play an important role in the regulation of pathogenic T cells in atherosclerosis. 
There are several studies underlining this hypothesis. Depletion of Treg cells by 
treatment with anti-CD25 antibodies results in aggravated atherosclerosis in ApoE-
/- mice.125 Furthermore, van Puijvelde et al. demonstrated that the induction of Treg 
cells via tolerance induction against oxLDL or HSP60 leads to attenuated 
atherosclerosis.154 Moreover, Foxp3 expression has been detected in human 
atherosclerotic plaques, indicating that Treg cells are present.155 
 
2.5.4 T helper 17 cells 
Th17 cells are a novel T cell subset with a separate lineage. Langrish et al. showed 
that IL-23 selectively induces the proliferation of in vivo-primed IL-17-expressing 
Th cells and that these cells do not produce IL-4 or IFN-γ, indicating a separate Th 
subset.156 Harrington et al. and Park et al. further established the idea of a separated 
lineage of Th cells distinct from the T helper type 1 and 2 lineages. A naive 
precursor T cell is potently inhibited by IFN-γ and IL-4 in differentiation towards 
Th17 cells, whereas committed Th17 cells are resistant to suppression by Th1 or 
Th2 cytokines.157 Together these data provide evidence for a new Th subset, which 
is regulated by cytokines of Th1/Th2 cells and is involved in autoimmunity. 
Hence the name, IL-17 is the most prominent cytokine produced by Th17 
cells. The IL-17 family consists of six members, IL-17A, IL-17B, IL-17C, IL-17D, IL-
17E and IL-17F. IL-17A and F are most related to each other and share a 50% 
homology in protein sequence.158 As IL-17A was the first member of the IL-17 
family which was identified, it is mostly designated as IL-17.  
The IL-17R family consists of five members, designated as IL-17RA, IL-
17RB, IL-17RC, IL-17RD and IL-17RE.158 The best-studied IL-17R is IL-17RA, also 
designated as IL-17R, and is expressed ubiquitously through the body, which 
explains the pleiotropic effects of IL-17. The primary source of IL-17A and F are 
Th17 cells.159 However, there are other cells of the innate and adaptive immune 
system which produce IL-17A and F. It has been shown that CD8+ T cells produce 
IL17A and F as well as the γδ T cells.160, 161 In many different cell types, binding of 
IL-17A and/or F to its receptor results in the upregulation of a number of pro-
inflammatory interleukins and chemokines.158, 162-165 IL-17A and F also exert a 
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chemotactic effect in recruiting and activating neutrophils, providing a mechanism 
by which Th17 cells can mediate the crosstalk between innate and adaptive 
immune responses.158,165,166 IL-17 exhibits pleiotropic biological effects on various 
atherosclerotic lesion-associated cell types, such as endothelial cells, vascular 
smooth muscle cells and macrophages.167-169 Upon activation by IL-17 these cells 
produce pro-inflammatory cytokines, chemokines and matrix metalloproteinases 
(MMPs), including IL-6, CXCL8, CCL2 and MMP-9.169, 170 However, the role of IL-
17 in atherosclerosis is not investigated yet. In this thesis, the role of IL-17 and its 
receptor in atherosclerosis will be discussed in chapter 3 and 4. 
Besides IL-17, Th17 cells also produce IL-21, IL-22 and CCL20. IL-21 is 
expressed by Th17 cells171, but also by other cell types, such as IL-6 stimulated T 
cells.172,173 The receptor for IL-21 is expressed only on lymphoid cells and 
predominantly on B cells.174 IL-21 has pleiotropic effects, such as stimulating 
proliferation and differentiation of CD8+ T cells175 and it promotes differentiation 
and isotype switching in B cells.176 IL-21 induces CXCL8 expression in 
macrophages177, which is involved in the recruitment of monocytes to the early 
lesion, thereby aggravating atherosclerosis.178 Furthermore, IL-21 regulates the 
differentiation of CD4+ T cells to Th17 cells in an autocrine manner.171, 179 
IL-22 is a member of the IL-10 family 180 and the IL-22 receptor subunits are 
primarily expressed on epithelial and parenchymal tissues. 181 IL-22 protects 
against liver damage in an acute inflammation model.182 
Finally, Th17 cells produce CCL20.183, 184 Interestingly, its receptor CCR6, is 
also expressed by Th17 cells.183, 185 This may imply an autocrine mechanism to 
regulate its own recruitment in inflamed tissues.The development pathway of the 
Th17 cell lineage is actively investigated. Initially is was thought that IL-23 was the 
driving force behind Th17 development.156  
IL-23 is a heterodimeric interleukin consisting of a p40 and a p19 subunit. 
IL-23 is closely related to IL-12 as they both share the p40 subunit. 186 The receptor 
of IL-23 consists of a heterodimeric complex consisting of  IL-12Rβ1 shared with 
the IL-12 receptor and a unique IL-23R. The IL-23R shares many features with IL-
12Rβ2, which is the other part of the IL-12 receptor. The IL-23R is mainly expressed 
on effector T cells and not on naive T cells, suggesting an important role for IL-23 
in ongoing inflammation.186, 187  
IL-23 is mainly produced by macrophages and dendritic cells. Like the 
subunits of IL-27, EBI3 and p28, p19 must be expressed together with p40 in the 
same cell in order to be functionally excreted as IL-23.186 Recently, it is 
demonstrated that the development of gut inflammation in T-cell-deficient mice 
depends on IL-23, in that the loss of IL-23 but not IL-12 was associated with a 
decrease in gut inflammation. Most striking is the role of IL-23 in autoimmune 
diseases, such as EAE and RA. The role of IL-23 is identified by the observation 
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that IL-23p19-deficient animals do not develop EAE and do not develop IL-17-
producing T cells.188 In patients with Crohn’s disease, a single nucleotide 
polymorphism (SNP) in the coding sequence of IL-23R results in a strong 
protection against this disease, indicating a pathogenic role of IL-23 in chronic 
inflammation. Since IL-23 can expand a population of IL-17-producing pathogenic 
cells, an important role of IL-23 in the development of autoimmune diseases was 
suggested.156 These data imply that IL-23 may be responsible for the differentiation 
of Th17 cells. However, in vivo experiments demonstrated that IL-23 functioned 
more like a maintenance interleukin for the Th17 cell population.189 Therefore, it 
has been proposed that IL-23 may play a role in maintaining or stabilizing the Th17 
cell phenotype, or in the survival of Th17 cells (Figure 1.4).190 
Interestingly, as research continued, two “old” cytokines with opposing 
effects, IL-6 and TGF-β, were associated with Th17 cell differentiation.171, 191 IL-6 is 
a pro-inflammatory cytokine and was shown to aggravate atherosclerosis.192 On 
the other hand, TGF-β is an anti-inflammatory cytokine, which is associated with 
the differentiation of natural Treg cells and attenuation of atherosclerosis.193 194 
Most research on Th17 cells is done in mice. However, there are differences 
observed in Th17 development between mice and humans. Recently, some studies 
showed that also TGF-β, in combination with IL-1β, IL-6 or IL-21 is able to induce 
the differentiation of human Th17 cells,195, 196 indicating some overlap. More 
research has to be performed to further clarify the different aspects of Th17 cell 
development in different organisms. 
FIGURE 1.4: DETAILED OVERVIEW OF TH17 CELL DIFFERENTIATION.  
Since the discovery of Th17 cells many research has been done to elaborate the developmental pathway 
of Th17 cells. The insight in the role of IL-23 in Th17 cell development changed over time and is now 
assigned as a stabilizing factor for Th17 cell differentiation. TFG-β and IL-6 are associated with the 
differentiation of naive T cells to Th17 cells. Furthermore, the recently identified IL-21 is assigned to 
amplify Th17 cell development via an autocrine positive feedback. (Adapted and modified from Bettelli 
and Kuchroo)190 
 
The discovery of Th17 cells has changed the view on initiation and 
development of autoimmune diseases. There is, however, almost no literature 
available which associates Th17 cells with cardiovascular disease, although Cheng 
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et al. recently identified increased Th17 cells in patients with acute coronary 
syndrome.197 
Nevertheless, there are indications that Th17 cells may play an important 
role in atherosclerosis. The prominent effector cytokine, IL-17 is discussed in 
chapter 3 and 4 of this thesis. Furthermore, the fact that IL-23 is involved in several 
autoimmune diseases, together with the finding that IL-23 is involved in the Th17 
pathway, which is likely to be pro-atherosclerotic, indicates a role for IL-23 in 
atherosclerosis. Again, there are hardly any reports addressing IL-23 in 
atherosclerosis. In chapter 5 the role of the IL-23R in atherosclerosis will be 
discussed. Finally, we also studied the role of IL-27, which can suppress the 
development of Th17 cells,198 as is described in chapter 6. 
 
2.5.5 Th17 and Treg cells, two different subsets with a close relationship 
Both, the Th17 lineage as well as the Treg lineage requires TGF-β for their 
development. Therefore, a reciprocal relationship between these two cell 
populations is likely.191 TGF-β is needed for both cell types and IL-6 has a pivotal 
role in shifting the balance toward Th17 cells.171, 191 Furthermore Laurence et al. 
demonstrated that IL-2, which is necessary for Treg cells, inhibits Th17 cells in a 
STAT5 dependent way.189 Interestingly, IL-21 synergizes with TGF-β to promote 
the differentiation of Th17 cells in mice and, as mentioned before, IL-21 has an 
autocrine loop to enhance its own production by inducing proliferation and 
recruitment of Th17 cells. 171, 179 
There is also an interesting relation between Treg cells and Th17 cells on 
the level of transcription factors (Figure 1.5). The Th17 cell specific transcription 
factors, RORγ and RORα, are able to bind and antagonize Foxp3, a Treg 
transcription factor, and vice versa.199, 200 To underline this fact, conditional 
deletion of Foxp3 protein in Treg cells in vivo results in an increase in RORγ and 
subsequent upregulated IL-17 and IL-21 expression.201, 202 These data may be 
interesting for the treatment of chronic inflammation and autoimmunity.  
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FIGURE 1.5: REGULATION OF TH17 AND TREG SPECIFIC TRANSCRIPTION FACTORS.  
The transcription factor STAT3 is crucial for Th17 development. IL-6 and IL-21 activate this pathway, 
however the exact role for TGF-β on transcriptional level remains to be elucidated (black arrow). 
Recently, IL-27 has been shown to inhibit Th17 cells and this process is probably mediated by STAT1 
dependent STAT3 inhibition. Furthermore, IL-2 is able to suppress Th17 development in a STAT1 
dependent way. These data suggest a reciprocal relationship between Th17 and Treg cells. (Adapted 
and modified from Dong)238 
 
2.6 B CELLS 
B cells are also an important cell type of the adaptive immune system and are 
pivotal in the production of antibodies against specific antigens. Depletion of B 
cells results in aggravated atherosclerosis.203, 204 A specific subpopulation of B cells, 
B-1 cells, produce IgM class antibodies (T15/EO6) directed against antigens that 
exert an atheroprotective function.139, 205 Therefore, it is speculated that B cells are 
atheroprotective.206 
However, B cells are also able to present antigens and produce cytokines. 
Positive correlations have been found between atherosclerosis burden in the 
carotid artery and activated B cells in the circulation.207, 208 Furthermore, these B 
cells produce IgG antibodies against autoantigens and are associated with 
aggravating atherosclerosis.209 
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3 COMMUNICATION BETWEEN IMMUNE CELLS, A CRUCIAL 
      STEP  
The immune system is a complex system capable of defending its host against 
many different pathogenic organisms. However, although tightly regulated, the 
immune system can become pathogenic when targeting autoantigens or by 
overexerting the immune response against a certain pathogenic antigen. The 
adaptive immune system depends on signals of the innate immune response to 
adjust and adapt the response against the antigen. However, when this line of 
communication is disturbed or deregulated, it may result in chronic or 
autoimmune diseases.  
Within atherosclerosis, the adaptive and innate immune response have an 
important role in all stages of the disease. The innate immune system initiates 
atherosclerosis and the adaptive immune system is involved in development of the 
lesion. An important way of communication between immune cells and non-
immune cells is done by interleukins. A number of interleukins of special interest 
for this thesis, as they are involved in autoimmune diseases or in the polarization 
of autoimmune associated immune cell population, are discussed below.  
3.1 INTERLEUKIN 15 
Interleukin 15 (IL-15) is a pro-inflammatory cytokine which is first described in 
1994 by Grabstein et al. as a T cell activating factor with structural resemblance to 
IL-2.210 Although, little primary homology on protein level is found, high 
homology on secondary level is observed between IL-15 and IL-2. In addition, IL-
15 is designated as a member of the α-helix bundle cytokine family, which also 
includes IL-2.210  
The IL-15 receptor shares two subunits, the ß and γc subunit, with the IL-2 
receptor. The third subunit is formed by a unique α-chain, IL-15Rα.211 The third 
subunit of the IL-2R is the IL-2Rα (CD25).  
IL-15 is expressed by several immune cells, in particular by monocytes and 
macrophages, but also by some non-lymphoid cells, such as fibroblasts.212 IL-15 is 
also involved in expansion and survival of Natural Killer T (NKT) cells, which 
form an important link between the innate and adaptive immune response and 
enhance atherosclerosis.213 IL-15 is also expressed in a biologically active form in 
association with IL-15Rα on the surface of monocytes and activated macrophages. 
This surface expressed IL-15 is approximately five times more effective than 
soluble IL-15 in the induction of T cell proliferation and is able to signal in a cis and 
trans fashion to neighboring cells.214-216 Since soluble IL-15 is difficult to detect in 
biological fluids, it is suggested that the membrane bound IL-15 exerts a more 
important function in inflammation.217  
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IL-15 is expressed in human and murine atherosclerotic lesions218, 219 and 
may therefore affect T cells within the plaque. Besides activating T cells, IL-15 is a 
strong chemo-attractant for T cells and Natural killer (NK) cells220, 221 and it 
enhances CD44 mediated T cell adhesion to endothelial cells.220, 222 Sanchi et al. 
demonstrated that in the presence of IL-15, activated endothelium at sites of 
chronic inflammation is able to recruit and activate peripheral blood T cells to the 
site of inflammation.223 Furthermore, IL-15 can indirectly aggravate atherosclerosis 
by autocrine regulation of the production of pro-inflammatory cytokines by 
macrophages, such as TNF-α, IL-6 and IL-1β224 and fibroblasts produce matrix 
metalloproteinases upon stimulation by IL-15.225 
 These data suggest a direct and indirect role for IL-15 in atherosclerosis. 
The role of IL-15 in atherosclerosis will be addressed in chapter 2 of this thesis. 
 
3.2 INTERLEUKIN 27  
Recently, a new interleukin was identified with structural resemblance with IL-12 
and IL-23, called IL-27 and is composed of Epstein-Barr virus induced gene 3 
(EBI3) and p28.226  It is produced by activated antigen presenting cells and by 
resident macrophages.227 The IL-27 p28 is poorly secreted unless it is co-expressed 
with its partner EBI3 and thus creating a situation where expression of IL-27 can be 
tightly controlled during an immune response.187 IL-27 is therefore an important 
regulator of the adaptive immune response by interpreting signals of the innate 
immune system.  
The receptor for IL-27 is a heterodimeric complex of gp130 (part of the IL-6 
receptor) and the novel IL-27R (also designated as WSX-1 or TCCR).228 IL-27 
receptor is expressed on lymphocytes, such as B cells and Tregs, but also on natural 
killer (NK) cells, NK T cells, activated endothelial cells, activated epithelial cells, 
activated DCs, monocytes and mast cells.187  
Interestingly, IL-27 is also associated with several autoimmune diseases. 
Initially IL-27 was assigned to have proinflammatory properties, based on early 
reports of the group of Goldberg et al. They illustrated that vaccination against p28 
resulted in the suppression of EAE and adjuvant induced arthritis.229, 230 Recent 
studies showed a more complex dualistic role for IL-27 with anti- and pro-
inflammatory properties.  
IL-27 is able to induce differentiation of naive CD4+ T cells to Th1 cells, but 
is also able to suppress the development of Th17 cells in EAE models thereby 
attenuating the disease.198, 227, 231 Furthermore, IL-27 inhibits the development of 
Tregs and Th2 cells.232, 233 IL-27 has an unexpected activity in the immune system, 
as in some events it has a proinflammatory activity and in other events it shows 
anti-inflammatory activities by suppression of immune hyperactivity. Yoshimura 
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et al. proposed a mechanism where IL-27 stimulates STAT1 and STAT3 in naive Th 
cells, whereas only STAT3 is activated in activated Th cells.234 Thus, IL-27 is 
capable to inhibit or stimulate T cells, depending on the IL-27R expression of the 
target cells and subsequent signal transduction. However, more research needs to 
be done to study the divergent effects of IL-27 on different cell types under 
different conditions.  
The role of IL-27 in atherosclerosis is not yet investigated. The complex 
role of IL-27 in atherosclerosis is studied in this thesis and will be discussed in 
chapter 6. 
 
4 VACCINATION AS RESEARCH AND THERAPEUTIC TOOL 
The current treatment of atherosclerosis is focused on reducing risk factors, such as 
hypercholesterolemia by the administration of statins and a change in life style. 
Since the inflammatory aspects of atherosclerosis are getting more and more 
elucidated, novel strategies may arise as potential therapy, such as vaccination. 
Vaccination is an ideal tool to generate a desired immune response against an 
antigen. In atherosclerosis, vaccinations may be directed against one or several 
autoantigens involved in this disease. This approach is already successfully 
demonstrated by vaccinating mice against oxLDL154 and HSP60235 (chapter 7), 
which resulted in attenuated atherosclerosis. Another possibility is the targeting of 
certain cell types to restore or shift a balance towards a favorable outcome. For 
example, vaccination against IL-12 resulted in a decrease of Th1 cells and 
subsequently in the reduction of atherosclerosis.131  
A relative new development is DNA vaccination and this may prove to be 
a promising strategy in the future. DNA vaccination is based on, hence the name, 
DNA and can be produced at relatively low costs. Furthermore, the manufacturing 
and storage conditions are less stringent compared to protein-based vaccines and 
thereby facilitating a broader distribution and availability of anti-atherosclerotic 
medicine. As atherosclerosis and its related symptoms are getting pandemic 
proportions, these issues may be considered.  
Furthermore, DNA vaccination may provide a good and again relatively 
cheap research tool to investigate the function of certain cell types, by inducing a 
cytotoxic response against these cells. Signaling molecules, such as interleukins, 
can be neutralized by raising a humoral response against them. Additionally, the 
effect of depletion or neutralization of the targets can be studied in different phases 
of the disease. This contributes to a better understanding of the disease and 
ultimately to its cure.  
Detailed information and perspectives about vaccination against 
atherosclerosis is described in chapter 9 of this thesis as a perspective review. 
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5 OUTLINE OF THE THESIS 
In this thesis, the role of several key interleukins and inflammatory cells is studied 
in relation to atherosclerosis.  
In chapter 2 a DNA vaccination strategy is used, which makes use of a 
living carrier, the Salmonella typhimurium to induce a cytotoxic T cell response. In 
this study, we investigated the effect of IL-15 neutralization in atherosclerosis. We 
observed a strong reduction in atherosclerosis, which suggest an important role for 
this cytokine in the initiation of atherosclerosis.  
Another proinflammatory interleukin, IL-17, is studied in chapter 3. In this 
study we made use of a novel vaccination strategy, where we inject a DNA vaccine 
in the muscle. By neutralizing IL-17 in LDLr-/- mice with a HEL-IL-17 DNA 
vaccine, a dramatic decrease in atherosclerotic lesion development was observed.  
In chapter 4 the role of IL-17 signaling is studied by performing a bone 
marrow transplantation of IL-17 receptor deficient bone marrow into LDLr-/- 
recipient mice. This study illustrates an important role for IL-17 signaling in 
atherosclerosis.  
In chapter 5, another bone marrow transplantation is described with p19 (a 
subunit of IL-23) deficient bone marrow to study the contribution of IL-23 
signaling in atherosclerosis. However, there is no change in plaque size observed 
in this experiment. 
In chapter 6, again a DNA vaccination strategy was used, although with 
another immunodominant T helper cell epitope, PADRE, to break the tolerance 
against the p28 subunit of IL-27. In this study, the effect of IL-27 depletion in 
atherosclerosis results in aggravated atherosclerosis, indicating an atherosclerotic 
protective role for IL-27.  
To study whether regulatory T cells can be induced against an 
atherosclerotic related autoantigen, we induced tolerance against HSP60 as 
described in chapter 7. The tolerance induction results in an increased number of 
Treg cells and attenuated atherosclerosis. These results further establish the 
protective role of regulatory T cells in atherosclerosis. 
Dendritic cell based vaccination is described in chapter 8. Here we used a 
novel mRNA based vaccine against the specific regulatory T cell transcription 
factor, Foxp3. Via electroporation, the dendritic cells are “loaded” with the mRNA 
and subsequently injected in LDLr-/- mice. We demonstrate again that regulatory T 
cells have a protective role in atherosclerose, as we observed aggravated 
atherosclerosis in Foxp3 vaccinated mice.  
In chapter 9, a prospective review describes the possibilities of vaccination 
in atherosclerosis. Based on our work and the work of others, we think that 
immunomodulation can provide a very useful approach against atherosclerosis. 
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Furthermore, we discuss, to our opinion, the best approach to vaccinate against 
atherosclerosis.  
Finally, in chapter 10, all results described in this thesis will be discussed in 
relation to the mechanism of atherosclerosis and possible future treatment of this 
disease in patients.  
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ABSTRACT 
Interleukin 15 (IL-15) is a pro-inflammatory cytokine involved in inflammatory 
diseases and IL-15 is expressed in atherosclerotic plaques. 
To establish the role of IL-15 in atherosclerosis we studied the effect of IL-
15 on atherosclerosis associated cells in vitro and in vivo by neutralizing IL-15 using 
a DNA vaccination strategy. 
Upon feeding a Western type diet, LDLr-/- mice do express higher levels of 
IL-15 within the spleen and the number of IL-15 expressing cells among blood 
leukocytes and spleen cells is increased. Addition of IL-15 to macrophages induces 
the expression of TNF-α and CCL-2. After the mice were vaccinated against IL-15, 
we observe a reduction in plaque size of 75%. Unexpectedly, the relative number of 
macrophages within the plaque was 2-fold higher in IL-15 vaccinated mice than 
that in control mice. Vaccination against IL-15 leads to an increased cytotoxicity 
against IL-15 overexpressing target cells, resulting in a reduction in IL-15 
overexpressing cells in the blood and within the spleen.  
Hypercholesterolemia leads to upregulation of IL-15 within the spleen and 
peripheral blood mononuclear cells. DNA vaccination against IL-15 does markedly 
reduce atherosclerotic lesion size, indicating that blockade of IL-15 by vaccination 
may be considered to be a promising strategy in the treatment of atherosclerosis. 
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INTRODUCTION 
Atherosclerosis is characterized as a dyslipidemic induced chronic inflammatory 
disease of the arterial wall.1 During the various stages of lesion development, 
monocytes and T cells are recruited to the arterial wall.2 Already in the early stages 
of atherogenesis, macrophages and T cells are present in the intima of the 
atherosclerotic plaque.3  
Interleukin 15 (IL-15) is a pro-inflammatory cytokine which is expressed by 
different immune cells such as monocytes and macrophages and promotes T cell 
proliferation independently of antigen-specific T cell receptor activation.4 IL-15 is 
also expressed in a biologically active form on the surface of monocytes and 
activated macrophages. This surface expressed IL-15 is approximately 5 times 
more effective than soluble IL-15 in the induction of T cell proliferation.5 IL-15 
expression is associated with chronic inflammatory diseases such as rheumatoid 
arthritis.6 In addition, IL-15 is found to be expressed in human and murine 
atherosclerotic lesions7,8 and may therefore affect T cells within the plaque.  
The IL-15 receptor shares two subunits, the ß and γc subunit, with the IL-2 
receptor, while the third subunit is formed by a unique α-chain, IL-15Rα.9 Because 
the IL-15 and IL-2 receptor share two subunits, IL-15 shares biological activities 
with IL-2, such as the induction of proliferation of T cell subsets. There are 
however opposing effects of IL-2 and IL-15. IL-2 is primarily involved in the 
maintenance of regulatory T cells and IL-15 plays mainly a role in the survival of T 
cells and thus in memory cell formation.10-12 IL-15 not only activates T cells, it is 
also a strong chemoattractant for T cells and Natural killer (NK) cells13, 14 and 
enhances CD44 mediated T cell adhesion to endothelial cells.15 IL-15 is also 
involved in expansion and survival of Natural killer T (NKT) cells, which form an 
important link between the innate and adaptive immune response and enhance 
atherosclerosis.16 IL-15 finally exerts an autocrine regulation of the production of 
pro-inflammatory cytokines by macrophages, such as TNF-α, IL-6 and IL-1β.17  
We studied the role of IL-15 in atherosclerotic lesion formation by applying 
an in vivo blockade of IL-15 using oral vaccination, which resulted in a 75% 
reduction in lesion size, thereby establishing an important role for IL-15 in 
atherogenesis. 
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METHODS 
ANIMALS, MATERIALS, BACTERIAL STRAINS AND CELL LINES 
All animal work was approved by Leiden University and was in compliance with 
the Dutch government guidelines. LDL receptor deficient (LDLr-/-) mice were 
purchased from Jackson Laboratories. The mice were kept under standard 
laboratory conditions and food and water were provided ad libitum. Recombinant 
murine IL-15 was purchased from PeproTech and biotinylated polyclonal mouse 
anti-IL-15 was obtained from R&D systems. The attenuated Salmonella typhimurium 
(Dam-;AroA-,strain:SL7207) was provided by Dr. Kriszitana M. Zsebo (Remedyne 
Corporation,Santa-Barbara,CA). The macrophage cell line (RAW246.7), the 
endothelial cell line (H5V) and mouse fibroblasts were cultured in DMEM with 
10% FCS, 2 mmol/L glutamin, 0.1 U/L penicillin, and 100 mg/L streptomycin. 
Vascular smooth muscle cells were isolated from a murine aorta and cultured as 
described previously.18 
 
IN VITRO ASSESSMENT OF IL-15 
Cells were added to a 24-well plate (2.5x105 RAW cells/ml, 1.0x105 cells for H5V 
and vSMC). Where stated, 100 ng/ml recombinant IL-15 was added to the 
culturing medium and culturing medium alone served as a control. Cells were 
incubated for 24 hours, and thereafter the cells were used for qPCR and the 
supernatant was used for ELISA. All experiments were performed in triplicate. 
 
RNA ISOLATION AND QPCR 
Total RNA was isolated using Trizol (Boehringer Mannheim) and reverse 
transcribed (RevertAidPTMP M-MuLV reverse transcriptase, Fermentas). qPCR was 
analyzed with SYBRgreen mastermix (Perkin&Elmer) and a final concentration of 
300 nM primers (Table 2.1), using acidic ribosomal phosphoproteinP0(36B4) as an 
internal standard. 
 
ELISA 
A mouse TNF-α set (PharMingen) was used to detect TNF-α in culture supernatant 
according to manufacturer’s protocol. 
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CONSTRUCTION OF THE DNA VACCINE 
Murine IL-15 (AI503618) was cloned into the eukaryotic expression plasmid 
pcDNA3.1 (Invitrogen). The 605bp. fragment encoding the entire IL-15 gene was 
amplified using PCR primers: 5’-GAA GCC CAT CGC CAT AGC–3’ and 5’-GAG 
CAG CAG GTG GAG GTA-3’ and subsequent cloned into pcDNA3.1 with EcoRV, 
generating pcDNA3.1-IL-15. Subsequently, S. typhimurium was electroporated with 
pcDNA3.1-IL-15 or an empty pcDNA3.1 plasmid.19 
 
TABLE 2.1: SEQUENCE OF PRIMERS. Primer sequences for the genes analyzed with qPCR.  
 
VACCINATION AND THE INDUCTION OF ATHEROSCLEROSIS  
Mice were vaccinated prior to the induction of atherosclerosis with 108 cfu S. 
typhimurium transformed with empty pcDNA3.1 (control) or pcDNA3.1-IL-15 as 
previously described.19 Male LDLr-/- mice 10-12 weeks of age were fed a Western-
type diet containing 15% cocoa butter and 0.25% cholesterol two weeks prior to 
collar placement. Atherosclerosis was induced by placement of collars (0.3 mm, 
Dow Corning, Midland, Michigan) around the carotid arteries as previously 
described.20 Hereafter, the mice were fed a Western-type diet for 8 more weeks. 
Total cholesterol levels during the experiment were quantified 
spectrophotometrically using an enzymatic procedure (Roche Diagnostics, 
Germany). Precipath standardized serum (Boehringer, Germany) was used as an 
internal standard. 
 
GENE FORWARD PRIMER REVERSE PRIMER 
IL-15 5’-TGAGGCTGGCATTCATGTCTT-3’ 5’-ATCTATCCAGTTGGCCTCTGTTTT-3’ 
IL-1β 5’-TGGTGTGTGACGTTCCCATTA-3’ 5’-AGGTGGAGAGCTTTCAGCTCATAT-3’ 
IL-10 5’-TCTTACTGACTGGCATGAGGATCA-3’ 5’-GTCCGCAGCTCTAGGAGCAT-3’ 
CXCL1 5’-GGCGCCTATCGCCAATG-3’ 5’-CCTGAGGGCAACACCTTCAA-3’ 
CCL2 5’-GCATCTGCCCTAAGGTCTTCA-3’ 5’-TTCACTGTCACACTGGTCACTCCTA-3’ 
CCR2 5’-CCTTGGGAATGAGTAACTGTGTGA-3’ 5’-TGGAGAGATACCTTCGGAACTTCT-3’ 
36B4 5’-GGACCCGAGAAGACCTCCTT-3’ 5’-GCACATCACTCAGAATTTCAATGG-3’ 
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CYTOTOXICITY ASSAY 
The murine fibroblast cells were used as target cells and were co-transfected with 
pcDNA3.1-IL-15 and pcDNA3.1-eGFP using ExGen500 (Fermentas, Germany) 
according to the manufacturer’s protocol. 24 hours after transfection, 106 spleen 
cells isolated from IL-15 vaccinated or control vaccinated mice were added to the 
target cells. 24 hours later, cells were fixed using FormalFixx (3.7%, Thermo 
Shandon, Pittsburgh, PA ), and the number of GFP-fluorescent cells per well was 
determined. 
 
HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
Carotid arteries were removed for analysis as described by Von der Thüsen et al.20 
The arteries were embedded in OCT compound (TissueTek; Sakura Finetek, The 
Netherlands). Cryosections of 5 µm were made proximally of the collar occlusion 
and stained with hematoxylin (Sigma Diagnostics, MO) and eosin (Merck 
Diagnostica, Germany). Corresponding sections on separate slides were stained 
immunohistochemically for macrophages using an antibody against a 
macrophage-specific antigen (MoMa-2, Research Diagnostics Inc.). Quantification 
of the staining was performed by using a Leica DM-RE microscope and Leica Qwin 
Imaging software (Leica Ltd., Germany). 
 
FACS ANALYSIS OF LEUKOCYTES  
Peripheral Blood Mononuclear Cells (PBMC) were isolated after orbital bleeding 
using Lympholyte (Cedarlane, Canada) as described in the manufacturer’s 
protocol. Spleens were dissected and single cell suspension was obtained by 
passing the spleen through a 70 µm cell strainer (Falcon, The Netherlands). 
Leukocytes were purified using Lympholyte. Cells were stained with FITC-
conjugated anti-mouse CD8 (0.125 µg/sample, Pharmingen) and PE-conjugated 
anti-mouse CD69 (0.125 µg/sample, eBioscience). For the staining of surface bound 
IL-15, the leukocytes were stained with biotinylated anti-mouse IL-15 (R&D 
systems) and PE-conjugated streptavidin (BD Pharmingen) and analyzed by 
flowcytometry on a FACSCalibur. All data was analyzed with CELLQuest 
software (BD Bioscience, The Netherlands). 
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STATISTICAL ANALYSIS 
All data are expressed as means ± SEM. The two-tailed student’s t-test was used to 
compare individual groups of mice or cells. When indicated, a Mann-Whitney test 
was used to analyze not normally distributed data. P values of <0.05 were 
considered significant. 
 
RESULTS 
IL-15 IS UPREGULATED IN HYPERCHOLESTEROLEMIC MICE 
The spleens of LDLr-/- mice were collected at different time points after the start of 
the Western-type diet feeding and mRNA expression of IL-15 was quantified. The 
expression of IL-15 mRNA was significantly elevated in the spleen at 6 weeks after 
the start of the diet (Figure 2.1A). Since IL-15 expression is also regulated at a post-
translational level and is mainly membrane bound5, we also determined the cell 
surface expression of IL-15. Spleen cells and PBMCs were isolated from LDLr-/- 
mice which were fed a Western diet or a normal Chow diet for 10 weeks. FACS 
analysis showed that the percentage of IL-15 expressing cells within the spleen and 
PBMCs was elevated after 10 weeks of Western type diet. (Figure 2.1B; 
12.59±0.65%versus 26.07±3.44%, P<0.05 and 0.28±0.06% versus 4.95±0.98%, P<0.05, 
respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.1: EXPRESSION OF IL-15 IN HYPERCHOLESTEROLEMIC MICE. 
IL-15 mRNA expression level was determined in spleen cells of LDLr-/- mice at different time points 
after Western-type diet feeding(A). PBMCs and spleen cells were isolated and stained for surface bound 
IL-15(B). The percentages of IL-15 positive cells are determined by FACS analysis after 0 weeks of 
Western type diet (white bars, N=5) and after 10 weeks of Western type diet (black bars, N=5). * P<0.05 
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IL-15 PREDOMINATELY AFFECTS MACROPHAGES IN VITRO 
We determined the effect of IL-15 on cell lines that represent the main cell types in 
the atherosclerotic lesion; macrophages (RAW cells), vascular smooth muscle cells 
(vSMCs) and endothelial cells (H5V cells). The relative expression of IL-15 is 
highest for macrophages (Figure 2.2A), while also for vSMCs and endothelial cells 
a distinct expression is found. Addition of recombinant IL-15 to the various cell 
types leads only for macrophages to increased expression of tumor necrosis factor 
(TNF)-α on protein level (Figure 2.2B). We observed in macrophages a distinct 
increase in the pro-inflammatory cytokine IL-1β, whereas there was no significant 
effect seen on mRNA encoding IL-10 (Figure 2.2C), IFN-γ or IL-12 (p40) (data not 
shown). In addition, IL-15 significantly induced the expression of CXCL1, CCL2 
and CCR2 in macrophages (Figure 2.2D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.2: EFFECT OF IL-15 ON GENE EXPRESSION IN PLAQUE RELATED CELL TYPES.  
IL-15 expression was determined in RAW cells, H5V cells and vSMC (A). IL-15 (black) or no IL-15 
(control; white) was added to different cell types. Cellular activation was measured by TNF-α release 
(B). The expression of several genes was measured in RAW cells after addition of 100 ng/mL IL-15 
(black), or without IL-15 (white) for inflammatory genes (C) and chemotaxic associated genes (D). 
*P<0.05, **P<0.01 and ***P<0.001 
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These results indicate that IL-15 may affect the chemokines induced 
migration of macrophages.21 Endothelial cells did not respond to IL-15 by 
upregulation of CXCL1, CCL2 or CCR2 on mRNA levels. In addition, IL-15 did not 
affect the expression of adhesion molecules such as VCAM-1, ICAM-1, PECAM 
and P-selectin in endothelial cells (data not shown). 
 
VACCINATION AGAINST IL-15 INDUCES AN IL-15 SPECIFIC CYTOTOXIC T CELL 
RESPONSE 
The Western-type diet induced IL-15 expression on spleen cells and PBMCs and 
the IL-15 mediated activation of macrophages stimulated us to analyze the effect of 
IL-15 blockade on atherosclerosis via vaccination. To this end, LDLr-/- mice were 
vaccinated against IL-15 by oral delivery using an attenuated strain of S. 
typhimurium transformed with an IL-15 expression vector (pcDNA3.1-IL-15) or 
with S. typhimurium transformed with an empty vector (pcDNA3.1) as a control. 
This vaccination strategy leads to the induction of CD8+ cytotoxic T cells that 
specifically lyse those cells that overexpress IL-15 and present IL-15 peptides via 
MHC class I. 19 This protocol was recently used to study the role of VEGFR2 and 
CD99 in atherosclerosis.19, 22, 23 Following vaccination, mice were fed a Western-
type diet for 2 weeks and collars were placed around the carotid arteries which 
results in flow-induced atherosclerotic lesion formation.20 We established the 
activation state of the CD8+ T cell population. Spleen cells were isolated and 
stained for CD8 and CD69, an early T cell activation marker, and analyzed by 
FACS analysis. The percentage of CD8+CD69+ double positive cells was increased 
significantly upon vaccination against IL-15 compared to the control vaccination 
(Figure 2.3A; 16.0±2.1% versus 10.4±0.1%, P<0.05). In order to study the specificity 
of CD8+ cytotoxic T cells, spleen cells from vaccinated and control mice were co-
cultured with murine fibroblasts that were co-transfected with pcDNA3.1-IL-15 
and pcDNA3.1-GFP. The number of surviving IL-15 expressing target cells was 
determined by counting GFP positive cells. The number of IL-15 expressing target 
cells was reduced by 50% after incubation with spleen cells from IL-15 vaccinated 
mice, whereas spleen cells from control vaccinated mice, did not significantly lyse 
IL-15 expressing cells (Figure 2.3B; 49±1% in vaccinated group versus 81±4% in 
control group, P<0.01).  
 
VACCINATION AGAINST IL-15 REDUCES ATHEROSCLEROTIC LESION SIZE IN 
HYPERCHOLESTEROLEMIC LDLR-/- MICE  
Atherosclerosis was determined 6 weeks after collar placement. During the 
experiment blood samples were obtained and plasma cholesterol concentration 
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was determined. IL-15 vaccination did not affect plasma cholesterol levels during 
the experiment (Figure 2.3C). Hematoxylin-Eosin (HE) staining of the 
atherosclerotic plaque was performed and plaque sizes were quantified. 
Vaccination against IL-15 resulted in a 75% decrease in lesion size as compared to 
the control group (Figure 2.4A, B and C; 13722±3116 µm2 versus 53977±15332 µm2, 
P<0.05). Immunohistochemical staining for macrophages showed a significant 
change in plaque composition (Figure 2.4F). The relative number of macrophages 
per plaque area was 2-fold higher in IL-15 vaccinated mice (Figure 2.4E) than that 
in control vaccinated mice (Figure 2.4D), indicative for a less advanced state of the 
lesions in the vaccinated mice. 
 
FIGURE 2.3: IN VIVO EFFECT OF THE VACCINATION AGAINST IL-15.  
The percentage of double positive cells (CD8+CD69+ cells) was determined in a single cell suspension of 
the spleen cells in vaccinated and control mice (A, N=5). The induction of specific cytotoxic CD8+ T cells 
against IL-15 expressing cells was determined by incubating spleen cells from vaccinated mice (black), 
control mice (white) or without spleen cells (grey) with fibroblast transfected with an IL-15 and GFP 
expression plasmid (B, N=5). Blood was taken from vaccinated and control mice at the indicated times 
and total cholesterol level was determined in serum (C, N=9). *P<0.05 and **P<0.01 
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FIGURE 2.4: THE EFFECTS OF VACCINATION ON ATHEROSCLEROTIC LESION DEVELOPMENT IN LDLR-/- 
MICE. 
5 µm cross sections of the carotid artery of the control group (A) and the vaccinated group (B) were 
made and subsequently stained for HE and quantified (C, N=8). To determine macrophage content, 
cross sections were made and stained with MoMa-2 (D and E) and the ratio of macrophage count and 
plaque area was determined (F, N=8). *P<0.05 
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SURFACE EXPRESSION OF IL-15 ON SPLEEN CELLS AND PBMC IS REDUCED AFTER 
VACCINATION 
As hypercholesterolemia induced surface expression of IL-15 on PBMCs and 
spleen cells (Figure 2.1B), we evaluated the effect of IL-15 vaccination on IL-15 
positive cells within the spleen and PBMCs. Spleen cells and PBMCs were stained 
for IL-15 and analyzed by FACS. Upon IL-15 vaccination, the surface expression of 
IL-15 on spleen cells was almost completely reduced to a similar level as found in 
mice before the start of the Western-type diet (Figure 2.5A, P<0.05). Within the 
PBMC population IL-15 surface expression was also decreased (Figure 2.5A, 
P<0.05). This indicates a systemic reduction of IL-15 expressing cells upon 
vaccination.  
FIGURE 2.5: LEUKOCYTE IL-15 EXPRESSION IN VACCINATED AND CONTROL LDLR-/- MICE.  
After vaccination and collar placement, PBMCs and spleen cells were isolated and stained for IL-15. The 
percentage of IL-15 positive cells is determined by FACS analysis, after control vaccination and 10 
weeks of diet (white, N=6) and after IL-15 vaccination and 10 weeks of diet (black, N=6) *P<0.05 
 
DISCUSSION 
Atherosclerosis is considered a dyslipidemic induced chronic inflammatory 
disease of the arterial wall. During atherosclerotic lesion formation, monocytes and 
subsequently T cells infiltrate the arterial wall.1 DNA vaccination against IL-15 
leads in LDLr-/- mice to a greatly blocked atherosclerotic lesion development, 
indicating that IL-15 accelerates lesion formation. 
Upon the start of a hypercholesterolemic diet in LDLr-/- mice the mRNA 
expression of IL-15 is increased within the spleen. Furthermore, 
hypercholesterolemia does increase the percentage of IL-15 expressing cells in both 
blood and in spleen. These findings point to a possible relation between IL-15 
expression and the induction of atherosclerosis. IL-15 appears to be highly 
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expressed by macrophages and to a lesser extend by endothelial cells and vSMCs. 
After stimulation of macrophages with IL-15, the mRNA levels of several pro-
inflammatory cytokines, such as TNF-α and IL-1β are upregulated, while the 
secretion of TNF-α is also increased by IL-15. Important proteins in the 
chemoattraction of macrophages, CXCL1, CCL2 and CCR2, are also upregulated 
after incubation with IL-15. These latter effects are also seen on human monocytes 
when stimulated with IL-15.24  
Vaccination against IL-15 was accomplished by oral administration of a 
live attenuated Salmonella typhimurium bacteria, transformed with an eukaryotic 
expression vector encoding IL-15. This vaccination method induces a strong, IL-15 
specific, cytotoxic immune response, resulting in the killing of cells overexpressing 
IL-15. This is a similar mechanism as achieved by the oral vaccination against FLK-
1 as described by Niethammer et al.19 and by Hauer et al.22 and vaccination against 
CD99 described by van Wanrooij et al.23 These vaccination procedures resulted in a 
cytotoxic T cell-mediated killing of cells expressing FLK-1 and CD99, respectively. 
The reduction in IL-15 expressing cells within the spleen and blood upon 
vaccination was accompanied by a 75% reduction in atherosclerotic lesion size. 
During the experiment no difference was detected in total cholesterol levels in the 
serum between the groups, indicating that IL-15 does not affect lipid-metabolism 
and the reduction in plaque is more likely due to changes in the inflammatory 
status of the mice. The reduced plaque size was accompanied by a two-fold 
increase in the relative amount of macrophages. As macrophage infiltration is a 
feature of early vascular lesion formation25, it may be speculated that plaque 
formation and progression is strongly retarded but not prevented due to the 
blocking of IL-15.  
Although IL-15 is involved in the expression of important 
chemoattractants for macrophages, it is likely that there are additional sources for 
these chemokines within the plaque, for example endothelial cells or vSMCs. We 
can also speculate that the recruited macrophages within the plaque do not, or to a 
lesser extent, express IL-15/IL15Rα as is demonstrated by the reduction of the 
surface expression of IL-15 on cells within spleen and PBMCs. Macrophages 
express IL-15/IL15Rα complexes on their surface upon activation and are able to 
activate T cells in an antigen-independent way. Membrane bound IL-15 is not only 
5-times more effective in inducing T cell proliferation than soluble IL-15, it also 
signals through different effectors and can therefore exert distinct biological 
responses. Membrane bound IL-15, expressed on macrophages can participate in 
reverse signaling between the IL-15Rα on T cells, whereas soluble IL-15 modulates 
cellular function in both a paracrine and autocrine fashion.17, 26 Macrophages which 
lack IL-15/IL15Rα complex on the surface are not able to sustain a full immune 
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response within the plaque and thereby are less capable to recruit inflammatory 
cells into the plaque.  
We suggest that the development of the lesion is arrested in the fatty streak 
stadium. This may provide an explanation for the increased number of 
macrophages in the vessel wall and the smaller lesion size, since mainly the innate 
immune response is activated and adaptive immune response is likely impaired. 
However, IL-15 expressing cells are activated inflammatory cells, which are also 
able to express other inflammatory mediators. Therefore it should be taken into 
account that the effect we observe may also be due to the absence of other 
mediators. The vaccination method used in this study may lead to the initiation of 
new therapies, which block the action of IL-15. There are some promising results 
with phase I/II clinical trails with an anti-IL-15 antibody treatment in patients with 
rheumatoid arthritis,27 which might be extended to cardiovascular patients. 
The vaccination strategy used in this study successfully evoked a cytotoxic 
response targeting IL-15 expressing cells. This resulted in a vast reduction in 
atherosclerosis, thereby providing new insights in the process of atherosclerosis 
and the contribution of IL-15 in this process. These new insights may contribute to 
a future immunomodulating treatment of patients with cardiovascular diseases.  
IL-15 aggravates atherosclerotic lesion development in LDLr-/- mice  
 
 
61 
2 
 
References 
1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115-126. 
2. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu 
Rev Pathol. 2006;1:297-329. 
3. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from 
human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci 
U S A. 1995;92:3893-3897. 
4. Liu K, Catalfamo M, Li Y, Henkart PA, Weng NP. IL-15 mimics T cell receptor crosslinking in 
the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T 
cells. Proc Natl Acad Sci U S A. 2002;99:6192-6197. 
5. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In 
trans to neighboring cells. Immunity. 2002;17:537-547. 
6. Yoshihara K, Yamada H, Hori A, Yajima T, Kubo C, Yoshikai Y. IL-15 exacerbates collagen-
induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol. 
2007;37:2744-2752. 
7. Houtkamp MA, van Der Wal AC, de Boer OJ, van Der Loos CM, de Boer PA, Moorman AF, 
Becker AE. Interleukin-15 expression in atherosclerotic plaques: an alternative pathway for T-
cell activation in atherosclerosis? Arterioscler Thromb Vasc Biol. 2001;21:1208-1213. 
8. Wuttge DM, Eriksson P, Sirsjo A, Hansson GK, Stemme S. Expression of interleukin-15 in 
mouse and human atherosclerotic lesions. Am J Pathol. 2001;159:417-423. 
9. Giri JG, Anderson DM, Kumaki S, Park LS, Grabstein KH, Cosman D. IL-15, a novel T cell 
growth factor that shares activities and receptor components with IL-2. J Leukoc Biol. 
1995;57:763-766. 
10. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death 
of lymphocytes: implications for immunotherapy. Immunity. 2001;14:105-110. 
11. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ 
memory T cells by opposing cytokines. Science. 2000;288:675-678. 
12. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-
phenotype CD8+ T cells in vivo by IL-15. Immunity. 1998;8:591-599. 
13. Allavena P, Giardina G, Bianchi G, Mantovani A. IL-15 is chemotactic for natural killer cells 
and stimulates their adhesion to vascular endothelium. J Leukoc Biol. 1997;61:729-735. 
14. Wilkinson PC, Komai-Koma M, Newman I. Locomotion and chemotaxis of lymphocytes. 
Autoimmunity. 1997;26:55-72. 
15. Estess P, Nandi A, Mohamadzadeh M, Siegelman MH. Interleukin 15 induces endothelial 
hyaluronan expression in vitro and promotes activated T cell extravasation through a CD44-
dependent pathway in vivo. J Exp Med. 1999;190:9-19. 
16. Matsuda JL, Gapin L, Sidobre S, Kieper WC, Tan JT, Ceredig R, Surh CD, Kronenberg M. 
Homeostasis of V alpha 14i NKT cells. Nat Immunol. 2002;3:966-974. 
17. Alleva DG, Kaser SB, Monroy MA, Fenton MJ, Beller DI. IL-15 functions as a potent autocrine 
regulator of macrophage proinflammatory cytokine production: evidence for differential 
receptor subunit utilization associated with stimulation or inhibition. J Immunol. 
1997;159:2941-2951. 
18. Michon IN, Hauer AD, von der Thusen JH, Molenaar TJ, van Berkel TJ, Biessen EA, Kuiper J. 
Targeting of peptides to restenotic vascular smooth muscle cells using phage display in vitro 
and in vivo. Biochim Biophys Acta. 2002;1591:87-97. 
19. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. 
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor 
growth. Nat Med. 2002;8:1369-1375. 
20. von der Thusen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by 
perivascular carotid collar placement in apolipoprotein E-deficient and low-density 
lipoprotein receptor-deficient mice. Circulation. 2001;103:1164-1170. 
21. Cybulsky MI, Gimbrone MA, Jr. Endothelial expression of a mononuclear leukocyte adhesion 
molecule during atherogenesis. Science. 1991;251:788-791. 
22. Hauer AD, van Puijvelde GH, Peterse N, de Vos P, van Weel V, van Wanrooij EJ, Biessen EA, 
Quax PH, Niethammer AG, Reisfeld RA, van Berkel TJ, Kuiper J. Vaccination against 
  Chapter 2  
 
62 
VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 
2007;27:2050-2057. 
23. van Wanrooij EJ, de Vos P, Bixel MG, Vestweber D, van Berkel TJ, Kuiper J. Vaccination 
against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice. 
Cardiovasc Res. 2008. 
24. Badolato R, Ponzi AN, Millesimo M, Notarangelo LD, Musso T. Interleukin-15 (IL-15) induces 
IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood. 
1997;90:2804-2809. 
25. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. 
Arteriosclerosis. 1989;9:567-578. 
26. Musso T, Calosso L, Zucca M, Millesimo M, Ravarino D, Giovarelli M, Malavasi F, Ponzi AN, 
Paus R, Bulfone-Paus S. Human monocytes constitutively express membrane-bound, 
biologically active, and interferon-gamma-upregulated interleukin-15. Blood. 1999;93:3531-
3539. 
27. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, 
Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW, Gracie JA, Jongbloed S, Liew FY, 
McInnes IB. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept 
study. Arthritis Rheum. 2005;52:2686-2692. 
 
 
Chapter 3 
 
Vaccination against 
interleukin-17 attenuates 
atherosclerosis in  
LDL receptor deficient  mice   
 
 
Thomas van Es, Arnaud D. Hauer, Gijs H.M. van 
Puijvelde, Eva J.A. van Wanrooij, Paula de Vos, Niels 
Peterse, Theo J.C. van Berkel and Johan Kuiper  
 
 
Submitted for publication 
 Chapter 3 
 
64 
ABSTRACT 
Interleukin-17 (IL-17) is a T cell-derived pro-inflammatory cytokine that is linked 
to autoimmune diseases. IL-17 exhibits pleiotropic effects on atheroma-associated 
cell types and induces the secretion of pro-inflammatory cytokines and 
chemokines.  
In this study, we investigated the effect of IL-17 blockade on the initiation 
of atherosclerosis by vaccination against IL-17. A plasmid (pcDNA3.1) encoding 
IL-17 and the dominant T helper cell HEL epitope was used to vaccinate LDL 
receptor deficient (LDLr-/-) mice prior to induction of atherosclerosis by feeding a 
Western-type diet and collar placement.  
Functional blockade of IL-17 upon vaccination was demonstrated by a 
reduced induction of serum IL-6 levels after administration of IL-17. DNA 
vaccination with the HEL-IL-17 plasmid resulted in a 90.2% reduction in lesion size 
in the carotid artery (P<0.01) and 59% reduction in the aortic root (P<0.05). This 
reduction was dependent on the HEL sequence to break tolerance against 
endogenous IL-17 during vaccination.  
Neutralizing the IL-17 production by vaccination forms a promising 
approach to inhibit atherosclerotic lesion development. 
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INTRODUCTION 
Cardiovascular disease (CVD), with atherosclerosis as the main underlying 
pathology is the leading cause of death in the Western world and atherosclerotic 
lesion initiation and progression has been shown to be associated with a chronic 
inflammatory response.1 Macrophages and T cells are present within the intima in 
early stages of atherogenesis and play a crucial role in the initiation and 
subsequently in the progression of the atherosclerotic plaque.1, 2 CD4+ effector T 
cells are the major T cell subset in atherosclerotic lesions and T cells are involved in 
atherosclerotic lesion formation.3  
Traditionally, it was postulated that activated T cells differentiate into 
either T helper 1 (Th1) or Th2 cells. Th1 cells produce mainly pro-inflammatory 
cytokines, such as interferon-γ (IFN-γ) and tumor necrosis factor (TNF)-α, whereas 
Th2 cells predominantly produce anti-inflammatory cytokines, such as IL-4, IL-5 
and IL-10.4 A disturbed balance between Th1 and Th2 cells is thought to be 
responsible for the immunopathological conditions in several autoimmune 
diseases, such as atherosclerosis.5  
More recently, a new subset of T helper cells with a T memory cell 
phenotype has been identified, the T helper 17 (Th17) cell and this cell type is 
associated with several (auto)immune diseases.6 Although the loss of IFN-γ 
receptor appears to be protective in atherosclerosis7, this newly identified Th cell 
may also be involved in the development of atherosclerosis.  
The differentiation of Th17 cells is subject to debate. TGF-β, IL-1β and IL-6 
in the presence of the appropriate antigen are ascribed to participate in the 
differentiation and initiation of Th17 cells.8, 9 Th1 and Th2 cytokines, such as IFN-γ 
and IL-4 may antagonize the Th17 development, but fully differentiated Th17 are 
unresponsive to these cytokines.10 IL-17 production is the hallmark of the Th17 cell 
and IL-17 has been identified in several autoimmune diseases, such as 
Experimental Autoimmune Encephalomyelitis (EAE) and rheumatoid arthritis to 
have a negative effect on disease progression.11, 12 IL-17 exhibits pleiotropic 
biological effects on various cell types , such as endothelial cells, vascular smooth 
muscle cells, and macrophages that are associated with atherosclerosis.13, 14 In these 
cells IL-17 can induce a number of pro-inflammatory cytokines, chemokines and 
matrix metalloproteinases (MMPs), including IL-6, IL-8, monocyte chemoattractant 
protein 1 (MCP-1) and MMP-9.15, 16 
However, the role of IL-17 is not yet established in atherosclerosis. 
Therefore, we vaccinated mice against endogenous IL-17 via DNA vaccination in 
order to neutralize endogenous IL-17. To break T cell tolerance for IL-17, a specific 
T helper cell epitope (HEL) was coupled to IL-17.17 Vaccination against HEL-IL-17 
established a strong protection against atherosclerosis, which may indicate that IL-
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17 is important in atherosclerosis and therapies to neutralize the action of IL-17 
may provide a new approach to treat atherosclerosis. 
 
METHODS 
ANIMALS 
All animal work was approved by Leiden University and was in compliance with 
the Dutch government guidelines. LDLr-/- mice on a C57/Bl6 background were 
from Jacksons Laboratory and were kept under standard laboratory conditions and 
food and water were administered ad libitum. 
 
VACCINE PREPARATION  
Genes coding for the antigen were cloned into pcDNA3.1(-) (Invitrogen, The 
Netherlands). cDNA coding for murine IL-17 was obtained by PCR on stimulated 
murine spleen cells. The following primers were used: IL-17, 5’- GAT CAG GAC 
GCG CAA ACA- 3’ (forward) and IL-17, 5’- GGG TTT CTT AGG GGT CAG- 3’ 
(reverse). The IL-17 PCR product was cloned into a pcDNA3.1(-) plasmid. The HEL 
sequence was derived from the amino acid sequence 81-95 of hen egg-white 
lysozyme and was cloned upstream of IL-17 with XbaI.21 The following HEL 
sequence was used: 5'- CTA GAA TGT CAG CCC TGC TGA GCT CAG ACA TAA 
CAG CGA GCG TGA ACT GCG CGC CT- 3'.  
 
TESTING THE CONSTRUCT 
Expression of constructs was tested by transient transfection of COS7 cells with the 
plasmid. COS7 cells were transfected with pcDNA3.1-HEL-IL-17 and pcDNA3.1 
using Exgen500 according to manufacturer’s protocol (Fermentas, Germany). 
Supernatant was collected 24 and 48 hours after transfection. Expression of IL-17 
was determined with a specific murine IL-17 ELISA according to manufacturer’s 
protocol (BD Bioscience, The Netherlands). To confirm the functional blockade of 
IL-17 after vaccination we performed an experiment in which we made use of the 
fact that IL-17 is able to induce IL-6 production. In a separate experiment LDLr-/- 
mice were vaccinated against IL-17 or control vaccinated. Three days after the last 
vaccination, 0.2 µg of murine IL-17 (1 µg/ml) was injected intravenously. Four 
hours after the injection of IL-17, blood was collected and serum IL-6 levels were 
quantified with a mouse IL-6 ELISA (eBioscience, Belgium). 
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CELL CULTURE 
The murine monocyte/macrophage cell line (RAW 246.7) and an endothelial cell 
line (H5V) were cultured in DMEM supplemented with 10% FCS, 2 mmol/L 
glutamin, 0.1 U/L penicillin, and 100 mg/L streptomycin. Primary vascular 
smooth muscle cells were isolated from murine aorta and cultured as described 
previously.22  
 
IN VITRO ASSESSMENT OF IL-17 
0.5 ml of cells were added to a 24-wells plate (2.5x105 RAW cells/ml, 1.0x105 cells 
for H5V and vSMC). Unless stated otherwise, 100 ng/ml recombinant IL-17 was 
added to the culture medium and culture medium alone served as a control. Cells 
were incubated for 24 hours, and thereafter the supernatant was used for ELISA. 
All experiments were performed in triplicate. Where indicated cells were used for 
qPCR. 
 
QUANTATIVE PCR ASSAYS 
Total RNA was isolated using guanidium isothiocyanate (GTC) method and 
reverse transcribed to cDNA (RevertAidTM M-MuLV reverse transcriptase, 
Fermentas). Gene expression was analyzed with an ABI PRISM 7700 (Applied 
Biosystems, Foster city, CA) using SYBR Green technology. Primer pairs as 
described in table 3.1 were used to quantify IL-17, ADAM-15 and MMP-9 gene 
expression. As a reference gene hypoxanthine phosphoribosyl transferase (HPRT) 
was used. The relative gene expression was calculated by subtracting the threshold 
of the target gene from the reference gene and raising 2 to the power of this 
difference. 
 
TABLE 3.1: SEQUENCE OF PRIMERS. Primer sequences for the genes analyzed with qPCR.  
 
GENE FORWARD PRIMER REVERSE PRIMER 
IL-17 5’-CCAGGGAGAGCTTCATCTGTGT-3’ 5’-AAGTCCTTGGCCTCAGTGTTTG-3’ 
ADAM-15 5’-TGTGGCTTCCCAGATGAATG-3’ 5’-GTTTTGACAACAGGGTCCATCA-3’ 
MMP-9 5’-CTGGCGTGTGAGTTTCCAAAAT-3’ 5’-TGCACGGTTGAAGCAAAGAA-3’ 
HPRT 5’-TTG CTCGAGATGTCATGAAGGA-3’ 5’-AGCAGGTCAGCAAAGAACTTATAG-3’ 
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VACCINATION AND INDUCTION OF ATHEROSCLEROSIS 
The DNA vaccine was isolated with an Endofree plasmid Giga kit (Qiagen, The 
Netherlands). Male low-density lipoprotein receptor deficient (LDLr-/-) mice, 10-12 
weeks old, were used for the i.m. vaccination. Three days prior to the first 
vaccination, mice received an i.m. bilateral Cardiotoxin I (Sigma, USA) injection, 10 
µM, 50 µl per muscle. Mice were vaccinated by a total of three bilateral i.m. 
injections of 100 µg plasmid in 100 µl PBS, 50 µl per muscle, with two-week 
intervals (N=15 each group). Immediately after the last vaccination, mice were put 
on a Western type diet, containing 0.25% cholesterol and 15% cocoa butter (Special 
Diet Services, UK). After two weeks of Western type diet feeding, atherosclerosis 
was induced within the carotid arteries by bilateral perivascular collar placement, 
as described previously.23 During the experiment, plasma samples were obtained 
by tail vein bleeding. Total cholesterol levels were quantified during the 
experiment using an enzymatic procedure (Roche Diagnostics, Germany) using 
Precipath as an internal standard.  
 
TISSUE HARVESTING 
Six weeks after collar placement, carotid arteries were obtained after in situ 
perfusion for 15 minutes with Formalfixx. Carotids were embedded in OCT 
compound (Sakura Finetek, The Netherlands), snap-frozen in liquid nitrogen and 
stored at -20°C until further use. Transverse 5 µm cryosections were prepared in a 
proximal direction from the carotid bifurcation and were mounted on a parallel 
series of slides. For analysis of atherosclerosis at the site of the aortic semilunar 
valves, 10 µm transverse cryosections were made of the aortic root as previously 
described.23, 24 
 
HISTOLOGICAL ANALYSIS AND MORPHOMETRY 
Cryosections were routinely stained with hematoxylin (Sigma Aldrich, 
Zwijndrecht, The Netherlands) and eosin (Merck Diagnostica, Germany). 
Corresponding sections were stained for lipids by Oil red O staining. Hematoxylin-
eosin stained sections of carotid arteries were used for morphometric analysis of 
atherosclerotic lesions. Each vessel was assessed ~0.5 mm proximal to the collar, 
and the site of maximal stenosis was used for morphometric assessment. 
Atherosclerosis in the aortic root was quantified with Oil red O stained sections of 
plaques developed in the region of the aortic semilunar valves, as previously 
described.24 
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STATISTICAL ANALYSIS 
All data are expressed as mean ± SEM. The two-tailed student’s t-test was used to 
compare individual groups of mice or cells. Mann-Witney test was applied to 
compare not normally distributed values. P values of <0.05 were considered 
significant. 
 
RESULTS 
EVALUATING THE EXPRESSION OF IL-17 IN ATHEROSCLEROSIS  
To define the role of IL-17 in atherosclerosis we determined the expression of IL-17 
in atherosclerosis prone mice, fed a Western type diet (WTD, 0.25% cholesterol). 
Starting from three weeks after the start of the Western type diet we observed a 
significant 2-fold increase in the IL-17 gene expression in the spleen (Figure 3.1; 1 ± 
0.22 versus 2.20 ± 0.32, P<0.05). Subsequently, the expression of IL-17 steadily 
increased, leading to a more than 3-fold increase at week 6 of Western type diet 
feeding (Figure 3.1; 3.18 ± 0.30, P<0.01). 
 
FIGURE 3.1: MRNA EXPRESSION OF IL-17 IN RESPONSE TO A WESTERN-TYPE DIET.  
At different time points spleen samples were obtained and mRNA was isolated using the guanidium-
isothiocyanate method and IL-17 expression was determined. Expression of IL-17 is expressed relative 
to HPRT and subsequently related to the expression of mice on chow diet. * P< 0.05, ** P<0.001 
 
Thereafter, the expression of IL-17 rapidly decreased and declined to basal levels at 
12 weeks of Western-type diet, indicating specifically the induction of IL-17 during 
the initiation of atherosclerosis. Next, we studied the effect of IL-17 on different 
athero-associated cell types in vitro. A macrophage cell line (RAW264.7), an 
endothelial cell line (H5V) and primary mouse vascular smooth muscle cells were 
stimulated with IL-17 and the production of IL-6 and TNF-α was determined. 
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RAW cells responded with a strong increase in TNF-α production (Figure 3.2A; 81 
± 10 pg/ml versus 372 ± 49 pg/ml, P<0.01), whereas H5V did not respond to IL-17 
(data not shown). Isolated VSMC responded to IL-17 with a significant increase in 
IL-6 production (Figure 3.2B; 65.6 ± 4.1 pg/ml versus 293.4 ± 7.9 pg/ml, P<0.001). 
 
FIGURE 3.2: STIMULATION OF RAW AND VSMCS WITH IL-17.  
RAW and vSMCs were stimulated with 100 ng/ml IL-17 and after 24 hours the supernatant was 
collected and analyzed with a TNF-α (A) or IL-6 (B) ELISA. **P<0.01, ***P<0.001 
 
Since, VSMC play an important role in the production of MMPs,25, 26 thereby 
contributing to remodeling and stability of the plaque, we measured the expression 
of MMP-9 and ADAM metallopeptidase domain 15 (ADAM-15) by VSMCs. IL-17 
specifically enhanced MMP-9 expression in vSMCs significantly but did not affect 
ADAM15 expression (Figure 3.3).  
 
 
FIGURE 3.3: EFFECT OF IL-17 ON METALLOPROTEINASE EXPRESSION IN VSMCS.  
vSMCs were stimulated with 100 ng/ml IL-17 and incubated for 24 hours. mRNA was isolated using 
the guanidium-isothiocyanate method. Expression of MMP-9 and ADAM15 are shown relative to 
HPRT. * P< 0.05 
Control +IL-17 
B A 
0 
100 
200 
300 
400 
 ** 
T
N
F
-α
 (
p
g
/m
l)
 
RAW 
Control +IL-17 
0 
100 
200 
300 
400 
 
  *** 
vSMC 
IL
-6
 (
p
g
/m
l)
 
ADAM15 
0.00 
0.01 
0.02 
0.03 
control 
+IL-17 
* 
* 
R
e
la
ti
v
e
 e
x
p
re
ss
io
n
 
MMP-9 
                                          Vaccination against IL-17 attenuates atherosclerosis in LDLr-/- mice 
 
 
71 
3 
CONSTRUCTION OF A HEL-IL-17 DNA VACCINE 
We cloned the IL-17 coding sequence of murine IL-17A into the eukaryotic 
expression vector, pcDNA3.1. The coding sequence is preceded by the Th cell 
epitope HEL, to enhance the breaking of tolerance against endogenous IL-17 as has 
been shown before for vaccination against several self antigens such as TNF-
alpha.17 In vitro experiments were performed to determine the expression and 
functionality of the used construct. COS7 cells were transfected with the HEL-IL-17 
plasmid and the supernatant was collected after 24 and 48 hours of incubation. We 
assessed the supernatant for IL-17 expression with a mouse specific IL-17 ELISA. 
24 hours after transfection the HEL-IL-17 protein was detectable in the supernatant 
of the COS7 cells using an IL-17 ELISA. At 48 hours the concentration of HEL-IL-17 
protein in the supernatant was almost doubled (Figure 3.4), indicating that IL-17 
together with the HEL epitope is translated and excreted into the medium. Cells 
transfected with the empty pcDNA3.1 plasmid or non-transfected cells showed no 
expression of IL-17 (Figure 3.4). 
 
 
FIGURE 3.4: EXPRESSION OF THE VACCINE IN AN EUKARYOTIC EXPRESSION SYSTEM.  
Expression of IL-17 was determined by transfection the plasmid to COS7 cells. Culture supernatant was 
collected 24 or 48 hours after transfecting with either HEL-IL-17 construct, an empty plasmid or PBS. IL-
17 production was determined using a mouse IL-17 specific ELISA. The optical density was measured 
at a wavelength of 450 nm. *P< 0.05; **P<0.01 
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IMPAIRED IL-17 SIGNALING IN IL-17 VACCINATED MICE 
To determine whether a functional blockade of IL-17 was established by 
vaccination, male LDLr-/- mice received a triple vaccination either with a plasmid 
encoding HEL-IL-17 or with an empty plasmid, both after pre-treatment of the 
mice with cardiotoxin I (CTX-I) at the site of vaccination to enhance the vaccination 
efficacy. Three days after the last i.m. vaccination, IL-17 was injected intravenously 
and 4 hours thereafter blood was collected to quantify the IL-17 response in terms 
of IL-6 production. Injection of IL-17 led to a significant 31% reduction in serum 
concentration of IL-6 in mice vaccinated against IL-17 as compared to control 
vaccinated mice (Figure 3.5; 7.87 pg/ml versus 11.44 pg/ml, P<0.05), indicating 
that the anti-IL-17 vaccination induced at least a partially blockade of the function 
of IL-17.  
 
FIGURE 3.5: DETERMINATION OF NEUTRALIZING ACTIVITY OF THE VACCINE. Serum IL-6 concentration 
was determined with an ELISA 4 hours after administration of IL-17 to mice that were either vaccinated 
against IL-17 or control vaccinated. *P<0.05 
 
EFFECT OF IL-17 VACCINATION ON ATHEROGENESIS 
As the vaccine proved to effectively reduce IL-17 signaling, we studied the effect of 
anti-IL-17 vaccination on de novo plaque formation in male LDLr-/- mice using the 
i.m. IL-17-HEL vaccine. Following the last DNA vaccination LDLr-/- mice were put 
on a Western-type diet to induce hypercholesterolemia. Two weeks later, 
perivascular carotid collars were placed to induce atherosclerosis within the 
carotid arteries. During the experiment, we did not detect any difference in 
cholesterol levels between the anti-IL-17 vaccinated group and the control 
vaccinated group (Figure 3.6A). Six weeks after collar placement mice were 
sacrificed and the plaque size proximal to the collar was quantified. Vaccination 
with the HEL-IL-17 plasmid significantly reduced the formation of atherosclerotic 
lesions by 90.2% (Figure 3.6 B-D; 5654 ± 2099 µm2 versus 57702 ± 14120 µm2, 
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P<0.01), indicating that the initiation of atherosclerosis was largely blocked in the 
IL-17 vaccinated group. Furthermore, a beneficial 87.5% reduction in intima/media 
ratio (Figure 3.6E; 0.13 ± 0.033 versus 1.00 ± 0.27, P<0.01) and a 79.6% reduction in 
intima/lumen ratio (Figure 3.6F; 0.14 ± 0.043 versus 0.70 ± 0.087, P<0.05) were 
observed, which indicates reduced stenosis in mice vaccinated with HEL-IL-17. We 
determined plaque development also at another site in the vascular bed, the aortic 
valve region. In mice vaccinated with HEL-IL-17 (Figure 3.7A) a significant 59% 
reduction in plaque size (Figure 3.7C; 126691 ± 20739 µm2 versus 310170 ± 78706 
µm2 P<0.05) was observed compared to the control group (Figure 3.7B). We 
assessed plaque composition in the lesions in terms of collagen and macrophage 
composition but detected no differences between the control group and vaccinated 
groups (data not shown). 
 
DISCUSSION 
Already in 1986 Mosmann et al. described two distinct Th subsets, Th1 and Th2 
cells, with their own specific production of cytokines.4 An exaggerated pro-
inflammatory response due to an overexpression of Th1 associated cytokines such 
as IL-12 and IFN-γ enhances atherosclerosis.24 Blockade of pro-inflammatory 
cytokines or cytokines involved in Th1 differentiation may introduce a new 
therapy for atherosclerosis. We previously demonstrated that vaccination against 
IL-12, a prominent Th1 cytokine, reduces atherosclerosis in LDLr-/- mice.25 
However, some experimental results with respect to the role of IL-4 in 
atherosclerosis can not be explained by the classical Th1/Th2 model.26-28 These 
observations may indicate that other T helper subsets are involved in 
atherosclerosis and we focused in our present work on the role of IL-17 a main 
product of the pro-inflammatory T helper cell subset, the Th17 cells.6, 10, 27, 29, 30 
Th17 cells and IL-17 have been identified in various autoimmune disease29, 
31  and may also play a role in atherosclerosis, which is also recognized as an 
autoimmune disease.32-34 IL-17 may have pleiotropic effects on the various cell 
types within the atherosclerotic lesion and may thereby stimulate a pro-
inflammatory environment, which aggravates atherosclerosis.14, 15, 29, 35-37 
To address the role of IL-17 in atherosclerosis we first examined the effect of 
hypercholesterolemia on the expression of IL-17 within the spleen by feeding 
LDLr-/- mice a Western-type diet. 6 weeks after starting Western-type diet feeding, 
the IL-17 expression was more than 3-fold increased compared to the level before 
the diet. This may indicate a relation between the initiation of the inflammatory 
response during atherosclerosis and IL-17 expression. 
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FIGURE 3.6: INITIAL ATHEROSCLEROTIC LESION FORMATION IN VACCINATED MICE. Mice were vaccinated 
by intramuscular (i.m.) injection of HEL-IL-17 plasmid or empty plasmid. Subsequently mice were put 
on a Western type diet and two weeks later equipped with a perivascular collar. At the indicated time 
points, cholesterol levels were determined in the various groups of mice (A).  Six weeks after collar 
placement mice were sacrificed and the carotid arteries of control mice (B) and vaccinated mice (C) were 
sectioned and stained with hematoxylin-eaosin. Lesion size from all mice(D) as well as intima/media 
ratio (E) and intima/lumen ratio (F) were determined by computer-assisted morphometric analysis to 
asses the degree of atherosclerosis. *P<0.05, **P<0.01 
 
FIGURE 3.7: EFFECT OF IL-17 VACCINATION ON PLAQUE FORMATION IN THE AORTIC ROOT. Mice were i.m. 
vaccinated with an empty plasmid (A) or with a HEL-IL-17 plasmid (B). Subsequently mice were put on 
a Western type diet and 8 weeks later the mice were scarified and sections of the aortic root were 
stained with Oil-red-O and hematoxylin. Plaque size was determined by computer assisted analysis (C). 
*P<0.05 
 
A 
200 µm  
 
Control HEL-IL-17 
0
100 
200 
300 
400 
P
la
q
u
e
 s
iz
e 
(x
10
3
 µ
m
2
) 
(µ
m
) 
 
B 
200 µm  
 * 
** 
 * 
** 
A B C 
D E F 
100 µm  100 µm  
Control Vaccinated 
0 
25 
50 
75 
L
e
si
o
n
 s
iz
e
 (
x
1
0
3
) 
(µ
m
2
) 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
In
ti
m
a
 /
 m
e
d
ia
 
ra
ti
o
 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
In
ti
m
a
 /
 l
u
m
e
n
 
ra
ti
o
 
2 4 6 
0 
500 
1000 
1500 
2000 
Weeks post-collar placement 
S
e
ru
m
 c
h
o
le
st
e
ro
l 
(m
g
/d
l)
 
Control Vaccinated Control Vaccinated 
                                          Vaccination against IL-17 attenuates atherosclerosis in LDLr-/- mice 
 
 
75 
3 
For the vaccination against IL-17, murine IL-17 was cloned into a 
pcDNA3.1 plasmid preceded by the specific immunodominant T-helper epitope 
HEL to break T cell tolerance. In this study we used a specific part of the HEL 
sequence which binds with high affinity to MHC class II and is able to activate T 
cells, which can subsequently provide the necessary stimuli to break the tolerance 
against self-antigens and help B cells to produce antibodies against IL-17.17, 38 This 
approach is in line with data from Dalum et al.  who used a HEL-TNF-α to 
vaccinate atherosclerosis prone apoE-/- mice against TNF-α.17, 38 We detected high 
concentrations of IL-17 in the supernatant of cells transfected with HEL-IL-17, 
which indicates that the HEL peptide did not alter the conformation of IL-17 and 
did not interfere with the excretion of the protein into the medium, which is 
important for successful vaccination. To study the role of IL-17 in the process of 
atherogenesis we vaccinated LDLr-/- mice against HEL-IL-17 and vaccination was 
preceded by treatment of the hind leg muscles with Cardiotoxin I, which improves 
the outcome of DNA vaccinations.39  
In the present study, we show that the function of IL-17 is partially blocked 
by vaccination against IL-17. Intravenous administration of recombinant IL-17 after 
anti-IL-17 vaccination resulted in a significant reduction in serum IL-6 levels. This 
indicates that vaccination against IL-17 induced a partial and functional blockade 
of IL-17 in vivo. In the HEL-IL-17 vaccinated mice we observed a highly significant 
reduction of 90.2% in plaque size in the carotid artery and a 59.0% reduction in the 
aortic valve region. Furthermore, the beneficial effect on lesion initiation is 
illustrated by an 87.5% reduction in intima/media ratio and a 79.6% reduction in 
intima/lumen ratio. Interestingly, unpublished data from our lab show that i.m. 
vaccination with an IL-17 plasmid lacking the HEL sequence did not have any 
effect on atherosclerosis, which clearly indicates that the HEL sequence in the 
vaccine is essential for a functional blockade of IL-17 (data not shown). In line with 
the findings on vaccination against Il-17, we have observed that transplantation of 
IL-17 receptor deficient bone marrow into LDLr-/- mice inhibits atherosclerosis by 
almost 50% (Van Es et al. unpublished results, chapter 4). It should be kept in mind 
that Th17 cells do not form the only source of IL-17, since more cell types such as 
γδT cells and NKT-like cells are able to produce IL-17.40 Additional research is 
therefore needed to assess the role of these different cell types to IL-17 production 
and their individual role in atherosclerosis. 
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In conclusion, in this study we describe a prominent role for IL-17 in 
atherosclerosis: IL-17 is upregulated in hypercholesterolemic LDLr-/- mice upon 
Western-type diet feeding and neutralization of IL-17 by vaccination, using a novel 
DNA vaccination strategy, attenuates atherosclerotic lesion formation. Therefore 
interfering in the IL-17 pathway will be an interesting target for therapeutic 
intervention in cardiovascular disease. 
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ABSTRACT 
Atherosclerosis is an inflammatory disease, which is illustrated by the influx of 
macrophages and T cells in the sub-endothelial layer. IL-17 is an important 
cytokine, which bridges the innate and adaptive immune response and moreover 
IL-17 is involved in the transition from an acute into a chronic inflammation.  
In this study we investigated the role of IL-17 receptor signaling in 
atherosclerosis. We therefore performed a bone marrow transplantation with IL-17 
receptor deficient donor bone marrow into LDL receptor deficient recipient mice. 
After full bone marrow reconstitution a Western-type diet feeding was started and 
atherosclerotic lesions were quantified after 12 weeks.  
A 46% reduction in lesion size in the aortic root was observed (P<0.05). 
Furthermore, a decrease in auto-antibodies against oxLDL was detected. The 
inflammatory status of IL-17 deficient bone marrow recipients was changed as 
indicated by the reduced IL-6 production by the spleen and increased IL-10 
production within the HLN and PBMCs. 
 In conclusion, the IL-17 signaling is involved in the aggravation of 
atherosclerosis. This is probably mediated by a decrease in IgG anti-oxLDL 
antibodies and a change in the inflammatory status. Therefore, interfering in the 
IL-17 receptor pathway could provide a new therapeutic approach for inhibiting 
atherosclerosis lesion development. 
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INTRODUCTION 
Atherosclerosis is an inflammatory disease, which involves both components of the 
immune system, the adaptive and innate immune system1. The inflammatory 
response is tightly regulated by several mechanisms for example via interleukins 
(IL).  
IL-17 is involved in the early activation of the immune system and plays an 
important role in bridging the innate immune response with the adaptive immune 
response.2 IL-17 is mainly produced by T cells, especially CD4+ effector memory T 
cells and has more recently been linked to a new class of T helper cells, the Th17 
cells.3, 4 IL-17 has a protective role, since IL-17 protects against infectious 
microorganisms such as Klebsiella pneumoniae , Candida albicans and Toxoplasma 
gondii.5,6 On the other hand an elevated concentration of IL-17 is associated with 
different autoimmune diseases such as, rheumatoid arthritis and multiple sclerosis, 
where IL-17 plays a pathogenic role. 7, 8 
The IL-17 family comprises six members (IL-17A, B, C, D, E and F) and the 
best characterized member is IL-17A, which is also designated as IL-17 as it is the 
founding member of the IL-17 family. The receptor for IL-17 (IL-17R) is a type I 
transmembrane protein consisting of a 293 amino acids long extracellular domain 
and a relatively long intra cellular domain consisting of 525 amino acids.9, 10 The IL-
17 receptor is widely expressed with a prominent mRNA  expression in lung, 
kidney, liver, spleen and also in isolated fibroblasts, endothelial cells, mesothelial 
cells and myeloid cells from mice.9 This wide expression is also seen in humans, 
were the IL-17R for example is found on peripheral blood T cells and vascular 
endothelial cells. 11,12 The pathogenic role of IL-17 in autoimmunity and the parallel 
in function with proinflammatory cytokines, such as tumor necrosis factor (TNF)-α 
and IL-1β makes IL-17 an interesting target for studying its role in 
atherosclerosis.13 
IL-17 induces the expression of a wide range of proinflammatory cytokines 
and chemokines in various cell types as a consequence of the broad expression of 
IL-17R.14 IL-17 stimulates the expression of IL-6 and CXCL8 (IL-8) by stromal cells 
and ICAM-1 by fibroblasts and keratinocytes.9, 10, 15 Even more interesting is the 
effect of IL-17 on macrophages, which produce IL-1β, IL-1Ra, IL-6, IL-10, TNF-α 
and prostaglandin E2 (PGE2) in response to IL-17. Matrix metalloproteinase (MMP)-
3 and MMP-9 are also induced by IL-17.16, 17 These proteinases and 
proinflammatory interleukins and chemokines have already been implicated in 
atherosclerotic lesion growth and destabilization of the plaque.18-20  
The role of the IL-17R signaling pathway, although extensively studied in 
other autoimmune diseases, is not yet established in the process of atherosclerosis. 
Therefore we transplanted bone marrow of IL-17R-/- mice to LDLr-/- mice, which 
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resulted in a 46% reduction in atherosclerotic lesion size. These data indicate an 
aggravating role of IL-17 in the process of atherosclerosis and establish a new 
target to beneficially influence atherosclerosis lesion development. 
  
METHODS 
ANIMALS 
All animal work was approved by Leiden University and was in compliance with 
the Dutch government guidelines. LDL receptor deficient (LDLr-/-) mice were 
purchased from Jackson Laboratories. IL-17 receptor knockout mice were a kind 
gift from J. Peschon (Amgen, Seattle, WA) and created as described by Ye et al.6 
The mice were kept under standard laboratory conditions and food and water 
were provided ad libitum. 
 
BONE MARROW TRANSPLANTATION (BMT) AND INDUCTION OF HYPER-
CHOLESTEROLEMIA 
To induce bone marrow aplasia, male LDLr–/– mice were exposed to a single dose 
of 9 Gy (0.19 Gy/min, 200 kV, 4 mA) total body irradiation, using an Andrex Smart 
225 Röntgen source (YXLON Int, Copenhagen, Denmark) with a 6-mm aluminum 
filter. Bone marrow was isolated by flushing the femurs and tibias from mice with 
phosphate-buffered saline (PBS). Single-cell suspensions were prepared by passing 
the cells through a 30 µm nylon gauze. Irradiated recipients received 0.5x107 bone 
marrow cells by intravenous injection into the tail vein. After a recovery of 8 weeks 
animals received a Western-type diet ad libitum containing 15% cocoa butter and 
0.25% cholesterol (Special Diet Services, Witham, Essex, UK) for 12 weeks. During 
the experiment the mice were weighted every week and checked for well-being. 
 
SERUM LIPID LEVELS 
Every 3 weeks the serum cholesterol levels were determined to assess the effect of 
the Western-type diet. Blood samples were collected by tail bleeding from non-
fasting animals. Total cholesterol levels were quantified spectrophotometrically 
using an enzymatic procedure (Roche Diagnostics, Germany). Precipath 
standardized serum (Boehringer, Germany) was used as an internal standard. 
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HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
Mice were anaesthetized with ketamine-hypnorm and perfused with PBS and 
subsequently with FormalFixx. The heart and complete aorta were removed. The 
heart was embedded in OCT compound (TissueTek; Sakura Finetek, The 
Netherlands) and cryosections of 10 µm were made of the aortic root containing 
the aortic valves. Cryosections were routinely stained with Oil-Red-O and 
hematoxylin (Sigma Diagnostics, MO). Corresponding sections on separate slides 
were stained immunohistochemically for macrophages using an antibody against a 
macrophage-specific antigen (MoMa-2, Research Diagnostics Inc.) and for collagen 
using Masson trichrome staining according to manufacturer's protocol (Sigma 
Diagnostics). Neutrophils were stained by specific esterase staining (Naphthol AS-
D chloroacetate, Sigma). Mast cells were stained by Toluidin Blue Staining (Sigma). 
The different histological stains were quantified using a Leica DM-RE microscope 
and Leica Qwin Imaging software (Leica Ltd., Germany).  
 
FACS ANALYSIS OF LEUKOCYTES  
Peripheral Blood Mononuclear Cells (PBMC) were isolated via orbital bleeding and 
erythrocytes were removed by incubating the cells with erythrocyte lysis buffer 
(0.15 M NH4Cl, 10 mN NaHCO3, 0.1 mM EDTA, pH 7.3). Spleens, Heart lymph 
nodes (HLN) and Mesenteric lymph nodes (MNL) were dissected from the mice 
and single cell suspension was obtained by passing the organs through a 70 µm cell 
strainer (Falcon, The Netherlands). Cells were stained with surface markers (0.20 
µg antibody/300.000 cells) and subsequently analyzed by flow cytometric analysis. 
The F4/80-FITC and CD19-FITC antibody were used for the detection of 
macrophages and B cells, respectively (Immunosource, Belgium). The unlabeled 
antibody for IL-17R was purchased from R & D systems and as a secondary 
antibody anti goat-IgG-PE (Abcam, UK) was used according manufacturers 
protocol. All data were acquired on a FACScalibur and analyzed with CELLQuest 
software (BD Biosciences, The Netherlands). 
 
OXLDL ANTIBODY DETECTION 
Cu-oxLDL was synthesized as described previously 21, 22. Antibodies against Cu-
oxLDL were determined according to Damoiseaux et al.23 MaxiSorp 96 wells plates 
(Nunc, Roskilde, Denmark) were coated overnight with 100 µg oxLDL in coating 
buffer (50mM NaHCO3, 50mM Na2CO3, pH=9.6) at 4 0C. IgM, IgG2a and IgG1 
antibodies directed against oxLDL were detected with an isotype Ig detection kit 
according manufacturer’s protocol (Zymed lab. Inc., CA). 
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CYTOKINE PRODUCTION 
Peripheral Blood Mononuclear Cells (PBMC), spleens, heart lymph nodes (HLN) 
and mesenteric lymph nodes (MNL) were dissected and a single cell suspension 
was made as described above. Subsequently the cells were cultured in a 96-wells 
round bottom plate which was coated with α-CD28 and α-CD3 (0.25 µg/well) at a 
cell density of 2.105 cells per well. Cells were cultured in RPMI 1640 (with L-
Glutamine) supplemented with 10 % FCS, 100 U/ml penicillin and 100 µg/ml 
streptomycin (all from BioWhittaker Europe). Supernatant was used for IL-10 and 
IL-6 ELISA’s according to manufacturer’s protocol (both from eBioscience, 
Belgium). 
 
STATISTICAL ANALYSIS 
All data are expressed as mean ± SEM. The two-tailed student’s t-test was used to 
compare individual groups of mice or cells. When indicated, a Mann-Whitney test 
was used to analyze not normally distributed data. P values of <0.05 were 
considered significant. 
 
RESULTS 
EFFICACY OF IL-17R-/- BONE MARROW TRANSPLANTATION 
To asses the efficacy of IL-17R-/- BMT, we determined the IL-17R expression by 
FACS analysis. 20 weeks after BMT the IL-17R expressing cells in different organs 
were analyzed. The number of IL-17R expressing cells was significantly reduced 
with 85% within the blood (Figure 4.1A, P<0.01). Furthermore, the IL-17R 
expression on circulating macrophages was analyzed. We observed a strong 
reduction of 84% in IL-17R expressing macrophages in IL-17R-/- transplanted mice 
(Figure 4.1B). Within the spleen of IL-17R-/- transplanted mice the expression of IL-
17R on mRNA level was also stongely reduced (Figure 4.1C). These data 
demonstrate an effective replacement of acceptor bone marrow by IL-17R-/- donor 
bone marrow. 
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FIGURE 4.1: IL-17 RECEPTOR EXPRESSING CELLS OF PBMCS IN IL17R-/- BM RECIPIENT AND CONTROL 
MICE. After sacrificing the mice, PBMCs were stained with an antibody directed against IL-17R and 
F4/80 or IL-17R alone and analyzed with a FACS machine. The expression of the IL-17R was significant 
lower within IL-17R-/- transplanted mice (A). Within the macrophage population of the PBMCs IL-17R 
was also significant lower in IL-17R-/- transplanted mice (B). Total RNA was isolated from the spleen 
cells and the expression of the IL-17R was assessed by qPCR analysis, illustrating almost complete 
abolishment of IL-17R expression IL-17R-/- transplanted mice (C). Control mice (N=5) and IL-17R-/- BM 
recipients (N=5). *P< 0.05, **P<0.01  
EFFECT OF IL-17R-/- BMT IN ATHEROSCLEROSIS 
Next we determined the effect on IL-17R-/- BMT in atherosclerosis whereby the 
mice were fed a Western-type diet for 12 weeks. The mice were subsequently 
sacrificed and the aorta and the aortic root were analyzed for the atherosclerotic 
burden. Atherosclerotic lesions were quantified in the aortic root of IL-17R-/- BM 
recipients (Figure 4.2B) and control transplanted mice (Figure 4.2A). In the  
IL-17R-/- BM recipients a significant reduction of 46% in plaque size was observed 
compared to the control group (Figure 4.2C; 245,000 ± 43,700 versus 454,000 ± 
91,200; P<0.05).  
 
FIGURE 4.2: IL-17R-/- BM RECIPIENTS DEMONSTRATE REDUCED LESION SIZE AT THE AORTIC ROOT. After 
BMT the mice were fed a Western-type diet for 12 weeks and were sacrificed. Cryosections of the aortic 
root of the control group (A) and the IL-17R-/- BM recipients (B) were made and subsequently stained 
for lipid with Oil-red-O. Within the IL-17R-/- BM recipients (open bar, N=10) there is a reduction of 46% 
in lesion size when compared to the control mice (closed bar, N=8) (C). *P<0.05 
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EFFECT OF IL-17R DEFICIENCY ON CHOLESTEROL LEVELS 
After the BMT we observed no difference in bodyweight between the IL-17R-/- BM 
recipients and control group (Figure 4.4A). The drop in weight during the first 
week is characteristic for bone marrow transplantation. In week 9 both groups of 
mice were put on a Western-type diet (0.25% cholesterol) to initiate atherosclerosis. 
During Western-type diet feeding serum cholesterol levels were determined and 
no significant difference was observed between mice which received IL-17R-/- and 
wild-type bone marrow (Figure 4.4B). 
 
FIGURE 4.4: BODYWEIGHT AND CHOLESTEROL LEVELS IN IL-17R-/- AND CONTROL BMT MICE. During the 
experiment the animal were weighted to study well being (A).  The mice were fed a Western-type diet 
and every three weeks blood samples were taken and cholesterol levels in the serum were determined 
(B). 
PLAQUE COMPOSITION IS ALTERED AFTER IL-17R-/- BMT 
IL-17R signaling is involved in the regulation of different MMP's24 and recruitment 
of polymorphonuclear leukocytes.25 Therefore we assessed whether a bone marrow 
transplantation with IL-17R-/- BM affected morphological parameters and 
composition within the lesions in the aortic root. To assess the collagen content and 
thus stability of the plaque, a Masson trichrome staining was performed. The 
collagen content within the lesion was not altered in IL-17R-/- BM recipient mice 
compared to control mice, indicating that the plaque stability is not affected 
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(Figure 4.5A; 0.12 ± 0.04 versus 0.14 ± 0.03, P=0.63). To examine the number of 
macrophages in the lesion, a MoMa-2 staining was performed. Interestingly, we 
observed a 25 % increase in macrophage content within the plaque of mice which 
received IL-17R-/- BM compared to control mice (Figure 4.5B; 0.32 ± 0.02 versus 0.43 
± 0.03, P=0.01). There was no significant difference in neutrophils content between 
the control group and the IL-17R-/- BM recipients (Figure 4.5C; 2.14 ± 0.63 versus 
1.14 ± 0.36, P=0.29). Interestingly, IL-17R-/- BM recipients demonstrated a 43.8% 
reduction in the number of mast cells as determined by toluidin blue staining in 
the aortic root section when compared to controls (Figure 4.5D; 4.18 ± 0.96 versus 
7.45 ± 1.20, P<0.05) 
 
FIGURE 4.5: COMPOSITION OF PLAQUE IN THE AORTIC ROOT IN IL-17R-/- BM RECIPIENT AND CONTROL 
MICE. Cryosections of the aortic root of control mice (open bars) and IL-17R-/- BM recipients (closed 
bars) were stained. There is no difference in collagen content within the plaque (A). The relative 
macrophage within the intima is significantly increased in the IL-17R-/- BM recipients (B). The amount 
of neutrophils within the plaque does not change in the IL-17R-/- BM recipient mice (C). Mast cells were 
significantly reduced in the IL-17R-/- BM recipient mice (D). *P<0.05  
REDUCTION OF IL-17R+ B CELLS AND REDUCED LEVELS OF AUTOANTIBODIES IN  
IL-17R-/- BM RECIPIENTS 
Recently, the role of IL-17R expressing B cells is described in relation to germinal 
center (GC) activity and spontaneous development of antibody mediated 
autoimmunity.26 As the IL-17R-/- BM recipients have reduced IL-17R expressing B 
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cells in the lymphoid organs (Figure 4.6A-C), we studied the effect thereof on the 
formation of oxLDL specific autoantibodies. We observed a significant reduction of 
33% in IgG antibodies directed against oxLDL in serum of mice that had received 
bone marrow from IL-17R deficient donors (Figure 4.6B, P<0.05). 
 
 
 
 
FIGURE 4.6: REDUCED IL-17R+ B CELLS AND REDUCED AUTOANTIBODIES AGAINST OXLDL IN IL-17R-/- BM 
RECIPIENT MICE. Single cell suspensions of lymphoid organs of control mice (white bars) and IL-17R-/- 
BM recipient mice (black bars ) was obtained and stained for CD19 and IL17R and subsequent analyzed 
with a FACS machine. Within the spleen (A), MLN (B) and HLN (C) there is a significant decrease in IL-
17R expressing B cells. The serum of control mice (open bars) and IL-17R-/- BM recipient mice (closed 
bars) was used for detection of antibodies directed against oxLDL (D). The level of total IgG 
autoantigens was significant lower in IL-17R-/- BM recipient mice. *P<0.05 
 
DOWNSTREAM SIGNALING OF IL-17 IS IMPAIRED IN IL-17R-/- BM  
IL-17 is involved in the activation of the immune system and therefore we wanted 
to study the effect of IL-17R deficiency on the production of interleukins by 
lymphoid cells. First we studied IL-6, a prominent downstream effector product of 
IL-17 signaling.9 We assessed IL-6 production with an ELISA on supernatant of α-
CD28 and α-CD3 activated cells from several lymphoid organs. The IL-6 
production dropped 66% in the spleen of IL-17R-/- BM recipients compared to 
control (Figure 4.7A; 215.17 ± 114.60 versus 635.5 ± 148.22 pg/ml, P<0.05), whereas 
there was no significant change detected in the MLN, HLN and PBMCs. 
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FIGURE 4.7: CYTOKINE PROFILE IS CHANGED IN IL-17R-/- RECIPIENT MICE. The spleen, HLN, MLN and 
PBMCs of control mice (open bars) and IL-17R-/- BM recipient mice (closed bars) were removed. Ex vivo 
stimulated lymphoid cells were used to analyze the cytokine production with an ELISA. The IL-6 
expression is decreased in spleen cells of IL-17R-/- recipient mice (A). IL-10 was significant induced in 
HLN and PBMCs of IL-17R-/- recipient mice(B) *P<0.05, **P<0.01 
 
Furthermore, we determined IL-10 production with an ELISA on activated 
lymphoid cells from different lymphoid organs. Interestingly, we observed a very 
significant increase in IL-10 expression of 24.61% in HLN and an increase of 28.28% 
in PBMCs in IL-17R-/- BM recipients (Figure 4.7B: HLN, 449.33 ± 15.20 versus 
596.00 ± 10.54, P<0.01; PBMCs, 473.33 ± 16.14 versus 660.00 ± 50.71, P<0.01). 
However, within the spleen and MLN IL-10 production was not changed. 
 
DISCUSSION 
The receptor for IL-17 (IL-17R) is a type I transmembrane protein that is 
ubiquitously expressed in the body.9 IL-17 exhibits pleiotropic biological actions on 
various atheroma-associated cell types, such as endothelial cells, vascular smooth 
muscle cells and macrophages.16, 17, 24 Upon activation by IL-17 these cells produce 
pro-inflammatory cytokines, chemokines and matrix metalloproteinases (MMPs), 
including TNF-α, IL-1β, IL-6, CXCL8, CCL2 and MMP-9.18-20, 24 Although, IL-17 is 
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considered to be an important interleukin in several autoimmune diseases, 
research on the role of IL-17 in atherosclerosis is limited.  
To investigate the role of IL-17 signaling in atherosclerosis, we performed a 
BMT with IL-17R-/- donor bone marrow into LDLr-/- recipients and evaluated the 
effect thereof on atherosclerosis after 12 weeks of Western-type diet. First, we 
verified whether the BMT was successful in replacing BM cells. We therefore 
analyzed the expression of IL-17R in the spleen with qPCR and observed a large 
reduction in IL-17R expression in IL-17R-/- transplanted mice. Furthermore, we 
analysed IL-17R expression with FACS analysis in PBMCs. We observed a large 
reduction of 85% in IL-17R expressing cells in the PBMCs, indicating that the BMT 
with IL-17R-/- bone marrow was successful and cells were effectively replaced by 
donor IL-17R-/- bone marrow. The reduction in IL-17R was further specified to 
macrophages, were we observed a reduction of 84% in the expression of the IL-
17R. This finding is in line with previous bone marrow transplantation 
experiments in our laboratory, for example with CCR2 deficient bone marrow. 27 
Next, we studied the effect of IL-17R deficiency on atherosclerosis. We 
observed a striking reduction in plaque size within the aortic valve region. This 
effect was independent of cholesterol levels and bodyweight as these parameters 
were unchanged between the IL-17R-/- transplanted and control transplanted mice. 
IL-17 signaling is involved in the regulation of different MMPs.24 Therefore we 
studied plaque stability, since MMPs, such as MMP-9, are well-known for their 
plaque destabilizing potential.19 We did however not detect any changes in 
collagen content, a marker for plaque stability, within the lesion. It should be noted 
that MMPs are also produced by smooth muscle cells and these cells are not 
(effectively) replaced by IL-17R-/- deficient bone marrow cells. Therefore, smooth 
muscle cells still expres the IL-17R and are thus responsive to IL-17 within the 
lesion.  
Interestingly, we observed an increase in relative macrophage content 
within the plaque of IL-17R-/- transplanted mice, which is in agreement with the 
decreased lesion size, as more initial plaques show a higher proportion of 
macrophages.28 The macrophages within the plaque are likely to be IL-17R 
deficient and thus not, or to a lesser extent, responding to IL-17 within the plaque. 
This impaired IL-17 signaling pathway may lead to a diminished production of 
pro-inflammatory interleukins, chemokines and proteinases, which have been 
implicated in lesion growth and destabilization. Furthermore, we observed a 
significant reduction in mast cells within the lesion of the IL-17R-/- BM recipients. 
Mast cells are more prominent in advanced stages of atherosclerotic plaque 
development, so their reduced presence do agree with the less advanced stage of 
lesion formation in the IL-17R-/- BM recipients.29,30, 31 IL-17 is able to induce the 
production of eotoxin-1 (CCL11), which is an important chemoattractant for mast 
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cells and is detected in atherosclerotic lesions.32, 33 IL-17R-/- BM recipients have an 
impaired IL-17 signaling and thus the eotoxin signaling may also be impaired, 
leading to the decreased number of mast cells within the atherosclerotic plaque in 
the IL-17R-/- transplanted mice. In contrast to the mast cells, we did not observe 
any change in neutrophil count within the plaque of IL-17R-/- BM recipients. This is 
surprising as IL-17 is involved in CXCL-1 mediated neutrophil recruitment.34 
However, neutrophils are normally observed in very low numbers within the 
atherosclerotic lesion in the aortic valve.  
Impairment in IL-17 signaling may also affect the general inflammatory 
status, since IL-17 is involved in bridging the innate and adaptive immune 
response.2, 35 We determined the expression of IL-6 and IL-10. IL-6 is a 
proinflammatory cytokine that provokes a broad range of cellular and 
physiological responses and was one of the earliest defined IL-17 induced target 
genes.3, 9 Indeed, within the spleens of IL-17R-/- BM recipients we observed a lower 
expression of IL-6. Interestingly, IL-10 expression is significantly increased in IL-
17R-/- BM recipients. IL-10 is known to reduce atherosclerosis in LDLr-/- mice upon 
overexpression.36-38  
Recently, Hsu et al suggested that IL-17 may result in spontaneous 
generation of autoreactive GCs as IL-17 increases the retention of B cells within the 
GCs through modulation of the activity of the Regulators of G-protein signaling 
(RGS) genes.26 In the spleens of mice transplanted with IL-17R-/- bone marrow, a 
reduction in IL-17R ecpressing B cells paralleled a reduction in anti-oxLDL IgG 
antibodies which is in line with the hypothesis of Hsu et al. Increased IgG 
autoantibodies against oxLDL are associated with a larger atherosclerotic burden, 
therefore this may provide an additional explanation for the reduced lesion size in 
the IL-17R-/- BM recipients.  
The IL-17R signaling is an interesting target for clinical applications to 
modulate the immune response in atherosclerosis. IL-17 forms a bridge between 
the innate and adaptive immune response and plays a crucial role in the 
progression from acute to chronic inflammation.2 In our laboratory we blocked IL-
17 via DNA vaccination, which resulted in a decreased atherogenesis in LDLr-/- 
mice.39 Furthermore, Th17 cells, profound producers of IL-17, have been identified 
in patients with acute coronary syndrome, underlining the potential role of IL-17 in 
atherosclerosis.40  
In conclusion, we demonstrate that an impaired IL-17R signaling results in 
less atherosclerosis, indicating an aggravating role for IL-17 in this disease. 
Therapies interfering in the IL-17 pathway may provide a newly explored 
treatment against atherosclerosis.  
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ABSTRACT 
Interleukin 23 (IL-23) has been associated with several autoimmune diseases. IL-23 
is a heterodimeric interleukin consisting of a p19 subunit and a p40 subunit, which 
is shared with IL-12. Previous studies in which p40 was neutralized indicate a 
possible role for IL-23 in atherosclerosis. 
To study the role of IL-23 in atherosclerosis, a bone marrow 
transplantation with p19 deficient bone marrow into LDL receptor deficient mice 
was performed and atherosclerosis was assessed after feeding a cholesterol rich 
diet. 
The degree of atherosclerosis was similar in mice transplanted with p19 
deficient bone marrow compared to mice receiving wild-type bone marrow. 
Furthermore, no change in IL-17 producing T cells and Tregs was observed. The 
expression of p40, p35 and p19 was not changed in the spleen of p19 deficient bone 
marrow transplanted mice, although bone marrow transplantation was successful.  
A bone marrow transplantation with p19 deficient bone marrow in LDL 
receptor deficient mice does not affect atherosclerotic lesion formation, possibly 
because of the contribution of non-bone marrow derived cells to the production of 
IL-23.  
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INTRODUCTION 
Since atherosclerosis is considered as an inflammatory disease, much research has 
been done to illuminate the contribution of different components of the immune 
system in atherosclerosis. In atherosclerosis, T cells and macrophages play an 
important role in bridging the innate and adaptive immune response and are able 
to exert pro- and anti-atherosclerotic properties.1-3 Within the atherosclerotic lesion 
and lymph nodes that drain from the lesions, macrophages and dendritic cells are 
capable to present antigens to T cells, thereby inducing an adaptive immune 
response. These antigen presenting cells have a pivotal role in immune regulation 
as they produce several cytokines and chemokines to “direct” the immune system 
to the appropriate immune response. An important cytokine in this process is 
interleukin (IL)-23, which is a heterodimeric interleukin consisting of a p40 and a 
p19 subunit. IL-23 is a close family member of IL-12 as they both share the p40 
subunit.4 
The receptor of IL-23 consists of a heterodimeric complex consisting of IL-
12Rβ1, which is shared with the IL-12 receptor and a unique IL-23R. The IL-23R 
shares many features with IL-12Rβ2, which is the other part of the IL-12 receptor. 
However, IL-23 induces a strong phosphorylation of Stat3 and a weak activation of 
Stat4, as for IL-12 the opposite is true, thereby explaining the different effect of 
these cytokines.4, 5 Furthermore, the IL-23R is mainly expressed on effector T cells 
and not on naive T cells, suggesting an important role of IL-23 in ongoing 
inflammation.4, 6 The expression of the IL-23R is also detected in human NK cells, 
murine bone marrow derived DCs and activated macrophages.4, 6 
IL-23 is mainly expressed by macrophages and dendritic cells and p19 is 
dependent on the expression of p40 in the same cell in order to be functionally 
excreted as IL-23.4 An important function for IL-23 was recently discovered by 
Langrish et al., where IL-23 is associated with the expansion of the IL-17-producing 
Th17 cells.7 Furthermore, p19-deficient animals do not develop IL-17-producing T 
cells and are protected from EAE.8 Moreover, in patients with Crohn’s disease a 
single nucleotide polymorphism (SNP) in the coding sequence of IL-23R results in 
a strong protection against this disease, indicating a pathogenic role of IL-23 in 
chronic inflammation.9 Besides the effect of IL-23 on Th17 cells, IL-23 also induces 
the production of IL-1β and TNFα by peritoneal macrophages, which occurred 
even in the presence of neutralizing antibodies to IFN-γ, thereby suggesting that 
these effects are independent from Th1 cells.8  
In our laboratory, we already demonstrated that vaccination against p40 
(IL-12/IL-23) results in a reduction of almost 70% in atherosclerotic lesion 
formation.10 However, p40 is shared by both IL-12 and IL-23 and consequently, it is 
not possible to elucidate the relative contribution of IL-12 and IL-23 in 
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atherosclerosis. Since IL-23 is involved in the development of Th17 cells and IL-17 
has been associated with aggravated atherosclerosis (van Es et al., unpublished 
results), studies into the role of IL-23 in atherosclerosis are of even more interest. 
We now show that a bone marrow transplantation with p19 deficient bone 
marrow into LDL receptor deficient mice did not affect lesion formation. More 
research should be performed with LDLr and p19 double knock outs to exclude the 
p19 expression by radiant resistant cells to  further elucidate the role of IL-23 in 
atherosclerosis. 
 
METHODS 
ANIMALS 
All animal work was approved by Leiden University and was in compliance with 
the Dutch government guidelines. LDL receptor deficient (LDLr-/-) mice were 
purchased from Jackson Laboratories. IL-23-p19 knockout mice were a kind gift 
from E. Lubberts and were created by Ghilardi et al. 11 The mice were kept under 
standard laboratory conditions and food and water were provided ad libitum. 
 
BONE MARROW TRANSPLANTATION AND INDUCTION OF HYPERCHOLESTEROLEMIA 
Male LDLr–/– mice were lethally irradiated by a single dose of 9 Gy (0.19 Gy/min, 
200 kV, 4 mA) total body irradiation, using an Andrex Smart 225 Röntgen source 
(YXLON Int, Copenhagen, Denmark) with a 6-mm aluminium filter. Bone marrow 
was isolated by flushing the femurs and tibias from mice with phosphate-buffered 
saline (PBS). Single-cell suspensions were prepared by passing the cells through a 
30-µm nylon gauze. Irradiated recipients received 0.5x107 bone marrow cells by 
intravenous injection into the tail vein. Some bone marrow was stored at -80 oC, 
which was used for genotyping as described later on. After a recovery of 8 weeks 
animals received a Western-type diet ad libitum containing 15% cocoa butter and 
0.25% cholesterol (Special Diet Services, Witham, Essex, UK) for 12 weeks. During 
the experiment the mice were weighted every week and checked for well-being 
and every 3 weeks the serum cholesterol levels were determined to assess the effect 
of the Western-type diet. Blood samples were collected by tail bleeding from non-
fasting animals. Total cholesterol levels were quantified spectrophotometrically 
using an enzymatic procedure (Roche Diagnostics, Germany). Precipath 
standardized serum (Boehringer, Germany) was used as an internal standard. 
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GENOTYPING THE BONE MARROW AFTER BONE MARROW TRANSPLANTATION 
After sacrificing the donor animals the bone marrow was isolated by flushing the 
femurs from mice with PBS. Genomic DNA was isolated by incubating with lysis 
buffer (25 mm NaOH, 0.2 mM EDTA, pH=12) for 20 minutes at 99°C. Subsequently 
100 µl neutralization buffer (40 mM TRIS HCl, pH=5) was added. A PCR was 
performed with the following primers: antisense primer (5'-GCC TGG GCT CAC 
TTT TTC TG-3'), wild type-specific (5'-GCG TGA AGG GCA AGG ACA CC-3') and 
knockout-specific (5'-AGG GGG AGG ATT GGG AAG AC-3') sense primers. This 
primer-triplet amplifies a 210-bp fragment for the wild-type allele and a 289-bp 
fragment for the mutant allele. 
 
HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
Mice were anaesthetized with ketamine-hypnorm and perfused with PBS and 
subsequently with FormalFixx. The heart and complete aorta were removed. The 
heart was embedded in OCT compound (TissueTek, Sakura Finetek, The 
Netherlands) and cryosections of 10 µm were made of the aortic root containing 
the aortic valves. Cryosections were routinely stained with Oil-Red-O and 
hematoxylin (Sigma Diagnostics, MO). Corresponding sections on separate slides 
were stained immunohistochemically for macrophages using an antibody against a 
macrophage-specific antigen (MoMa-2, Research Diagnostics Inc.) and for collagen 
using Masson trichrome staining according to manufacturers protocol (Sigma 
Diagnostics. The different histological stainings were quantified using a Leica DM-
RE microscope and Leica Qwin Imaging software (Leica Ltd., Germany). The 
complete aorta was longitudinally cut open and subsequently stained for lipids 
with Oil-Red-O. The aortas were en face fixated and high resolution pictures were 
taken and the plaque was quantified using Leica Qwin imaging software (Leica 
Ltd., Germany). 
 
QPCR ON SPLEEN SAMPLES 
Total RNA was isolated using guanidium isothiocyanate (GTC) method and 
reverse transcribed to cDNA (RevertAidTM M-MuLV reverse transcriptase, 
Fermentas). Gene expression was analyzed with an ABI PRISM 7700 (Applied 
Biosystems, Foster city, CA) using SYBR Green technology and a final primer 
concentration of 300 nM. Primer pairs as described in table 5.1 were used to 
quantify IL-17, IL-10, IL-6 and IL-4 gene expression. As an internal standard 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used. The samples 
were analyzed on an ABI Prism® 7700 sequence detector (Applied Biosystems). 
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TABLE 5.1: SEQUENCE OF PRIMERS. Primer sequences for the genes analyzed with qPCR.  
 
STATISTICAL ANALYSIS 
All data are expressed as mean ± SEM. The two-tailed student’s t-test was used to 
compare individual groups of mice or cells. When indicated the data was analyzed 
with linear mixed model analysis. P values of <0.05 were considered significant. 
 
RESULTS  
BONE MARROW OF RECIPIENTS IS REPLACED WITH DONOR BONE MARROW 
The mice were sacrificed after 12 weeks of feeding a Western-type diet and a PCR 
on genomic DNA of the BM of the recipients was performed. We also analyzed the 
donor BM, which served as a positive control (Figure 5.1, lane 6 and 12). In the 
p19-/- BM recipients we observed a PCR fragment corresponding with the knock 
out genotype (Figure 5.1 , lane 7-11). PCR on the mice that received wild-type BM 
resulted in a smaller fragment, corresponding with the wild-type p19 genotype 
(Figure 5.1 A, lane 1-5), indicating that the BMT was successful. 
 
SERUM CHOLESTEROL LEVELS ARE INCREASED IN P19-/- BM RECIPIENTS 
During the experiment the mice were weighted. There was no difference observed 
between the p19-/- transplanted mice and control (Figure 5.2A). During Western-
type diet feeding serum cholesterol was determined and we observed a significant 
higher level in total serum cholesterol level in p19-/- BM recipients during the 
experiment (Figure 5.2B; 48% on week 3, 23% on week 6, 33% on week 9 and 44 % 
on week 12 on Western-type diet. P<0.01). 
 
GENE FORWARD PRIMER REVERSE PRIMER 
IL-17 5’-GAAACATGGTTGATGACTCCAAA-3’ 5’-CTCCACAGAGGGGGTGGT-3’ 
IL-10 5’-TCCCCTGTGAAAATAAGAGCA-3’ 5’-ATGCAGTTGATGAAGATGTCAAA-3’ 
IL-6 5’-GAAGAATTTCTAAAAGTCACTTTGAGATCTAC-3’ 5’-CACAGTGAGGAATGTCCACAAAC-3’ 
IL-4 5’-ACTTGAGAGAGATCATCGGCATTT-3’ 5’-AGCACCTTGGAAGCCCTACAG-3’ 
HPRT 5’-TTGCTCGAGATGTCATGAAGGA-3’ 5’-AGCAGGTCAGCAAAGAACTTATAG-3’ 
                            BMT with p19-/- bone marrow does not alter the atherosclerotic burden in LDLr-/- mice  
 
103 
5 
 
 
 
FIGURE 5.1: BONE MARROW OF RECIPIENTS IS REPLACED WITH DONOR BONE MARROW. After the mice 
were sacrificed, the bone marrow was flushed out of the femurs and genomic DNA of control mice 
(lanes 1-5) and p19-/- BM recipients (lanes 7-11) was isolated and a PCR was performed to amplify the 
wild type or p19-/- gene. In lane 6 and 12 Genomic DNA was isolated from BM of wild type (lane 6) and 
p19-/- donor mice (lane 12) and served as a positive control.  
 
 
 
Figure 5.2: Bodyweight and serum cholesterol levels in p19-/- BM recipients. During the experiment 
the mice were weighted every week to determine the well-being of the mice (A, N=13-15). Every three 
weeks, blood was taken via tail vein bleeding and the serum cholesterol levels were determined using 
an enzymatic procedure (B, N=13-15). A linear mixed model analysis was used to analyze the results. 
*P<0.05 
PLAQUE SIZE AND STABILITY IS NOT CHANGED IN P19-/- BM RECIPIENT MICE 
To determine the effect of p19-/- BMT in atherosclerosis, the mice were fed a 
Western-type diet for 12 weeks after recovery from BMT. The level of 
atherosclerosis in the aortic root within the control group was not significantly 
different from the p19-/- BM recipients (Figure 5.3 A-C, P=0.28). In addition, we 
observed no difference in plaque size in the entire aorta between wild type and 
p19-/- BM transplanted mice (Figure 5.3 D-F, P=0.11). Furthermore, we analyzed 
plaque stability in the aortic root by determining the collagen content of the 
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plaque. However, we did not observe any difference between the control mice and 
p19-/- BM recipients (Figure 5.4 A-C, P=0.55). 
 
EXPRESSION OF P40, P35 AND P19 IS NOT CHANGED WITHIN THE SPLEEN 
To study whether the expression of the subunits of IL-12 and IL-23 was affected by 
the bone marrow transplantation, a qPCR analysis was performed on mRNA for 
the various subunits in spleen cells. The expression of the IL-23 subunit p19 was 
determined (Figure 5.5A) and surprisingly, we did not observe any difference in 
p19 expression between the groups. Furthermore, when we analyzed the 
expression of p40, a subunit shared with IL-12, and p35, the other subunit of IL-12, 
there were no differences observed. The mRNA expression of IL-10, IL-17, IL-6 and 
IL-4 was also determined in the spleen (Figure 5.5B). The expression of IL-10 was 
76% decreased, IL-17 was 66% decreased, IL-6 was 87% decreased and IL-4 was 
64% decreased in the p19-/- transplanted mice, indicating a change in the 
inflammatory status in these mice. 
 
 
 
Figure 5.3: Plaque size is not changed in p19-/- BM recipient mice. After the mice were sacrificed hearts 
were removed and cryosections of the aortic root were made of the control mice (A, N=13) and the p19-
/- BM recipients (B, N=12) and subsequently stained for Oil-red-O and the lesions were quantified (C). 
The aorta was also removed from control mice (D, N=13) and p19-/- BM recipients (E, N=12) and stained 
with Oil-Red-O staining and quantified (F).  
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Figure 5.4: Collagen content of the atherosclerotic lesion is not changed.  After the mice were 
sacrificed hearts were removed and cryosections of the aortic root were made. For collagen detection, 
cryosections of the aortic root of the control mice (A, N=12) and p19-/- BM recipient mice (B, N=12) were 
stained with a Masson’s trichrome staining and the relative collagen amount in the plaque was 
quantified (C). 
 
 
Figure 5.5: Effect of p19-/- BMT on the expression of interleukins in the spleen. Spleens were 
dissected and mRNA was isolated and subsequently reverse transcribed into cDNA. Expression of p40, 
p35 and p19 was determined with qPCR (A, N=9-13). Furthermore, the expression of IL-10, IL-17, IL-6 
and IL-4 was also assed within the spleen with qPCR and are depicted relative to the expression in the 
control mice. (B, N=9-13) *P<0.05, **P<0.01 
 
DISCUSSION 
IL-23 has been associated with several autoimmune diseases.7, 8, 12 
Immunization against p40, which is shared by both IL-12 and IL-23, resulted in a 
reduction of almost 70% in atherosclerotic lesion formation.10 Together with the 
relation between IL-23 and the development of Th17 cells, this interleukin is an 
interesting subject to study in relation to autoimmune diseases, such as 
atherosclerosis.7 Therefore we performed a BMT with BM of p19 deficient mice 
into LDLr deficient mice to study the role of IL-23 in atherosclerosis.  
To determine the efficacy of the BMT, a genotyping was performed on the 
BM in p19-/-  BM and wild type BM transplanted mice. Within the wild type 
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recipients we detected the wild type p19 gene and the p19-/- recipients 
demonstrated a knockout fragment. This indicates after irradiation and subsequent 
BMT, the BM is replaced with the donor BM.  
Surprisingly, already after 3 weeks of Western-type (11 weeks after the 
BMT) diet the serum cholesterol levels were 48% increased in the p19-/- recipient 
group and remained significantly higher throughout the experiment. However, 
little is known about IL-23 in relation with cholesterol metabolism and this remains 
to be investigated.  
Since the dramatic reduction in lesion size upon IL-12 vaccination we 
expected a reduction in lesion size upon p19-/- BMT. However, we did not observe 
any difference in atherosclerotic lesion size between p19-/- BM recipient and 
control mice. Dubin et al. demonstrated that p19-/- mice have reduced matrix 
metalloproteinase-9 (MMP-9).13 MMP-9 is associated with atherosclerotic plaque 
stability14 and therefore the collagen content was assessed as a marker for plaque 
stability. However there was no difference in collagen content detected between 
the groups, which indicate that p19 deficiency does not affect plaque stability. 
These data are surprising, since Hauer et al. demonstrated that vaccination against 
p40 (IL-12/IL-23) resulted in a reduction of almost 70% in atherosclerotic lesion 
formation.10 Furthermore, Hauer et al. also demonstrated an increase in plaque 
stability.10 Neither of these events is observed in p19-/- BM recipients. This may 
suggest that IL-23 is not involved in initial atherosclerosis and that the reduction 
seen with p40 vaccination is mediated via a reduction in IL-12.  
Within the spleen we determined the expression of the subunits p40, p35 
and p19. Interestingly, none of the subunits displayed an altered expression level 
after p19-/- BMT, indicating that the spleen is still capable of expressing IL-12 and 
IL-23. This may suggest another source of p19, besides bone marrow derived cells. 
An unpublished report of S. Pflanz and R.A. Kastelein demonstrates a heterodimer 
consisting of p19 and EBI3 in vitro.6 Whether these heterodimers may be formed in 
vivo and what function this new interleukin has and by which cell type(s) it is 
expressed remains to be elucidated. 
Together with the observation that T cells are able to express p19 (E. 
Lubberts, personal communication) it may be suggested that not only bone 
marrow derived antigen presenting cells express p19 to form IL-23. Furthermore 
p19 may also be expressed by radiant resistant cells (including T cells) within the 
spleen. Whether this resulted in functional IL-23 remains to be determined using 
intracellular FACS analysis. These data may explain the fact that we do not observe 
any change in atherosclerotic parameters. 
However, when we assessed the expression of IL-6, IL-17, IL-10 and IL-4 
expression we observed a reduction in gene expression in p19-/- BM recipient mice. 
This indicated that there is a change in the inflammatory status of p19-/- BM 
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recipient mice. A decrease in IL-10 may be causative for the elevated serum 
cholesterol level in p19-/- BM recipients, since it has been demonstrated that IL-10 
may reduce cholesterol levels.15  
Although atherosclerosis is considered an autoimmune disease with many 
similarities with other autoimmune diseases, there may be differences in the 
involvement of the immune system in the pathogenesis of different autoimmune 
diseases. Recently, Mangino et al. demonstrated that there is no relation between 
several polymorphisms of p19 and IL-23R genes and a myocardial infarction.16 
This study indicates that the role of IL-23 in atherosclerosis may be distinct from 
other autoimmune diseases. 
In conclusion, we demonstrate that a BMT with p19-/- BM in LDLr deficient 
mice does not result in an alteration in atherosclerosis. Conclusions on the role of 
IL-23 are however hard to draw since we still observed p19 expression in the 
spleens of mice receiving p19-/- bone marrow, indicating that non-bone marrow 
derived cells contribute in vivo to the production of IL-23. To definitively 
determine the role of IL-23 in atherosclerosis, we will have to generate p19 and 
LDL receptor double knockout mice and investigate the effects on atherosclerosis. 
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ABSTRACT 
Interleukin 27 (IL-27) is a heterodimeric cytokine consisting of p28 and EBI3. It has 
opposing effects on a number of lymphoid and non-lymphoid cell types and is 
related to the IL-12, IL-23 and IL-6 family, which are associated with 
atherosclerosis. We now studied the expression of both the subunits of IL-27, p28 
and EBI3, during atherosclerosis and studied the role of IL-27 in atherosclerosis by 
vaccinating LDLr-/- mice against the p28 subunit of IL-27 using a DNA vaccine.  
During atherosclerosis, we observed an increase in the expression of both 
subunits of IL-27 in the atherosclerotic lesion. Vaccination against the p28 subunit 
of IL-27 led to a significant increase in lesions size in the carotid artery and in the 
aorta as assessed by en face staining, but did not significantly affect lesion size in 
the aortic root. Atherosclerotic plaque composition within carotid artery and the 
aortic root was not affected by vaccination against p28. FACS analysis of the spleen 
demonstrated an increase in the Th17 population and a decreased Treg population. 
Furthermore, a significant reduction in B cells was observed within the spleen.  
We conclude that both subunits of IL-27 are upregulated in initial 
atherosclerosis and the results on vaccination against IL-27 suggest that IL-27 has 
anti-atherosclerotic properties. From this data we propose that IL-27 may be used 
as therapeuticum to treat atherosclerosis. 
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INTRODUCTION 
Atherosclerosis is an inflammatory disease of the vessel wall, which progresses in 
the context of high plasma cholesterol levels.1 Accumulation of inflammatory cells 
within the lesion results in a complex auto-immune like disease, which results in a 
destabilized and ultimately ruptured lesion, leading to cardiovascular 
complications.2 The innate immune response and the subsequent adaptive immune 
response, illustrated by the differentiation of naïve T cells into effector T cells plays 
an important role in the process of atherosclerosis.2  
The recently discovered interleukin IL-27 is a cytokine that shows 
structural resemblance with IL-12 and IL-23 and IL-27 affects T cell function and 
cytokine production.3 IL-27 is a heterodimeric cytokine composed of Epstein-Barr 
virus induced gene 3 (EBI3) and p28. IL-27 is produced by activated antigen 
presenting cells (APCs), as well as resident macrophages, early in the immune 
response against pathogens such as, Mycobacteria tuberculosis, Trichuris muris, and 
Toxoplasma gondi.4-6 The IL-27 subunit p28 is poorly secreted unless it is co-
expressed with its partner EBI3, thus creating a situation where expression of IL-27 
can be tightly controlled during an immune response by regulating the 
transcription of both subunits.4 IL-27 exerts its effects via the IL-27 receptor, a 
complex of gp130 and the novel IL-27R (also designated as WSX-1 or TCCR) and 
the heterodimeric IL-27 receptor is mainly expressed by lymphocytes but 
expression on monocytes is also reported.7 
Initially, IL-27 was assigned to have proinflammatory properties, 
illustrated by studies performed in the group of Goldberg et al. They demonstrate 
that vaccination against p28 suppresses experimental autoimmune 
encephalomyelitis (EAE) and adjuvant induced arthritis, suggesting a 
proinflammatory role for IL-27 in these autoimmune diseases.8, 9 However, recent 
studies show a more complex role for IL-27. For example, IL-27 suppresses the 
development of the pro-inflammatory T helper cell, the Th17 cell, in EAE models 
and thereby attenuates the disease.4, 10, 11 Furthermore, IL-27 also inhibits the 
development of regulatory T (Treg) cells and Th2 cells.12, 13 This divergent effect of 
IL-27 on T cell populations was explained by Yoshimura et al., who proposed that 
IL-27 stimulates Signal Transducers and Activator of Transcription (STAT)1 and 
STAT3 in naive Th cells and only STAT3 in activated Th cells, thereby enabling IL-
27 to exert a stimulating effect on naive cells and an inhibiting effect on  
effector T cells.14 
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The role of IL-27 in atherosclerosis is to our knowledge not yet 
investigated. Since IL-27 affects T cell development and may specifically affect 
regulatory T cell function, we vaccinated LDLr-/- mice against the p28 subunit of 
IL-27. We observed a strong increase in atherosclerosis, which may suggest a 
protective role for IL-27 in the context of atherosclerosis. 
 
MATERIAL AND METHODS 
ANIMALS 
All animal work was approved by Leiden University and was in compliance with 
the Dutch government guidelines. Low-density lipoprotein receptor deficient 
(LDLr-/-) mice were purchased from Jackson Laboratories. The mice were kept 
under standard laboratory conditions and food and water were provided ad 
libitum. 
 
IN VITRO CYTOKINE PROFILE 
A spleen was dissected from a LDLr-/- mouse and a single cell suspension was 
obtained by passing the spleen through a 70 µm cell strainer (Falcon, The 
Netherlands). Spleen cells were subsequently incubated with erythrocyte lysis 
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Spleen cells were 
cultured in a 96-wells round bottom plate (2x105 cells per well), coated with anti-
CD28 and anti-CD3 (0.25 µg/well). Cells were cultured in RPMI supplemented 
with 10% FCS, 100 U/ml penicillin and 100 µg/ml streptomycin (all from 
BioWhittaker Europe). Where indicated cells were incubated with either: 0, 2.5 or 5 
ng/ml IL-27 (R&D sytems) for 48 hours. Supernatant of the cells was used for an 
IL-17 (OptEIA kit, PharMingen), IL-6 (eBioscience, Belgium), TGF-β1 (eBioscience, 
Belgium) and an IL-2 ELISA (ebioscience, Belgium) all according to manufacturer’s 
protocol. 
  
EXPRESSION OF P28 AND EBI3 IN ATHEROSCLEROSIS 
LDLr-/- mice were fed a Western-type diet, containing 0.25% cholesterol and 15% 
cocoa butter (Special Diet Services, UK) and after two weeks collars were placed 
around both carotid arteries and continued for 10 more weeks on Western-type 
diet. Mice were sacrificed at several time points on Western-type diet and at 
several times after collar placement. The carotid arteries were removed and total 
RNA was isolated and reversed transcribed as is described later on. Subsequently, 
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the expression of EBI3, p28 and CD86 was determined with qPCR relative to HPRT 
as described later on. Sequences of used primers are described in table 6.1.  
 
TABLE 6.1: SEQUENCE OF PRIMERS. Primer sequences for the genes analyzed with qPCR. 
  
CLONING OF THE PADRE-P28 VACCINE 
The amino acid sequence of PADRE was derived from the protein sequence: 
aKXVAAWTLKAAC (X=cyclohexylamin, a=R-Alanin) Cyclohexylamin was 
replaced with phenylalanine, which has the most resemblance. The R-Alanine was 
replaced with L-Alanine. The following nucleotide sequence was used for PADRE: 
5’-ATG GCT AAA TTT GTG GCT GCT TGG ACA CTT AAA GCT GCT GCT-3’ 
and subsequently cloned into the pcDNA3.1 with Nhe I and BamH I. The p28 
subunit of IL-27 (NM_145636) was amplified with a primer set with an additional 
BamH I recognition site at the N-terminus (5’-ATA TAT GGA TCC GGC CAG GTG 
ACA GGA GAC CT-3’) and an Acc65I recognition site at the C-terminus (5’-ATA 
TAT GGT ACC TTA GGA ATC CCA GGC TGA GC-3’, Genomic, Oligo-
eurogentech). The construct was used for transfection into DH5α (Invitrogen) 
according to the manufacturers protocol. The amplified plasmid was isolated with 
a Quickclean miniprep kit (Genescript Corp., USA) and sequenced. All sequences 
were analyzed with a BigDye terminator v3.1 cycle sequencing kit (Applied 
Bioscience) according to the manufacturer’s protocol and analyzed on an ABI-
Prism® 3100 Avant Genetic Analyzer (Applied Biosystems).  
Subsequently, COS7 cells were transfected with pcDNA3.1-PADRE-p28 
construct and pcDNA3.1-PADRE using Exgen500 according to manufacturer's 
protocol (Fermentas, Germany). Total RNA was isolated using guanidium 
isothiocyanate (GTC) method and reverse transcribed to cDNA (RevertAidTM M-
MuLV reverse transcriptase, Fermentas). P28 expression was analyzed with an ABI 
Gene Forward primer Reverse primer 
P28 5’-CACAGGCACCTCCGCTTT-3’ 5’-TTGGGATGACACCTGATTGG-3’ 
EBI3 5’-CCCGGACATCTTCTCTCTCA-3’ 5’-CAATACTTGGCATGGGGTTT-3’ 
CD68 5’-CCTCCACCCTCGCCTAGTC-3’ 5’-TTGGGTATAGGATTCGGATTTGA-3’ 
HPRT 5’-TTGCTCGAGATGTCATGAAGGA-3’ 5’-AGCAGGTCAGCAAAGAACTTATAG-3’ 
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PRISM 7700 (Applied Biosystems, Foster city, CA) using SYBR Green technology 
and a final primer concentration of 300 nM. 
 
VACCINATION AND INDUCTION OF ATHEROSCLEROSIS  
The DNA vaccine was isolated with an Endofree plasmid Giga kit (Qiagen, The 
Netherlands) from transfected DH5-α. Three days prior to the first vaccination, 
male LDLr-/- mice, 10-12 weeks old, received an intra muscular (i.m.) bilateral 
Cardiotoxin I (Sigma, USA) injection (10 µM, 50 µl per muscle). Mice were 
vaccinated by a total of three bilateral i.m. injections of 100 µg plasmid in 100 µl 
PBS, 50 µl per muscle, with two-week intervals. After the last vaccination mice 
were fed a Western-type diet. After two weeks of diet feeding, local atherosclerosis 
was induced within the carotid arteries by bilateral perivascular collar placement, 
as described previously.15 During the experiment plasma samples were obtained 
by tail vein bleeding for cholesterol measurements. Total cholesterol levels were 
quantified during the experiment using an enzymatic procedure (Roche 
Diagnostics, Germany) using Precipath as an internal standard.  
 
FACS ANALYSIS OF SPLEEN CELLS 
Spleens were dissected from the mice and single cell suspension was obtained by 
passing the spleen through a 70 µm cell strainer (Falcon, The Netherlands). Cells 
were stained with surface markers (0.20 µg antibody/300.000 cells) and 
subsequently analyzed by flow cytometric analysis. The following antibodies were 
used: CD4-FITC, CD25-APC, Foxp3-PE, CD19-FITC, CD62L-APC and IL-17-PE. All 
antibodies were purchased from eBioscience (Immunosource, Belgium). For the 
Th17 cell FACS analysis, the cells were incubated with Golgiplug (BD Bioscience) 
for 4 hours before the staining. All data were acquired on a FACScalibur and 
analyzed with CELLQuest software (BD Biosciences, The Netherlands). 
 
TISSUE HARVESTING 
Eight weeks after collar placement mice were sacrificed and carotid arteries were 
obtained after in situ perfusion for 15 minutes with Formalfixx. Carotid arteries 
were embedded in OCT compound (TissueTek, Sakura Finetek, The Netherlands), 
snap-frozen in liquid nitrogen and stored at -20 °C until further use. Transverse 5 
µm cryosections were prepared in a proximal direction from the carotid bifurcation 
and were mounted on a parallel series of slides. The heart was embedded in OCT 
compound (TissueTek; Sakura Finetek, The Netherlands) and cryosection of 10 µm 
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were made of the aortic root containing the aortic valves. The complete aorta was 
removed for en face analysis. 
 
HISTOLOGICAL ANALYSIS AND MORPHOMETRY 
Cryosections were routinely stained with hematoxylin (Sigma Aldrich, 
Zwijndrecht, The Netherlands) and eosin (Merck Diagnostica, Germany). 
Corresponding sections were stained for lipids by Oil-red-O staining. 
Hematoxylin-eosin. Corresponding sections on separate slides were stained 
immunohistochemically for macrophages using a macrophage-specific antigen 
(MoMa-2, Research Diagnostics Inc.) Collagen was stained with Masson’s 
trichrome staining according to manufacturer’s protocol (Sigma Diagnostics). 
Atherosclerosis in the aortic root was quantified with Oil-red-O stained sections of 
plaques developed in the region of the aortic semilunar valves. The complete aorta 
was longitudinally cut open and subsequently stained for lipids with Oil-Red-O. 
The aortas were en face fixated and high resolution pictures were taken and the 
lipid rich areas were quantified. All sections and images were analyzed with Leica 
Qwin software using a Leica DM-RE microscope.  
 
OXLDL ANTIBODY DETECTION 
Cu-oxLDL was synthesized as described previousely 16, 17. Antibodies against Cu-
oxLDL were determined according to Damoiseaux et al.18 MaxiSorp 96 wells plates 
(Nunc, Roskilde, Denmark) were coated overnight with 100 µg oxLDL in coating 
buffer (50 mM NaHCO3, 50 mM Na2CO3, pH=9.6) at 4 0C. IgM, IgG2a, IgG2b and 
IgG1 antibodies directed against oxLDL were detected with an isotype Ig detection 
kit according manufacturer’s protocol (Zymed lab. Inc., CA). 
 
STATISTICAL ANALYSIS 
All data are expressed as mean ± SEM. The two-tailed student’s t-test was used to 
compare individual groups of mice or cells. When indicated, a Mann-Whitney test 
was used to analyze not normally distributed data. P values of <0.05 were 
considered significant.  
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RESULTS  
IL-27 INHIBITS THE EXPRESSION OF SEVERAL CYTOKINES IN ACTIVATED SPLEEN CELLS. 
We determined the effect of IL-27 on the cytokine production in spleen cell cultures 
from LDLr-/- mice. A commonly used bioassay for IL-27 is its ability to inhibit IL-2 
production by activated T cells within the spleen.19 To that end, we used anti-CD3 
and anti-CD28 activated T cells from the spleen. We observed a rapid decline in IL-
2 expression when IL-27 was added and a low dose of IL-27 already optimally 
inhibited IL-2 production, confirming the results of Villarino et al.19 (Figure 6.1 A).  
IL-27 is recently associated with the regulation of Treg and Th17 cells.11, 12 
To study these T cell populations indirectly, we measured the production of IL-6 
(involved in Th17 proliferation, figure 6.1 B), IL-17 (the product of Th17 cells, 
figure 6.1 C) and TGF-β (a product of Tregs, figure 6.1 D). IL-17 and TGF-β showed 
a similar pattern as IL-2, as they were already effectively inhibited by low doses of 
IL-27. IL-6 production displays a different kinetic response to IL-27, as only the 
highest concentration IL-27 (5 ng/ml) resulted in a significant decline in IL-6 
production. 
EXPRESSION OF P28 AND EBI3 IS UPREGULATED IN ATHEROSCLEROTIC PLAQUES  
To determine whether the two subunits of IL-27 are induced in atherosclerotic 
lesions, we assessed the mRNA expression of the IL-27 subunits in the carotid 
artery. CD68 mRNA expression was performed to determine the macrophage 
content of the lesion. 
First, the effect of Western-type diet feeding alone was studied to 
determine diet-induced effects on IL-27 expression in the arterial wall without 
atherosclerotic lesions. No effect of the Western-type diet on the expression of both 
subunits of IL-27 in the arterial wall was observed, indicating that IL-27 is not 
induced upon hypercholesterolemia in the healthy vessel wall (Figure 6.2 A). 
Secondly, we studied the expression of IL-27 in carotid artery lesions. CD68 
expression increased after 2 weeks of collar placement, indicating the presence of 
macrophages in the carotid artery and thus of initial lesion formation (Figure 6.2 
B). The expression of p28 and EBI3 was significantly increased at 2 and 4 weeks 
after the induction of lesion formation, indicating a possible role for IL-27 in the 
initiation of atherosclerosis (Figure 6.2 B). These data demonstrate that p28 and 
EBI3 were both upregulated at the same time, indicating that EBI3 can form a 
hetero dimer with p28 leading to secretion of functional IL-27. 
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FIGURE 6.1: EFFECTS OF IL-27 ON CYTOKINE PRODUCTION OF ACTIVATED SPLEEN CELLS. Spleen cells were 
activated by plate-bound anti-CD3 and anti-CD28. Spleen cells were exposed to increasing levels of IL-
27 and incubated for 48 hours. Supernatant was analyzed for the expression of IL-2 (A, N=3), IL-6 (B, 
N=4), IL-17 (C, N=4) and TGF-β (D, N=3). **P<0.01, ***P<0.001 
 
CONSTRUCTION OF THE PADRE-P28 VACCINE 
Since both subunits of IL-27 are upregulated in early phases of atherosclerosis, we 
aimed to study the effect of IL-27 in vivo. Therefore we constructed a DNA vaccine 
against the p28 subunit in order to block the function of IL-27. The coding 
sequence of the p28 subunit was cloned into pcDNA3.1, an eukaryotic expression 
vector. The coding sequence was preceded by the sequence coding for a dominant 
Th cell epitope, PADRE, to break tolerance against the self-antigen p28.  
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FIGURE 6.2: EXPRESSION OF P28 AND EBI3 IN COLLAR INDUCED ATHEROSCLEROSIS. LDLr-/- mice were fed 
a Western type diet (WTD) and at the indicate time points carotid artery was removed and analyzed for 
gene expression of the indicated genes (A, N=2-4). After two weeks of Western-type diet, collars were 
placed around both carotid arteries and diet feeding was continued. Mice were sacrificed at the 
indicated time points as indicated on x-axis. mRNA was isolated and subsequently reverse transcribed 
into cDNA and the expression of the indicated genes was analyzed by qPCR (B, N=2-4). All genes are 
depicted relative to HPRT. *P<0.05 
 
FIGURE 6.3: PADRE-P28 EXPRESSION IN COS7 CELLS. COS7 cells were transfected with PBS, pcDNA3.1-
PADRE or pcDNA3.1-PADRE-p28 (N=3) and incubated 24 or 48 hour. mRNA was isolated and reverse 
transcribed into cDNA, subsequently, the expression of p28 was determined relative to HPRT. *P<0.05, 
**P<0.01. 
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Expression of the vaccine was assessed in vitro by transfecting COS7 cells 
with the PADRE-p28 plasmid. Cells were harvested after 24 or 48 hours of 
incubation and total RNA was isolated. Expression was determined using qPCR. 
At 24 hours a significant increase in p28 expression is observed, which continued 
to augment until 48 hours after transfection, whereas the PBS and control 
transfected cells do not express p28 at the indicated time points (Figure 6.3) 
VACCINATION AGAINST P28 AGGRAVATES ATHEROSCLEROSIS 
We studied the effect of p28 vaccination on de novo plaque formation in male  
LDLr-/- mice using a DNA vaccination strategy. Mice were vaccinated three times 
i.m. at a two-week interval with the PADRE-p28 or control (same plasmid without 
the p28 encoding region). After the third vaccination, the LDLr-/- mice were put on 
a Western type diet (0.25% cholesterol) to induce hypercholesterolemia. Two 
weeks later this was followed by collar placement around the carotid arteries. To 
study the consequence of p28 vaccination on serum cholesterol levels, we 
determined serum cholesterol levels after vaccination, but we did not observe any 
difference between PADRE-p28 vaccinated mice and control vaccinated mice (data 
not shown). 
Six weeks after collar placement mice were sacrificed and the plaque size 
in the carotid artery of control mice (Figure 6.4A) and p28 vaccinated mice (Figure 
6.4B) was quantified. Vaccination against p28 resulted in a significant 74.57% 
increase in atherosclerotic lesion size compared to control vaccination (Figure 6.4C; 
36,610±8,568 µm2 (control vaccinated) versus 63,910±8,541 µm2 (p28 vaccinated), 
P<0.05).  
FIGURE 6.4: EFFECT OF P28 VACCINATION ON PLAQUE SIZE IN THE CAROTID ARTERY.  LDLr-/- mice were 
vaccinated and 6 weeks after collar placement (8 weeks Western-type diet) the carotid arteries were 
removed. Plaque size was quantified in HE stained cryosections of the carotid artery in control mice (A, 
N=8) and in PADRE-p28 vaccinated mice (B, N=9) (C). *P<0.05 
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To study atherosclerotic lesion formation along the aorta, the aortas from control 
mice (Figure 6.5A) and vaccinated mice (Figure 6.5B) were dissected and stained en 
face for lipids. We observed a significant 69.18% increase in the atherosclerotic 
burden in the PADRE-p28 vaccinated mice (Figure 6.5 C: 8.89±1.19% (control 
vaccinated) versus 15.04±1.78% (p28 vaccinated); P<0.05). Furthermore, we studied 
the atherosclerotic lesion formation in the aortic root, and observed a non-
significant 30% increase in lesion size after vaccination against p28 (Figure 6.6A-C, 
P=0.08).  
 
FIGURE 6.5: INCREASED ATHEROSCLEROTIC BURDEN IN THE AORTA IN P28 VACCINATED MICE. The aorta 
was removed after 8 weeks of Western type diet and stained with O-Red-O staining. The plaque (red 
staining) of PADRE vaccinated mice (A, N=7) and PADRE-p28 vaccinated mice (B, N=9) was 
quantified, subsequently the percentage of plaque was calculated(C). *P<0.05 
 
 
FIGURE 6.6: PLAQUE SIZE IN THE AORTIC ROOT UPON P28 VACCINATION. After 8 weeks of Western type 
diet the hearts were dissected and cryosections of the aortic root were made of the PADRE vaccinated 
mice (A, N=9) and the PADRE-p28 vaccinated mice (B, N=9) and subsequently stained for Oil-red-O 
and the lesions were quantified (C). 
EFFECT OF VACCINATION AGAINST PADRE-P28 ON PLAQUE COMPOSITION  
To study the effect of IL-27 blockade on plaque composition, we analyzed the 
collar induced plaques in the carotid artery for macrophage content. Vaccination 
against IL-27 did not result in a significant difference in relative macrophage 
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content in the p28 vaccinated group compared to the control group (Figure 6.7A-
C). To assess whether IL-27 is involved in plaque stability, we studied the collagen 
content within the intima. Blocking of IL-27 did not result in a difference in relative 
collagen staining between the p28 vaccinated mice and control vaccinated mice 
(Figure 6.7D-F). 
 
VACCINATION AGAINST P28 ALTERS THE BALANCE BETWEEN TH17 CELLS AND TREGS 
Since IL-27 has an inhibiting effect on Treg development12 and is also able to 
suppress the development of Th17 cells,4, 10, 11 we analyzed these T cell populations 
within the spleen of p28 and control vaccinated mice. We observed a significant 
increase of 28.6% in IL-17 expressing cells within the CD4+CD62Lhigh cells in the 
spleen upon vaccination against p28 (Figure 6.8A: 21.51±1.58% versus 29.81±1.39% 
; P<0.01). Next we studied the Tregs and in the PADRE-p28 vaccinated mice we 
observed a significant reduction of 18.5% in Foxp3+ CD4+CD25+ cells within the 
spleen compared to control vaccinated mice (Figure 6.8A: 54.49±3.019% (control) 
versus 44.39±2.739% (p28 vaccinated); P<0.05). 
 
FIGURE 6.7: PLAQUE COMPOSITION IN THE CAROTID ARTERY IS NOT ALTERED UPON VACCINATION 
AGAINST P28. Cryosections were made of the carotid arteries after 8 weeks of Western type diet. PADRE 
vaccinated mice (A, N=8) and PADRE-p28 vaccinated mice (B, N=9) were stained with MoMa-2 and 
quantified (C). For the collagen detection the cryosections of PADRE vaccinated mice (D, N=8) and 
PADRE-p28 vaccinated mice (E, N=9) were stained with a Masson’s trichrome staining and the relative 
collagen amount in the plaque was quantified(C).  
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B CELL POPULATION DECLINED WITHIN THE SPLEEN OF P28 VACCINATED MICE 
Little is known about the effect of IL-27 on B cells, however there is some evidence 
that IL-27 plays a role in different stages of B cell development.20 To study the 
effect of p28 vaccination on the B cell population, we stained the spleen cells for 
CD19. Vaccination against p28 resulted in a highly significant 20.1% decrease in 
the number of CD19+ cells within the spleen compared to the control mice (Figure 
6.8C: 37.55±0.28% versus 47.02±0.95%; P<0.001). Since the B cell population is 
declined in p28 vaccinated mice we determined the level of IgG auto-antibodies 
against oxLDL in the circulation. Despite the decline in B cells, there was no 
difference in the level of anti-OxLDL auto-antibodies (Figure 6.8D). 
 
FIGURE 6.8: EFFECT OF P28 VACCINATION ON TH17 CELLS, REGULATORY T CELLS AND B CELLS. Spleens 
were removed after 8 weeks of Western type diet and a single cell suspension was made and 
subsequently stained for Th17 cells (A, N=6) , Treg cells (B, N=6) and B cells (C, N=6) and analyzed 
with a FACScalibur. The serum of control mice and p28 vaccinated mice was used for detection of 
antibodies directed against oxLDL. The autoantibody levels of IgM, IgG1, IgG2a and IgG2b were not 
changed in p28 vaccinated mice (D, N=9). *P<0.05, **P<0.01, ***P<0.001 
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DISCUSSION 
In this study, we demonstrate that IL-27 acts as an anti-atherogenic cytokine 
during the initiation of atherosclerosis. Vaccination against the p28 subunit of IL-27 
aggravates atherosclerosis and this effect may be explained by an altered balance 
between Th17 cells and Treg cells favoring the Th17 cells.  
IL-27 has pleiotropic effects on the various T cell subsets. Therefore we 
assessed the effect of IL-27 on activated T cells within the spleen of LDLr-/- mice 
and studied the cytokine profile. A decrease in IL-2, IL-6, TGF-β and IL-17 
production by activated spleen cells was observed in vitro, when exposed to IL-27. 
Decreased levels of IL-6, IL-2 and IL-17 may result in attenuated atherosclerosis as 
they are associated with aggravation of atherosclerosis 21,22 (van Es et al., 
unpublished results) and this suggests an anti-atherosclerotic role for IL-27. On the 
other hand a reduced level of TGF-β as induced by IL-27 may suggest that IL-27 
has a pro-atherosclerotic role as TGF-β has shown to be atheroprotective.23-25 We 
therefore wanted to know what the in vivo effect of IL-27 on atherosclerosis was 
since, to our knowledge, IL-27 has not been studied in the context of 
atherosclerosis.  
To determine whether IL-27 plays a role in atherosclerotic lesion 
development, expression of the separate sub-units of IL-27 was determined in the 
carotid artery. We observed an increase in p28 and EBI3 gene expression in initial 
atherosclerotic lesion in the carotid artery. This induction of both subunits at the 
same time indicates that EBI3 can form a heterodimer with p28 to facilitate its 
secretion.4 The upregulation of p28 and EBI3 expression was accompanied by an 
increase in the expression of the macrophage marker (CD68), indicating an influx 
of macrophages into the intima and this suggests that macrophages may be 
responsible for the IL-27 expression. 
The fact that IL-27 is upregulated in atherosclerotic lesions, led to an 
investigation of the role of IL-27 on atherosclerotic lesion development in vivo. 
Therefore, we developed a vaccine against p28 and vaccinated LDLr-/- mice. The 
DNA sequence of p28 was preceded by the DNA sequence of a specific 
immunodominant T-helper epitope to overcome T cell tolerance. In this study we 
used PADRE, which binds with high affinity to MHC class II and is able to activate 
helper T cells, thereby providing the necessary stimuli to break tolerance.26  
During the experiment we analyzed blood samples for the presence of 
antibodies against p28. However we were not able to obtain a positive read-out. 
This may be due to the low concentrations of anti-p28 antibodies that may not 
exceed the threshold of the developed assay. Despite the lack of detection of 
antibodies directed towards p28, the vaccination against p28 resulted in a clear 
change in T cell populations. Since IL-27 has been shown to affect Th17 cells and 
Tregs11, 12, we investigated whether these T cell populations were altered upon p28 
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vaccination. Vaccination against p28 resulted in a reduction in Treg cells within the 
spleen. Furthermore, we studied the Th17 cell population within the spleen of 
vaccinated mice and observed an increase in the Th17 cell population compared to 
the control group. An explanation may be that IL-27 is a strong inhibitor of TGF-β 
and IL-6, as we have demonstrated in this study in vitro. TGF-β is needed for both 
Th17 cells and Tregs, whereas IL-6 has a pivotal role in shifting the balance 
towards Th17 cells.27, 28 Another explanation for the increased Th17 cell population 
may be that IL-27 is able to stimulate the expression of suppressor of cytokine 
signaling (SOCS) and thereby inhibit STAT3 activation, which is crucial for Th17 
cells development.29 More so, IL-27 can also directly inhibit STAT3 as described by 
Huber et al.30, 31 Therefore it is likely that vaccination against p28 results in more 
Th17 cells and reduced numbers of Treg cells by increased STAT3 signaling and 
thereby shifting the balance towards Th17 cells.  
Next we studied the effect of p28 vaccination in atherosclerosis. We 
observed a 74.5% increase in plaque size in the carotid artery of p28 vaccinated 
mice. Furthermore, we observed an increase of 70% in plaque burden in the aorta 
after p28 vaccination. The serum cholesterol level did not change in p28 vaccinated 
mice versus control treated mice. The increased plaque size is therefore likely due 
to changes in the inflammatory status of the vaccinated mice and is not related to 
serum cholesterol levels. These results demonstrate an anti-atherosclerotic function 
of IL-27. 
This anti-atherosclerotic function of IL-27 is probably mediated by the 
altered balance between Treg and Th17 cells, as mentioned before. Tregs are 
associated with the protection against atherosclerosis23,25,32-34 and therefore, the 
reduction in Treg cells within the spleen of p28 vaccinated mice may be an 
explanation for the aggravated atherosclerotic lesions. 
Although the role of Th17 cells is not directly associated with 
atherosclerosis yet, the main product, IL-17, is associated with aggravated 
atherosclerosis (van Es et al. unpublished results). The suppressing effect of IL-27 
on Th17 cells is further supported by observation of Stumhofer et al., where they 
observed enhanced inflammation during chronic inflammation of the central 
nervous system in IL-27 receptor deficient mice, which was a result of increased 
Th17 cell population.39  
The effect of vaccination against p28 on plaque composition was studied 
by determining the macrophage and collagen content. However, we did not 
observe any effect on relative macrophage content, indicating that IL-27 is not 
involved in the influx of macrophages into the lesion. Furthermore, the collagen 
content remained the same in the p28 vaccinated and control mice. This suggests 
that IL-27 does not affect plaque stability in this stage of atherosclerosis. 
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IL-27 also has an effect on B cells by promoting proliferation of naive cells, 
which express the IL-27 receptor.35 Interestingly, we observe a 20% reduction in B 
cell content in the p28 vaccinated mice. IL-27 plays a role in the induction of T-bet 
expression and IgG2a class switching.35 IgG2a (IgG2c in the case of C57BI/6 mice) 
class auto-antibodies are associated with aggravating atherosclerosis.36 However, 
we did not detect any difference in auto-antibodies directed against oxLDL 
between the vaccinated and control mice, which indicates that p28 vaccination did 
not interfere with antibody class switching.  
Recently, a novel property of IL-27 is described by several groups. They 
demonstrated that IL-27 is able to induce IL-10 in CD4+ and CD8+ T cells.37-39 These 
new insights provide a new pathway that leads to the production of this key 
inhibitor of inflammation, which is demonstrated to be athero-protective.40-43  
In conclusion, both subunits of IL-27 are upregulated in atherosclerotic 
lesions. We demonstrated, via vaccination against the p28 subunit of IL-27, that IL-
27 has a protective role in atherosclerosis. Vaccination resulted in an increase of 
Th17 cells and a decrease in Treg cells, thereby, partly, explaining the aggravated 
atherosclerosis. Based on these results, overexpression or administration of IL-27 
may be a potential therapeutic application to treat atherosclerosis in the future. 
However, based on the pleiotropic nature of IL-27, more research is necessary to 
unravel the IL-27 signaling mechanism and effects. 
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ABSTRACT 
HSP60-specific T cells contribute to the development of the immune responses in 
atherosclerosis. This can be dampened by regulatory T cells activated via oral 
tolerance induction and we explored the effect of oral tolerance induction to HSP60 
and the peptide HSP60(253-268) on atherosclerosis.  
 HSP60 and HSP60(253-268) were administered orally to LDLr-/- mice prior 
to induction of atherosclerosis and resulted in a significant 80% reduction in 
plaque size in the carotid arteries and in a 27% reduction in plaque size at the 
aortic root. Reduction in plaque size correlated with an increase in 
CD4+CD25+Foxp3+ regulatory T cells in several organs and in an increased 
expression of Foxp3, CD25 and CTLA-4 in atherosclerotic lesions of HSP60-treated 
mice. The production of IL-10 and TGF-β by lymph node cells in response to 
HSP60 was observed after tolerance induction.  
 Oral tolerance induction to HSP60 and a small HSP60-peptide leads to an 
increase in the number of CD4+CD25+Foxp3+ regulatory T cells, resulting in a 
decrease in plaque size as a consequence of increased production of IL-10 and TGF-
β. We conclude that these beneficial results of oral tolerance induction to HSP60 
and HSP60(253-268) may provide new therapeutic approaches for the treatment of 
atherosclerosis.  
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INTRODUCTION 
Heat shock proteins (HSPs) are a family of highly conserved proteins with various 
functions in normal and stressful situations. Expression of HSPs on endothelial 
cells and macrophages1, 2 can be induced by fluid shear stress,3 oxidized 
lipoproteins4 and cytokines.2 Under these circumstances, HSPs repair or prevent 
degradation of denaturated proteins and increase the cell’s ability to survive 
stressful stimuli.5, 6 HSPs such as HSP60 are also involved in inflammatory 
diseases, probably resulting from their raised expression in cells exposed to pro-
inflammatory mediators.7, 8 In human atherosclerotic lesions,9 enhanced HSP60 
expression has been detected. In addition, patients with atherosclerosis show an 
elevated concentration of HSP60-specific antibodies in serum,2 and T cell clones 
with self-HSP60 reactivity have been detected within the atherosclerotic plaques.10 
This may be related to initial immune responses against bacterial HSPs which are 
highly homologous to HSPs in various other species including men, rats and 
mice.11 HSP60-specific antibodies may contribute to endothelial damage and the 
inflammatory response in the vessel wall accelerating atherosclerosis.12  
The autoimmune process in atherosclerosis is characterized by a T cell 
response to different autoantigens, e.g. oxidized LDL13, glycoproteins14 and HSPs15. 
HSP60-specific T cells are mainly of a Th1 phenotype, producing pro-atherogenic 
cytokines, such as IFN-γ, IL-12 and TNF-α and causing a disturbed balance 
between Th1 and Th2 cytokines.16, 17 For a long time, this disturbed balance was 
regarded as the cause of the ongoing inflammation in atherosclerosis. Recent 
publications however suggest that regulatory T cells (Tregs) play an important role 
in prevention of Th1 mediated autoimmune diseases such as multiple sclerosis,18 
diabetes mellitus19 and atherosclerosis.20 Mallat et al. hypothesized that in 
atherosclerosis an imbalance exists between pathogenic T cells (Th1 and Th2) and 
Tregs specific for ‘altered’ self and non-self antigens (e.g. oxidized phospholipids, 
heat shock proteins).21   
One way to increase the number of antigen specific Tregs is “low dose” 
oral tolerance induction. This method is already used as a treatment in animal 
models for Th1 mediated autoimmune diseases such as multiple sclerosis,22 
rheumatoid arthritis23 and type I diabetes.24 Initial studies also show that oral 
tolerance induction to β2-glycoprotein I25 and HSP6526, 27 results in the suppression 
of early atherosclerosis. However, these studies do not show the involvement of 
Tregs. We describe in a recent study an increase in the number of 
CD4+CD25+Foxp3+ cells after oral tolerance induction to oxidized LDL (oxLDL)28 
and a subsequent reduction in plaque size. These CD4+CD25+Foxp3+ cells form a 
class of Tregs that may either be natural Tregs which act via cell-cell contact via 
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surface-bound TGF-β29 or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)30 
or adaptive Tregs operating via the secretion of TGF-β.31 
The present study shows that induction of oral tolerance to HSP60 and a 
highly conserved sequence of HSP60 (HSP60(253-268)) attenuates atherosclerosis. 
The effect on atherosclerosis is explained by an increased number of 
CD4+CD25+Foxp3+ Tregs in both lymphoid organs and the atherosclerotic lesion. 
This is accompanied by an increase in HSP60-specific TGF-β and IL-10 production 
in mesenteric lymph node cells. 
  
METHODS 
ANIMALS 
All animal work was approved by the regulatory authority of Leiden University 
and carried out in compliance with the Dutch government guidelines. Male LDLr-/- 
mice were obtained from the Jacksons Laboratory. Mice were kept under standard 
laboratory conditions and were fed a normal chow diet or a ‘Western-type’ diet 
containing 0.25% cholesterol and 15% cocoa butter (Special Diet Services, Witham, 
Essex, UK). All mice used were 10-12 weeks of age. Diet and water were 
administered ad libitum. 
 
ANTIGENS AND ADJUVANT 
Dimethyl dioctadecyl ammonium bromide (DDA; Sigma Diagnostics, MO), used 
as adjuvant, was dissolved in phosphate buffered saline (PBS) and 100 µg was 
mixed with 100 µg of the antigen (HSP60, HSP60(253-268) or HSP70(111-125)) 
before immunization. Purified recombinant HSP60 of Mycobacterium bovis bacillus 
Calmette-Guérin was kindly provided by J.D.A. van Embden (National Institute of 
Public Health and Environmental Hygiene, Bilthoven, The Netherlands). 
HSP60(253-268) based on the sequence of mycobacterial HSP60 aa 253-268 (NH2-
EGEALSTLVVNKIRGT-amide), was made by regular peptide synthesis (FMOC 
protection). Another peptide HSP70(111-125) was based on a partially conserved 
(human, rat, mouse) sequence of the HSP70 peptide aa 111-125 (NH2-
ITDAVITTPAYFNDA-amide).32 
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IMMUNIZATIONS  
LDLr-/- mice were immunized via one i.p. injection with PBS or 100 µg of HSP60, 
HSP60(253-268) or HSP70(111-125). The antigens were dissolved in 200 µl of PBS 
containing 100 µg DDA. After 14 days the spleens were dissected and used in the 
proliferation assay described below. 
 
SPLEEN CELL PROLIFERATION ASSAY 
Spleens from either naive (n=3), immunized (n=3) or oral treated mice which were 
immunized subsequently (n=12 per group) were dissected and squeezed through a 
70 µm cell strainer (Falcon, The Netherlands). The erythrocytes were eliminated by 
incubating the cells with erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 
0.1 mM EDTA, pH 7.3). The splenocytes were cultured for 48 hours in triplicate at 
2⋅105 cells per well of a 96-wells round-bottom plate in the presence or absence of 
different concentrations of HSP60, HSP60(253-268) or HSP70(111-125). RPMI 1640 
(with L-Glutamine, 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 µg/ml 
streptomycin (all from BioWhittaker Europe)) was used as culture medium. 
Concanavalin A (Con A; Sigma-Diagnostics, MO) (2 µg/ml) was used as a positive 
control. Cultures were pulsed for an additional 16 hours with [6-3H]-thymidine (1 
µCi/well, sp. act. 24 Ci/mmol; Amersham Biosciences, The Netherlands). The 
amount of [6-3H]-thymidine incorporation was measured using a liquid 
scintillation analyzer (Tri-Carb 2900R). The magnitude of the proliferative response 
is expressed as stimulation index (SI) defined as the ratio of the mean counts per 
minute of triplicate cultures with antigen to the mean counts per minute in culture 
medium without antigen.   
 
INDUCTION OF ATHEROSCLEROSIS 
To determine the effect of oral tolerance induction on the initiation of 
atherosclerosis, atherosclerosis was induced in LDLr-/- mice. The mice were put on 
a Western-type diet three weeks prior to surgery. Atherosclerosis was induced by 
placement of perivascular collars, prepared from elastic tubing (0.3 mm inside 
diameter; Dow Corning, Midland, Michigan), around both carotid arteries (method 
described by von der Thüsen et al.33). During the experiment, the diet response was 
followed by measuring the cholesterol and triglyceride levels in serum of these 
mice. Total cholesterol levels were quantified spectrophotometrically using an 
enzymatic procedure (Roche Diagnostics, Germany). Precipath standardized 
serum (Boehringer, Germany) was used as an internal standard.  
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ORAL TOLERANCE INDUCTION  
After one week of Western-type diet and two weeks prior to collar placement, the 
LDLr-/- mice were treated 4 times over a period of 8 days with intragastrically 
administered antigens. Before each intragastrical administration, the animals were 
deprived of food but not water for 16 hours. To prevent degradation of the 
administered antigen, 2 mg of soybean trypsin inhibitor (STI, Sigma-Diagnostics, 
MO) was administered intragastrically. Ten minutes after the STI administration, 
the control group received 100 µl of PBS (n=7). The other mice received 30 µg of 
HSP70(111-125) (n=6), HSP60 (n=6) or HSP60(253-268) (n=7). All antigens and STI 
were diluted and dissolved in physiological saline (0.9% NaCl) prior to injection. 
After administering the antigens intragastrically, the mice were kept on Western-
type diet for another week before collars were placed. 
 
PLAQUE ANALYSIS 
Six weeks after collar placement the mice were euthanized and exsanguinated by 
femoral artery transsection. The mice were perfused and fixated through the left 
cardiac ventricle with PBS and FormalFixx (Thermo Shandon, Pittsburgh, PA) for 
30 min. Common carotid arteries and the heart with the aortic root were removed 
for analysis as described by von der Thüsen et al.33 The arteries were embedded in 
OCT compound (TissueTek; Sakura Finetek, The Netherlands) and proximally of 
the place of collar occlusion 5 µm sections were made on a Leica CM 3050S 
Cryostat (Leica Instruments, UK). These cryosections were stained with 
hematoxylin (Sigma Diagnostics, MO) and eosin (Merck Diagnostica, Germany). 10 
µm section were made of the aortic root and these sections were stained with Oil-
red-O and hematoxylin. Plaque areas and intima/lumen ratios were measured 
using a Leica DM-RE microscope and LeicaQwin software (Leica Imaging Systems, 
UK).  
 
SPLENOCYTE PROLIFERATION AFTER TOLERANCE INDUCTION 
To test the effect of tolerance induction to HSP60 on the proliferation of 
splenocytes, mice were treated orally with PBS or HSP60 as described. 
Subsequently, all mice were immunized with HSP60 and two weeks thereafter, 
splenocytes of these mice were re-stimulated in vitro with HSP60. The proliferation 
was measured as described above.  
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FLOW CYTOMETRIC ANALYSIS 
For the detection of CD4+CD25+Foxp3+ T cells, a three color flow cytometry was 
performed. 4 and 14 days after oral treatment with HSP60, spleen, mesenteric 
lymph nodes, Peyer’s patches, and blood were isolated from HSP60-treated and 
untreated mice (n=5). Mononuclear cells were isolated using Lympholyte 
(Cedarlane, Ontario, Canada) conform the manufacturers protocol. Cells were 
subsequently stained with FITC-conjugated anti-CD4 (0.125 µg/sample) and APC-
conjugated anti-CD25 (0.06 µg/sample) mAb (eBioscience, Belgium) for 30 min. 
Cells were then fixed and permeabilized for 16 hrs with Fixation/Permeabilization 
solution according to the suggested protocol (eBioscience, Belgium). Subsequently, 
the cells were stained with PE-conjugated anti-Foxp3 (0.2 µg/sample) (eBioscience, 
Belgium) for 30 min. Cells were analyzed immediately by flow cytometry on a 
FACSCalibur. All data were analyzed with CELLQuest software (BD Biosciences, 
The Netherlands). 
 
CYTOKINE ASSAYS 
Mesenteric lymph nodes were isolated from untreated and HSP60-treated mice 
(n=5) 14 days after oral treatment with HSP60. The lymph nodes were squeezed 
through a cell strainer and the cells were cultured at 1⋅106 cells per well of a 24-
wells plate in the presence or absence of 20 µg/ml HSP60. Culture supernatants 
were harvested after 48 hours of incubation. IL-10, IFN-γ (both from eBioscience, 
Belgium) and TGF-β (Bender MedSystems, Austria) concentrations were 
determined by enzyme-linked immunosorbent assays (ELISA) according to the 
manufacturers suggestions. 
 
REAL-TIME PCR ASSAYS 
Carotid arteries from control and HSP60-treated mice were isolated and mRNA 
was extracted using the guanidium isothiocyanate (GTC) method and reverse 
transcribed (RevertAid M-MuLV reverse transcriptase). Quantitative gene 
expression analysis was performed on an ABI PRISM 7700 sequence detector 
(Applied Biosystems, CA) using SYBR green technology. Primer pairs as described 
in table 8.1 were used to quantify Foxp3, CD25, CTLA4 gene expression. Acidic 
ribosomal phosphoprotein PO (36B4) was used as the endogenous reference gene.  
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TABLE 7.1: SEQUENCE OF PRIMERS. Primer sequences for the genes analyzed with qPCR.  
DETECTION OF ANTI-HSP60 ANTIBODIES 
HSP60 (10 µg/ml) dissolved in a NaHCO3/Na2CO3 buffer (pH 9.0) was coated. 
Measurement of IgG1, IgG2a and IgM levels in serum was performed using an 
ELISA Ig detection kit (Zymed Laboratories, CA) conform the manufacturer’s 
protocol and appropriate controls were performed. 
 
STATISTICAL ANALYSIS 
All data are expressed as mean ± SEM. The Mann-Whitney test was used to 
compare the data. When required  an ANOVA test (Kruskal-Wallis test with post-
test) was used.  P-values less than 0.05 are considered to be statistically significant.  
  
RESULTS 
T CELLS SPECIFIC FOR HSP60 AND HSP60(253-268) EPITOPES ARE PRESENT IN LDLR-/- 
MICE 
Because of the important role of HSP60-specific T cells in atherosclerosis, we first 
investigated the presence of T cells specific for HSP60, HSP60(253-268) or 
HSP70(111-125) epitopes in the LDLr-/- mice. HSP60 is homologue in bacteria, 
mice, rats and human and therefore mycobacterial HSP60 was used in this study. 
The peptide (HSP60(253-268)) was used because this peptide is present in all 
species. Splenocytes were isolated out of naive LDLr-/- mice and were incubated 
with several concentrations of the HSP epitopes. Incubation with 5 µg/ml HSP60 
or HSP60(253-268) had no effect on naive splenocytes while incubation with 20 
µg/ml HSP60 or HSP60(253-268) resulted in a 2.70±0.42 and 2.04±0.35 fold increase 
in proliferation, respectively (Figure 7.1A and B; P<0.05). HSP70(111-125) did not 
stimulate proliferation of the splenocytes (data not shown). In all experiments 2 
µg/ml ConA, a general pan T cell mitogen, was used as a positive control, which 
resulted in a more than 50-fold increase in proliferation (data not shown).  
GENE FORWARD PRIMER REVERSE PRIMER 
FOXP3 5’-GGAGCCGCAAGCTAAAAGC-3’ 5’-TGCCTTCGTGCCCACTGT-3’ 
CD25 5’-CTTATATTGCAAATGTGGCACAATC-3’ 5’-ATCAATCATCAGTGGGACAATCTG-3’ 
CTLA4 5’-CGAGGTCCTGCACCAACTG-3’ 5’-TCCATCACCATCGGTTTATGC-3’ 
36B4 5’-GGACCCGAGAAGACCTCCTT-3’ 5’-GCACATCACTCAGAATTTCAATGG-3’ 
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To determine whether the T cell response to HSP-epitopes can be induced 
in vivo we immunized LDLr-/- mice by an intraperitoneal injection of 100 µg of 
HSP60, HSP60(253-268) or HSP70(111-125) using DDA as adjuvant. After two 
weeks mice were killed, and isolated splenocytes from HSP60-immunized mice 
incubated with 5 and 20 µg/ml of HSP60 showed a 7.40±1.29 (P<0.05) and 
12.71±2.30 (P<0.05) fold increase in proliferation, respectively (Figure 7.1C). 
Incubation of splenocytes from HSP60(253-268)-immunized mice with 5 and 20 
µg/ml HSP60(253-268) resulted in a 7.29±2.32 (P<0.05) and 9.26±2.58 (P<0.05) fold 
increase, respectively (Figure 7.1D). Incubation of splenocytes from HSP70(111-
125)-immunized mice with HSP70(111-125) did not result in a significant effect on 
proliferation (Figure 7.1E). 
 
FIGURE 7.1: SPLEEN CELL PROLIFERATION IN RESPONSE TO HSP60 AND HSP60(253-268).  
Splenocytes were isolated from naïve LDLr-/- mice (A and B) and mice immunized via one i.p. injection 
with 100 µg of HSP60, HSP60(253-268) or HSP70(111-125) (C,D and E). The naive and primed 
splenocytes were re-stimulated in vitro with HSP60 (A and C), HSP60(253-268) (B and D) or HSP70(111-
125) (E) for 48 hours. Proliferation was measured by incorporation of 3H-thymidine. Data are shown as 
the stimulation index (S.I.) ± SEM. The S.I. is the ratio of the mean cpm of cultures with antigen to the 
mean cpm of cultures without antigen. *P<0.05. 
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EFFECT OF ORAL TOLERANCE INDUCTION TO HSP60, HSP60(253-268) AND 
HSP70(111-125) ON ATHEROSCLEROSIS 
Next we investigated the immunomodulatory effect of oral tolerance induction to 
these compounds on atherosclerosis. LDLr-/- mice were put on a Western-type diet 
for one week prior to oral administration of PBS (n=7) or 30 µg of HSP60 (n=7), 
HSP60(253-268) (n=6) or HSP70(111-125) (n=6). The oral treatment was given 4 
times in total, every other day. Subsequently, mice were equipped with collars 
around both common carotid arteries and fed a Western-type diet. Six weeks 
thereafter, atherosclerotic plaque formation was analyzed. Representative 
hematoxylin-eosin stained cryosections of the carotid arteries of PBS, HSP70(111-
125), HSP60, and HSP60(253-268)-treated mice are shown in figure 7.2A-D.  
 
 
FIGURE 7.2: ORAL TOLERANCE INDUCTION TO HSP60 AND HSP60(253-268) ATTENUATES PLAQUE 
FORMATION IN COLLAR INDUCED ATHEROSCLEROSIS IN LDLR-/- MICE.  
LDLr-/- mice were treated intragastrically with PBS, HSP70(111-125), HSP60 or HSP60(253-268) four 
times before induction of atherosclerosis and six weeks thereafter mice were sacrificed and the carotid 
arteries of PBS-treated (A), HSP70(111-125)-treated (B), HSP60-treated (C) and HSP60(253-268)-treated 
(D) mice were sectioned and stained with hematoxylin-eosin. Lesions were quantified by computer-
assisted morphometric analysis and plaque size (E) and intima/lumen ratio (F) were determined. 
During the experiment plasma cholesterol levels of PBS-treated (closed squares), HSP70(111-125)-
treated (closed triangles), HSP60-treated (open squares) and HSP60(253-268)-treated (open triangles) 
mice were monitored (G). *P<0.05 
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No significant difference in plaque size was observed in mice fed HSP70(111-125) 
(21181±5273 µm2) compared to PBS-treated mice (20471±5273 µm2). Oral 
administration of HSP60 (3959±582 µm2) resulted in a significant 80.7% (P<0.05) 
reduction in plaque size when compared to PBS-treated mice. Oral tolerance 
induction to HSP60(253-268) (3419±460 µm2) resulted in an 83.3% (P<0.05) 
reduction in plaque size (Figure 7.2E).  
Furthermore, the intima/lumen ratio was reduced significantly with 68.8% 
in the HSP60 treated mice (P<0.05; 0.082±0.007) and with 74.3% in the HSP60(253-
268)-treated mice (P<0.05; 0.067±0.010) when compared to the PBS-treated mice 
(0.261±0.074) (Figure 7.2F). During the experiment no significant differences in 
total plasma cholesterol levels were detected between the different groups (Figure 
7.2G). In addition, a 27.4% reduction in plaque size at the aortic root was observed 
in HSP60-treated mice (377000±37200 µm2) when compared with PBS-treated mice 
(Figure 7.3 A-C; 519000±44600 µm2; P<0.05). Immunohistochemical analysis of all 
plaques showed that oral tolerance induction to HSP60 and HSP60(253-268) had no 
effect on the relative macrophage and smooth muscle cell content (data not 
shown). 
 
 
 
 
 
 
 
 
FIGURE 7.3: ORAL TOLERANCE INDUCTION TO HSP60 REDUCES PLAQUE FORMATION AT THE AORTIC ROOT 
IN LDLR-/- MICE. 
LDLr-/- mice were fed a Western-type diet and were treated intragastrically four times with PBS or 
HSP60 as in figure 7.2. After 8 weeks, sections of the aortic root of PBS-treated (A) and HSP60-treated 
(B) mice were stained with Oil-red-O and hematoxylin and subsequently lesions were quantified and 
plaque size was determined (C). Values are mean lesion size ± SEM. *P<0.05 
EFFECT OF ORAL TOLERANCE INDUCTION TO HSP60 ON CD4+CD25+FOXP3+ TREGS 
To evaluate whether oral tolerance induction to HSP60 was associated with an 
effect on Tregs, flow cytometry analysis was performed. HSP60-treated LDLr-/- 
mice were sacrificed 4 and 14 days after the last oral treatment. In untreated 
control mice, CD4+CD25+Foxp3+ T cells are present in low numbers in Peyer’s 
patches (0.79±0.16%), blood (2.21±0.12%), spleen (0.80±0.07%) and mesenteric 
lymph nodes (3.82±0.25%).  
200 µm  
A 
200 µm  
B 
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FIGURE 7.4: ORAL TOLERANCE INDUCTION TO HSP60 LEADS TO AN INCREASED AMOUNT OF 
CD4+CD25+FOXP3+ CELLS.  
LDLr-/- mice were fed HSP60 four times and killed 4 and 14 days after oral treatment. As a control, 
untreated animals were used. The dot plots show representative examples of lymphoid cells isolated 
from Peyer’s patches, blood, spleen and mesenteric lymph nodes stained for CD4 and CD25 (left panel). 
The right panels show the percentage of Foxp3+ cells within the CD4+CD25+ population. 
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Spleen Mesenteric lymph nodes  
Untreated 
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The dot-plots in figure 7.4 represent examples of FACS analysis on CD4+CD25+ 
cells (left panels) and Foxp3+ cells within the CD4+CD25+ population (right panels) 
in Peyer’s patches, blood, spleen and mesenteric lymph nodes, respectively. 4 days 
after oral treatment with HSP60, the number of CD4+CD25+Foxp3+ T cells in the 
Peyer’s patches and blood was increased significantly to 1.73±0.30% (P<0.05) and 
2.86±0.21% (P<0.01), respectively, when compared to untreated mice. No 
significant change was seen in the spleen (0.85±0.06%) and mesenteric lymph 
nodes (4.67±0.41%). 14 days after oral treatment, the number of CD4+CD25+Foxp3+ 
T cells decreased again to 1.07±0.08% in the Peyer’s patches and was not 
significantly different from untreated mice whereas the number of 
CD4+CD25+Foxp3+ T cells in blood was still enhanced (2.81±0.20%, P<0.01). In the 
spleen and mesenteric lymph nodes a significant increase to 1.24±0.11% (P<0.01) 
and 5.36±0.10% (P<0.01) was observed when compared with the situation without 
treatment (Figure 7.5). 
 
FIGURE 7.5: ORAL TOLERANCE INDUCTION TO HSP60 LEADS TO AN INCREASED AMOUNT OF 
CD4+CD25+FOXP3+ CELLS.  
LDLr-/- mice were treated intragastrically four times with HSP60 and killed 4 and 14 days after the last 
oral treatment. As a control, untreated animals were used. The graphs represent the amount of 
CD4+CD25+Foxp3+ cells in the different organs measured via FACS analysis (mean±SEM). *P<0.05, 
**P<0.01 
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REGULATORY T CELL MARKERS IN ATHEROSCLEROTIC PLAQUES 
After tolerance induction to HSP60 and the induction of atherosclerosis, carotid 
arteries were dissected and mRNA was isolated. Subsequently, the expression of 
different Treg markers (CD25, CTLA-4 and Foxp3) in the atherosclerotic plaques in 
the carotid arteries was determined. After oral treatment with HSP60 (n=5) and 8 
weeks of Western-type diet feeding, the mRNA expression of CD25, CTLA-4 and 
Foxp3 was significantly upregulated in the atherosclerotic plaque when compared 
with control mice (n=9). CD25 showed a 4.9-fold increase (P<0.05), CTLA-4 a 4.1-
fold increase (P=0.068) and Foxp3 a 6.4-fold increase (P<0.05) (Figure 7.6).  
 
 
FIGURE 7.6: INCREASED EXPRESSION OF TREG MARKERS IS OBSERVED WITHIN LESIONS OF HSP60-
TREATED LDLR-/- MICE. 
To investigate the presence of Tregs within atherosclerotic lesions, mRNA was isolated from carotid 
arteries of PBS (n=9) and HSP60-treated (n=5) mice and the mRNA expression of CD25, CTLA-4 and 
Foxp3 was quantitatively determined and expressed relative to 36B4. *P<0.05 
 
EFFECT OF TOLERANCE INDUCTION ON CYTOKINE PRODUCTION 
Furthermore, we investigated whether the increased number of CD4+CD25+Foxp3+ 
T cells also demonstrated a change in the production of cytokines in response to 
stimulation with HSP60. Mesenteric lymph node cells, isolated 14 days after the 
oral treatment with HSP60, were stimulated in vitro in presence or absence of 20 
µg/ml of HSP60. Incubation with HSP60 resulted in a significant larger production 
of TGF-β (1.86±0.22 versus 0.93±0.15 ng/ml; P<0.05) and IL-10 (19.52±5.51 versus 
6.41±1.72 pg/ml; P<0.05) when compared with mesenteric lymph node cells 
cultured without HSP60 (Figure 7.7A-B). Furthermore, HSP60-stimulated 
mesenteric lymph node cells isolated from HSP60-treated mice (14 days after 
treatment) produced significantly more TGF-β than HSP60-stimulated mesenteric 
lymph node cells isolated from untreated mice (1.86±0.22 ng/ml versus 0.96±0.22 
ng/ml; P<0.05; data not shown). In all cases IFN-γ levels were below the detection 
threshold. 
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FIGURE 7.7: ORAL TOLERANCE INDUCTION TO HSP60 INDUCES ANTI-ATHEROGENIC CYTOKINE 
PRODUCTION BY MESENTERIC LYMPH NODE CELLS. 
LDLr-/- mice were treated intragastrically four times with HSP60. 14 days after the treatment, 
mesenteric lymph nodes were isolated from HSP60-treated mice and the lymphocytes were cultured in 
vitro with or without HSP60 for 48 hours. The production of TGF-β (A) and IL-10 (B) was monitored 
using ELISA. Data are mean±SEM. *P<0.05. 
 
ORAL TOLERANCE INDUCTION TO HSP60 REDUCES THE PROLIFERATIVE RESPONSE OF 
SPLENOCYTES TO HSP60 
To determine the effect of tolerance induction to HSP60 on the HSP60-specific 
proliferation, LDLr-/- mice were treated orally with PBS or HSP60. After oral 
treatment all mice were immunized with HSP60 and two weeks later splenocytes 
were isolated and cultured with or without 5 and 20 µg/ml of HSP60. Splenocytes 
from PBS-treated mice respond to HSP60 with an increased proliferation; a 
stimulation index of 4.4±0.7 and 10.4±2.5 when incubated with 5 and 20 µg/ml of 
HSP60, respectively. Mice orally treated with HSP60 showed a 56.8% and 68.2% 
reduction in the proliferative response to 5 and 20 µg/ml of HSP60, respectively 
(Figure 7.8; 1.9±0.2 and 3.3±0.4; P<0.05). 
 
FIGURE 7.8: ORAL TOLERANCE INDUCTION TO HSP60 
REDUCES THE PROLIFERATIVE RESPONSE OF 
SPLENOCYTES TO HSP60. 
LDLr-/- mice were treated 4 times intragastrically 
with PBS or HSP60. Subsequently, all mice were 
immunized with HSP60 and after two weeks the 
mice were sacrificed and splenocytes were isolated. 
Splenocytes of PBS-treated mice (white bars) and 
HSP60-treated mice (black bars) were cultured with 
or without 5 and 20 µg/ml of HSP60. The extent of 
proliferation is shown as stimulation index after 
incorporation of 3H-thymidine. Values are 
mean±SEM. *P<0.05 
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EFFECT OF ORAL TOLERANCE TO HSP60 ON HSP60-SPECIFIC ANTIBODIES 
After oral treatment with HSP60 and the induction of atherosclerosis, HSP60-
specific IgG1, IgG2a and IgM levels in serum were determined. No detectable 
differences in HSP60-specific IgG1, IgG2a and IgM levels were observed  
(Figure 7.9) 
 
FIGURE 7.9: EFFECT OF TOLERANCE INDUCTION TO HSP60 ON HSP60-SPECIFIC ANTIBODY-LEVELS. 
LDLr-/- mice in which atherosclerosis was induced by a combination of Western-type diet feeding and 
collar placement around both carotid arteries were treated 4 times intragastrically with PBS or HSP60 
and serum levels of HSP60-specific IgG1, IgG2a and IgM were measured using a capture enzyme-linked 
immunosorbent assay. Values are mean OD(405) values ± SEM. 
 
DISCUSSION 
Previous studies have demonstrated the importance of HSPs in the pathology of 
atherosclerosis. HSP70 is expressed in atherosclerotic lesions34 and oxLDL 
enhances the expression of HSP70.35, 36 Autoantibodies to HSP60 causing 
endothelial damage12 and macrophage lysis37, are associated with an increase in 
susceptibility in atherosclerosis. T cells reactive to HSP60 are found to correlate 
with early atherosclerotic events38 and are found in atherosclerotic plaques in 
rabbits39 and humans.40 Furthermore, Chlamydia pneumoniae, can induce an 
immune response because of its HSP60 expression, which is highly homologous to 
human and mouse HSP60.  
We now show that LDLr-/- mice contain T cells specific for HSP60 and for 
the small peptide HSP60(253-268), but no T cells with any reactivity against the 
HSP70(111-125) peptide. HSP60 was derived from Mycobacterium bovis bacillus, but 
due to the high degree of amino acid sequence homology between different 
species, T cells specific for this HSP60 were found to be cross reactive against self-
HSP6041. A spleen cell proliferation assay demonstrated a 2-3-fold increase in T cell 
proliferation in response to HSP60 or HSP60(253-268). Immunization of LDLr-/- 
mice with HSP60 or HSP60(253-268) and a subsequent proliferation assay with 
HSP60 or HSP60(253-268) resulted in a 13- and 9-fold increase in proliferation, 
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respectively. These data confirm that HSP60 but also the small HSP60-peptide can 
induce a T cell response in LDLr-/- mice, while the small HSP70-peptide was not 
effective.  
Intervention in the anti-HSP60 autoimmune response could be beneficial 
for atherosclerosis. Many strategies are used to interrupt autoimmune responses 
directed towards autoantigens and one of these strategies is mucosal tolerance 
induction. Mucosal tolerance induction, can lead to a deletion of Th1 and Th2 cells 
or to an activation of Tregs depending on the administered dose of the antigen. 
Tregs, induced by low doses of the antigen, are known for the production of TGF-β 
and IL-10, which both have anti-atherogenic properties. Recently, Mallat et al. 
hypothesized that in atherosclerosis an imbalance exists between pathogenic T 
cells (Th1 and/or Th2) and Tregs specific for ‘altered’ self and non-self antigens.21 
Tregs play an important role in controlling the development of atherosclerosis in 
mice20 and a transfer of HSP60-specific Tregs to RAG1-/-LDLr-/- mice reduced the 
development of atherosclerotic lesions.42 Consequently, mucosal tolerance 
induction and the subsequent activation of Tregs may be a useful strategy to 
ameliorate atherosclerosis. It was already shown that oral tolerance induction to 
β2-glycoprotein I,25 HSP6526, 27 and oxLDL28 reduced early atherosclerosis. 
However, the studies on β2-glycoprotein I and HSP65 do not give a clear 
explanation for the observed reduction in atherosclerosis and they do not show 
whether Tregs are involved in this process. Oral administration of HSP60 
suppresses adjuvant arthritis due to an expansion of T cells specific for HSP60 
producing IL-1043. We showed that an induction of Tregs after oral administration 
of oxLDL was observed and these oxLDL specific Tregs were found to be 
responsible for the reduction in atherosclerotic plaque formation.28 
We now show that oral tolerance induction to HSP60 and HSP60(253-268) 
attenuates atherosclerosis. A relatively low dose of HSP60 significantly reduced 
early atherosclerotic lesion formation by 80.7%. We now propose that an 
immunogenic peptide present in HSP60 (aa 253-268) can also induce regulatory T 
cells and reduces plaque size by 83.3%. The specificity of the response is reflected 
by the finding that HSP70(111-125), a peptide based on a conserved sequence 
found in the HSP70 protein of men, rats, and mice, was not effective in reducing 
atherosclerosis. The experimental setup of our current study is comparable with 
two previous studies on oral tolerance induction to HSP65/HSP60.26, 27 Both Harats 
et al.26 and Maron et al.27 show a decreased proliferation of splenocytes after oral 
treatment but no effects on Tregs were described. Maron et al.27 observed a 
decreased IFN-γ and an increased IL-10 production by lymphocytes after oral 
treatment with HSP65. This could indicate an activation of Tr1 cells, a subset of 
adaptive Tregs, particularly producing IL-10.28 In our current study low doses of 
HSP60 and HSP60(253-268) were administered and therefore we investigated the 
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possible activation of Tregs. Four days after the oral HSP60-treatment, the number 
of CD4+CD25+Foxp3+ Tregs was significantly increased in Peyer’s patches and 
blood. After two weeks, the number of CD4+CD25+Foxp3+ T cells was significantly 
increased in blood, mesenteric lymph nodes and spleen. In the Peyer’s patches, the 
first site of activation, the number of Tregs decreased after two weeks, which may 
be attributed to the migration of the activated CD4+CD25+Foxp3+ T cells to 
peripheral lymphoid organs and the site of inflammation (atherosclerotic lesions) 
where they may recognize self-HSP60. We also investigated the mRNA-expression 
of markers for Tregs within the lesions and we observed an increased expression of 
CD25, CTLA-4 and Foxp3. In addition, oral treatment with HSP60 reduced the 
proliferative response of splenocytes to HSP60 which is in line with the studies by 
Maron et al. and Harats et al.26, 27 Furthermore, mesenteric lymph node cells of 
HSP60-treated mice also produced increased levels of TGF-β and IL-10 after in vitro 
re-stimulation with HSP60. All these data suggest that oral administration of 
HSP60 induced Tregs, which were may be able to dampen the immune response to 
HSP60 in atherosclerosis prone mice.  
Natural Tregs, which are CD4+CD25+Foxp3+ T cells can display their 
specific immunosuppressive effects via cell contact. TGF-β on their surface may 
bind to TβRII expressed on T cells specific for the same antigen. This TGF-β-TβRII 
interaction leads to the activation of a Smad-dependent pathway, resulting in a 
blockade of IL-2 production and a reduced proliferation of antigen-specific T cells. 
CTLA-4 is also important in the cell-cell interaction between Tregs and other T 
cells. It is however more likely that adaptive Tregs (Th3 and Tr1 cells) are involved 
in oral tolerance induction31. Th3 cells are known for the production of anti-
inflammatory TGF-β and upon activation they may express Foxp3.44, 45 Tr1 cells, 
which can also be activated in the periphery, produce particularly anti-
inflammatory IL-10 but whether these Tregs express Foxp3 is still not clear. 
Therefore we assume that oral tolerance induction led to an increase in Foxp3-
expressing natural Tregs or Th3 cells, producing excessive amounts of TGF-β but 
also IL-10. IL-10 may also be produced by activated Tr1 cells, which however do 
not contribute to the increase in Foxp3+ Tregs. To definitively prove that the 
protection against atherosclerosis after oral administration of bacterial HSP60 is 
due to the induction of Tregs specific for murine HSP60 additional experiments are 
required, for example by deletion of Tregs after tolerance induction or transfer of 
the Tregs. 
In conclusion, we describe that LDLr-/- mice can be tolerized to HSP60 and 
a HSP60 peptide (HSP60(253-268)) which results in an attenuation of early 
atherosclerotic lesions. The mechanism underlying this effect can be attributed to 
the induction of CD4+CD25+Foxp3+ Tregs, which may produce TGF-β and IL-10 in 
atherosclerotic lesions. In this way they may down-regulate the inflammatory 
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response locally. Altogether, these beneficial results of oral tolerance induction to 
HSP60 and HSP60(253-268) on atherosclerosis may provide new therapeutic 
approaches for the treatment of atherosclerosis. 
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ABSTRACT 
Regulatory T cells are crucial for immune homeostasis and an impaired regulatory 
T cell function results in many pathological conditions, such as atherosclerosis. 
Regulatory T cells can be divided in adaptive regulatory T cells and natural 
regulatory T cells, the latter expressing the transcription factor Foxp3. Regulatory T 
cells have already been described to be protective in atherosclerosis. However the 
exact contribution of Foxp3 expressing regulatory T cells in atherosclerosis has not 
been elucidated yet. In this study we vaccinated LDL receptor deficient mice 
with dendritic cells which are transfected with Foxp3 encoding mRNA and studied 
the effect on initial and advanced atherosclerosis. 
Vaccination against Foxp3 resulted in a reduction of Foxp3 expressing cells 
and an increase in both initial and advanced atherosclerotic lesion formation. 
Furthermore we observed an increase in plaque cellularity and increased T cell 
proliferation in the Foxp3 vaccinated mice. 
In conclusion, in this study we further establish the protective role of Tregs 
in atherosclerosis. The results illustrate the important role for Foxp3 expressing 
regulatory T cells in atherosclerosis, thereby providing a potential opportunity for 
therapeutic intervention against this disease. 
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INTRODUCTION  
Atherosclerosis is an autoimmune like disease, in which both innate and adaptive 
immune responses are involved.1 T helper (Th) cells are crucial for an adequate 
immune response and can be divided in Th1 (cell mediated immunity) and Th2 
(humoral immunity) cells. Several studies show that inflammatory processes in 
atherosclerosis are associated with a Th1-driven immune response (IFN-γ, IL-12), 
while the Th2 cells (IL-5 and IL-13) exert an anti-atherogenic role.2, 3 It was 
postulated that an imbalance between Th1 and Th2 cells was, at least partially, 
responsible for the development of atherosclerotic lesions. However, more 
recently, IL-4, a Th2-cytokine, was found to be pro-atherogenic in early lesion 
formation.4, 5 This finding, together with studies establishing an anti-atherogenic 
role for regulatory T cells (Tregs), suggested another mechanism of immune 
regulation in atherosclerosis, where T cells (both Th1 and Th2) are suppressed by 
regulatory T cells (Tregs). 
Tregs are characterized by the expression of both CD4 and CD25 and are 
subdivided in adaptive Tregs and natural Tregs. Adaptive Tregs develop form 
naive T cells in the periphery and can produce IL-10 (Tr1 cells) and TGF-β (Th3 
cells). Natural Tregs originate from the thymus as CD4+CD25+ cells and exert their 
suppressive function especially via cell-cell contact and membrane bound TGF-β 
and CTLA-4. Forkhead box protein P3 (Foxp3) is characteristically expressed in 
this subclass of Tregs and this transcription factor is necessary for the development 
of Tregs. Deficiency in Foxp3 leads to a lack of Tregs and severe auto-immune 
disorders.6-9  
Recently, we showed that oral administration of atherosclerosis-related 
antigens (HSP60 and oxLDL) increases the number of Foxp3-expressing Tregs in 
several organs, which leads to a decrease in development of atherosclerotic lesions 
in LDLr-/- mice.10, 11 These results are in line with studies on the role of Tregs in 
atherosclerosis after oral and nasal tolerance induction12,13, 14 but our studies 
specifically demonstrate the contribution of Foxp3+ Tregs. Furthermore, a study 
showed that a transfer of Tregs selected on basis of CD4 and CD25 expression 
reduced lesion formation in ApoE-/- mice15, while another study showed that 
treatment of ApoE-/- mice with a CD25-specific antibody (PC61) which depletes 
CD25 positive T cells, results in an increase in lesion size. Additionally, bone 
marrow transplantation of CD80-/-CD86-/- bone marrow into LDLr-/- mice results in 
a decrease in the number of Tregs and an increase in lesion size again indicating an 
inverse relationship between the presence of Tregs and atherosclerotic lesion 
development.15 
However, these studies do not directly demonstrate the role of Foxp3 
expressing cells in atherosclerosis. This can be achieved via vaccination against 
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Foxp3 using DCs expressing Foxp3 as described by Nair et al. Vaccination with 
these DCs results in a decline in the number of intratumoral Tregs due to an 
induction of a cytotoxic T lymphocyte response against Foxp3 and subsequently in 
an enhanced antitumor immunity.16  
To specifically establish the role of Foxp3-expressing Tregs, we targeted 
Foxp3 expressing cells using DCs electroporated with mRNA encoding for Foxp3. 
Vaccination against Foxp3 results in a reduction of Foxp3+ Tregs and a subsequent 
increase in both initial and advanced atherosclerotic lesion formation, thereby 
establishing a prominent role for Foxp3+ Tregs in these processes. 
  
MATERIAL AND METHODS 
ANIMALS 
All animal work was approved by the regulatory authority of Leiden University 
and carried out in compliance with the Dutch government guidelines. Female 
LDLr-/- mice were obtained from the Jacksons Laboratory. Male C57BL/6J mice 
were from Charles river Laboratories. All mice were kept under standard 
laboratory conditions and were fed a normal chow diet or a ‘Western-type’ diet 
containing 0.25% cholesterol and 15% cocoa butter (Special Diet Services, Witham, 
Essex, UK). All mice used were 10-12 weeks of age. Diet and water were 
administered ad libitum. 
 
SYNTHESIS OF FOXP3 AND GFP MRNA 
The pSP73-Spf/Foxp3/A64 construct was kindly provided by E. Gilbao (Duke 
University Medical Center, Durham, NC, USA)16. As a control we created a pSP73-
Spf/eGFP/A64 construct. The pSP73-Spf/Foxp3/A64 and pSP73-Spf/eGFP/A64 
constructs were used as a DNA template in a T7 mMessage mMachine® (Ambion, 
Austin, TX) reaction to produce large amounts of capped Foxp3 and GFP in vitro 
transcribed mRNA. To eliminate excessive DNA the reaction, a TurboDNase® 
(Ambion, Austin, TX) treatment was performed. The Megaclear Kit® (Ambion, 
Austin, TX) was used for purifying mRNA from the in vitro transcription 
reactions. All reactions were performed according to the manufacturer’s protocol.  
 
GENERATION AND ASSESSMENT OF THE DC BASED VACCINE  
Bone marrow cells were isolated from the tibia and femora of C57BL/6J mice. Cells 
were pooled and cultured for 10 days in IMDM supplemented with 8% fetal calf 
serum (FCS, PAA), 100 U/ml streptomycin/penicillin (PAA), 2 mM glutamax 
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(Invitrogen, The Netherlands) and 20 µM β-mercaptoethanol, in the presence of 
granulocyte-macrophage colony-stimulating factor (GM-CSF). Hereafter, the DCs 
were harvested, washed, and resuspended in Opti-MEM (GIBCO, Grand Island, 
NY). The used DC culture media were saved as conditioned media for later use. 5 x 
106 DCs in 200 µL Opti-MEM were electroporated with either GFP or Foxp3 mRNA 
as described by Nair etal.17 After electroporation the DCs were transferred to 
culture petridishes containing GM-CSF and a 1:1 combination of conditioned DC 
growth media and fresh media. Transfected DCs were incubated at 37 °C, 5% CO2 
overnight, washed 2 times in PBS, for vaccination. To assess the maturation profile 
the electroporated DCs were stained against surface markers: CD80-FITC, CD86-
PE and CD40-PE. To detect surface bound and intracellular Foxp3 expression in 
the electroporated DCs, the cells were stained with Foxp3-APC. For intracellular 
staining of Foxp3, DCs were fixated and permeabilized overnight and subsequent 
stained against Foxp3. All FACS antibodies were purchased from eBioscience 
(Belgium) and used according manufacturer’s protocol. DCs were analyzed by 
flow cytometry on a FACSCalibur (Becton Dickinson, Mountain View, CA). Data 
were analyzed using Cell Quest software (BD Biosciences, The Netherlands). Total 
RNA was isolated from the electroporated DCs using the GTC method.18 cDNA 
synthesis was performed using Revert AidTM M-MuZV Reverse Transcriptase 
(Fermentas Life Science). Quantitative gene expression analysis was performed on 
a 7500 fast Real-Time PCR System (Applied Biosystem) using SYBR Green 
technology. Acidic ribosomal phosphoprotein PO (36B4) and hypoxanthine 
phosphoribosyl transferase (HPRT) were used as reference genes. Primer pairs as 
described in table 8.1 were used to quantify Foxp3 gene expression. 
 
TABLE 8.1: SEQUENCE OF PRIMERS. Primer sequences for the genes analyzed with qPCR. 
 
GENE FORWARD PRIMER REVERSE PRIMER 
FOXP3 5’-GGAGCCGCAAGCTAAAAGC-3’ 5’- TGCCTTCGTGCCCACTGT-3’ 
36B4 5’-GGACCCGAGAAGACCTCCTT-3’ 5’-GCACATCACTCAGAATTTCAATGG-3’ 
HPRT 5’-TTGCTCGAGATGTCATGAAGGA-3’ 5’-AGCAGGTCAGCAAAGAACTTATAG-3’ 
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VACCINATION AND THE INDUCTION OF ATHEROSCLEROSIS 
Mice (GFP N=15, Foxp3 N=16) were vaccinated with 5x105 DCs in 100 µl per 
mouse subcutaneously at the base of the ear pinna at day 0. Mice of the control 
group (N=15) were injected with 100 µl PBS. After vaccination, the mice were 
directly fed a Western-type diet (0.25% cholesterol and 15% cocoa butter) to induce 
hypercholesterolemia and atherosclerosis. For the advanced atherosclerosis study, 
mice were fed a Western-type diet for 10 weeks and were subsequently vaccinated 
against GFP (N=15) Foxp3 (N=16) or sham vaccinated with PBS (N=15). After 
vaccination the mice were fed a Western-type diet for 12 more weeks before they 
were sacrificed. During both experiment blood samples were obtained by tail vein 
bleeding. The concentrations of serum cholesterol were determined using an 
enzymatic colorimetric procedure (Roche/Hitachi). Precipath (Roche/Hitachi, 
Mannheim, Germany) was used as an internal standard. Blood samples of week 5 
were also used to determine the percentage Tregs. 8 weeks after vaccination, the 
mice were sacrificed and tissues were harvested after in situ perfusion using PBS 
and subsequent perfusion with Zinc Formal-Fixx (Shandon Inc. Pittsburg, USA). 
Tissues were snap-frozen in nitrogen and stored at –80 °C until further use.  
 
FLOW CYTOMETRY 
Peripheral Blood Mononuclear Cells (PBMC) were isolated via orbital bleeding and 
erythrocytes were removed by incubating the cells with erythrocyte lysis buffer 
(0.15 M NH4Cl, 10 mN NaHCO3, 0.1 mM EDTA, pH 7.3; N=5 each group). Spleens, 
heart lymph nodes (HLN) and mesenteric lymph nodes (MLN) were dissected 
from the mice and single cell suspension was obtained by passing the organs 
through a 70 µm cell strainer (Falcon, The Netherlands; N=5 each group). Cells 
were stained with surface markers (0.20 µg antibody/300.000 cells) and 
subsequently analyzed by flow cytometric analysis. For the detection of 
CD4+CD25+Foxp3+ T cells, the spleen, blood, MLN and HLN were stained with 
CD4-FITC and CD25-PE and subsequently with an intracellular Foxp3 staining as 
described above. All antibodies were purchased from eBioscience (Immunosource, 
Belgium). All data were acquired on a FACScalibur (Becton Dickinson, Mountain 
View, CA) and analyzed with CELLQuest software (BD Biosciences, The 
Netherlands).  
 
SPLEEN CELL PROLIFERATION 
The splenocytes (N=5 per group) were cultured for 48 hours in triplicate in a 96-
wells round-bottom plate (2 x 105 cells/well) in RPMI 1640 supplemented with L-
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Glutamine, 10% FCS and 100 U/ml streptomycin/penicillin. As a positive control 
cells were stimulated with Concanavalin A (2 µg/ml, Con A, Sigma Diagnostics, 
MO). Proliferation was measured by addition of 3H-thymidine (0.5 µCi/well, 
Amersham Biosciences, The Netherlands) after 16 hours. The amount of 3H-
thymidine incorporation was measured using a liquid scintillation analyzer (Tri-
Carb 2900R). The proliferation is expressed in disintegration per minute (dpm).  
 
HISTOLOGICAL ANALYSIS 
The heart was embedded in OCT compound (TissueTek; Sakura Finetek, The 
Netherlands) and cryosections (10 µm) of the aortic root containing the three aortic 
valves were made. Cryosections were routinely stained with Oil-Red-O and 
hematoxylin (Sigma Diagnostics, MO). Corresponding sections on separate slides 
were also stained for collagen using Masson trichrome staining according to 
manufacturers protocol (Sigma Diagnostics). For the cellularity assessment a 
hematoxylin staining was performed. The different histological stainings were 
quantified using a Leica DM-RE microscope and Leica Qwin Imaging software 
(Leica Ltd., Germany).  
 
STATISTICAL ANALYSIS 
All data are expressed as mean ± SEM. The two-tailed student’s t-test was used to 
compare individual groups of mice or cells. When indicated, a Mann-Whitney test 
was used to analyze not normally distributed data. The frequency of thickened cap 
structure was analyzed by a Fisher’s exact test. P values of <0.05 were considered 
significant. 
 
RESULTS 
ELECTROPORATION OF DCS WITH MRNA RESULTS IN AN ACTIVATED PHENOTYPE 
To test whether a reduction in Foxp3-expressing Tregs affects atherosclerosis, 
LDLr-/- mice were vaccinated with DCs transfected with mRNA encoding for 
Foxp3. A significant increase in the surface expression of the co-stimulatory 
molecules, CD80, CD86 and CD40 was observed in DCs that were electroporated 
with mRNA encoding Foxp3 or GFP, when compared with electroporation without 
mRNA (Control) (Figure 8.1).  
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FIGURE 8.1: EXPRESSION OF SURFACE MARKERS ON ELECTROPORATED DCS. After electroporation with 
either PBS (control, N=3), GFP mRNA (N=3) or Foxp3 mRNA (N=3) the DCs were cultured o/n. DCs 
were also stimulated with LPS as a positive control for maturation (mDCs). Unstimulated DCs (imDCs) 
were used as a negative control for maturation. DCs were subsequently stained for CD80, CD86 and 
CD40 and analyzed by FACS. ***P<0.001 
 
The increase upon transformation with mRNA is comparable to the LPS induced 
TLR4 dependent maturation of DCs (mDCs). Interestingly, no upregulation was 
observed in DCs electroporated without mRNA. These DCs had the same 
expression level of the activation markers as immature DCs (imDCs), indicating 
that exposure of DCs to electroporation conditions alone did not result in the 
maturation of DCs (Figure 8.1A).  
 
ELECTROPORATION WITH MRNA ENCODING FOR FOXP3 RESULTS IN THE EXPRESSION 
OF FOXP3 
After electroporation with mRNA encoding for Foxp3 a strong increase in Foxp3 
expression was observed on mRNA level, which indicated a successful transfection 
of the DCs (Figure 8.2A). To determine the intracellular protein expression of 
Foxp3, an intracellular Foxp3 FACS staining was performed (Figure 8.2B and C). 
Foxp3 transfected DCs expressed 6.3 fold more intracellular Foxp3 compared to 
GFP transfected DC, which expressed no Foxp3.  
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FIGURE 8.2: DETECTION OF FOXP3 SPECIFIC MRNA WITH QPCR AND SUBSEQUENT EXPRESSION BY FACS 
ANALYSIS. 
After electroporation total RNA was isolated and cDNA was synthesized. Subsequently the amount of 
mRNA was detected with Foxp3 specific qPCR primers (A). The expression is relative to HPRT and 
36B4. Next we determined, with FACS analysis, the intracellular expression of Foxp3 in PBS (green), 
GFP (blue) and Foxp3 (pink) electroporated DCs. DCs were cultured o/n after electroporation and 
stained intracellularily for Foxp3 and analyzed by FACS. A representative histogram (B) and percentage 
of intracellular Foxp3 expression is depicted (C).  
EFFECT OF VACCINATION AGAINST FOXP3 ON FOXP3 EXPRESSING T CELLS 
To asses the efficacy of the Foxp3 vaccine, LDLr-/- mice were vaccinated with 
Foxp3 electroporated DCs. As a control, mice were vaccinated with DCs 
electroporated with mRNA encoding for GFP. Five weeks after vaccination, the 
number of Foxp3+ Tregs in blood was analyzed. A 34% reduction in the number of 
Foxp3+ Tregs in Foxp3 vaccinated mice was observed, compared to GFP vaccinated 
mice (Figure 8.3A; 0.773±0.032% versus 1.175±0.065%; P<0.001). Eight weeks after 
vaccination, mice were sacrificed and blood, spleen, mesenteric lymph nodes 
(MLN) and mediastinal lymph nodes draining from the aorta (HLN) were isolated 
to determine the percentage of Tregs. Vaccination with Foxp3 transfected DCs 
resulted in a 27-30% decrease in Foxp3+ Tregs in blood (0.67±0.045% versus 
0.92±0.096%, P<0.05), spleen (2.88±0.24% versus 3.94±0.34%, P<0.05), MLN 
(3.59±0.10% versus 5.01±0.45%, P<0.05) and HLN (3.68±0.08% versus 5.50±0.46%, 
P<0.01), when compared to mice vaccinated with DCs electroporated with mRNA 
encoding for GFP (Figure 8.3B). As a control for the DC vaccination, one group of 
mice was treated with PBS. We observed no differences in the numbers of Foxp3+ 
Tregs in lymphoid organs and blood between mice treated with PBS alone and 
mice vaccinated with DCs electroporated with mRNA encoding for GFP (data not 
shown).  
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FIGURE 8.3: EFFECT OF FOXP3 VACCINATION ON THE PERCENTAGE OF TREGS IN THE LYMPHOID ORGANS. 5 
weeks after vaccination blood was taken from the mice vaccinated with either GFP (N=5, white bar) or 
Foxp3 (A, N=5, black bar) and we stained for CD4+CD25+Foxp3+ cells and subsequently performed a 
FACS analysis. 8 weeks after vaccination the mice vaccinated with either GFP (B, N=5, white bar) or 
Foxp3 (B, N=5, black bar) were sacrificed. Blood, spleen, MLN and HLN, were isolated and stained for 
CD4+CD25+Foxp3+ cells and analyzed. *P<0.05, **P<0.01, ***P<0.001 
 
VACCINATION AGAINST FOXP3 INCREASES PLAQUE FORMATION IN LDLR-/- MICE IN 
BOTH INITIAL AND ADVANCED ATHEROSCLEROSIS 
Eight weeks after vaccination and Western-type diet feeding the plaque size at the 
aortic root was analyzed. Representative slides of the aortic root of GFP and Foxp3 
vaccinated mice are shown in Figure 8.4A and B. Mice vaccinated against Foxp3 
showed a significant 34% increase in plaque size compared to the GFP vaccinated 
mice (Figure 8.4C; 538.932±46.043 µm2 versus 382.865±29.044 µm2, P<0.01). During 
the experiment, all mice developed hypercholesterolemia, however no significant 
differences in serum cholesterol levels (Figure 8.4D) and body weight (data not 
shown) were observed between the different groups of mice. Again, no differences 
in plaque size were observed between PBS treated mice and mice vaccinated 
against GFP (data not shown).  
In an advanced atherosclerosis study, LDLr-/- mice were vaccinated against 
GFP and Foxp3 while they were on a Western-type diet for already 10 weeks. 12 
weeks after vaccination and continuous Western-type diet feeding, mice were 
sacrificed and lesions at the aortic root were investigated. Representative slides of 
the aortic root of GFP and Foxp3 vaccinated mice are shown in Figure 8.5A and B. 
A 14% increase in lesion size, although not significant, was observed between 
Foxp3 vaccinated mice and GFP vaccinated mice (Figure 8.5C; 993.620±44.946 µm2 
versus 869.165±46.884 µm2; P=0.07). However, during analysis we observed an 
increased diameter of the hearts and therefore we calculated the ratio between the 
intima and the luminal space. We observed an increase of 28% in intima/lumen 
ratio, indicating aggravated atherosclerosis (Figure 8.5D; 0.37±0.015 versus 
0.473556±0.028, P<0.01). These effects are unrelated to serum cholesterol levels, 
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since there were no differences observed in cholesterol levels between the two 
groups (data not shown). Again, no difference in lesion size was observed between 
PBS treated mice and GFP vaccinated mice (data not shown). 
 
 
FIGURE 8.4: EFFECT OF FOXP3 VACCINATION ON INITIAL LESION SIZE. After 8 weeks of vaccination and 
Western type diet feeding the LDLr-/- mice were sacrificed and the heart of GFP treated (A) and Foxp3 
treated (B) mice were sectioned and stained with Oil-red-O and hematoxylin. The lesions were 
quantified and the plaque size was determined (C). During the experiment, blood was taken by tail vein 
bleeding and total cholesterol concentration was determined within the serum (D). **P<0.01 
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FIGURE 8.5: THE EFFECT OF FOXP3 VACCINATION ON ADVANCED LESION SIZE. After 22 weeks on Western 
type diet feeding and 12 weeks after vaccination the LDLr-/- mice were sacrificed and the heart of GFP 
treated (A) and Foxp3 treated (B) mice were sectioned and stained with Oil-red-O and hematoxylin. The 
lesions were quantified and the plaque size was determined (C). Additionally, the ratio between intima 
and luminal space was calculated (D). **P<0.01 
 
VACCINATION AGAINST FOXP3 RESULTS IN INCREASED PLAQUE CELLULARITY  
To investigate whether there is a change in plaque composition in the enlarged 
initial plaques of the Foxp3 vaccinated mice we quantified the number of cells 
within the lesions. The plaques of Foxp3 vaccinated mice showed a 27% increase in 
cellularity compared to GFP vaccinated mice (Figure 8.6; 3.84x10-3±0.19x10-3 
cells/µm2 versus 2.81x10-3±0.79x10-3 cells/µm2; P<0.01). Increased cellularity may 
indicate an increased level of inflammation within the plaque. Therefore we 
determined the plaque stability by measuring both the amount of collagen within 
the plaque and the fibrous cap thickness. The collagen content of the plaque was 
not significantly changed between the Foxp3 and GFP vaccinated mice (Figure 8.7, 
9.0±1.1% versus 6.5±1.9%). Additionally, we noticed that the lesions in 9 of the 13 
Foxp3-vaccinated mice displayed significant characteristic changes in morphology. 
These lesions are characterized by a thickened structure in the fibrous cap (Figure 
8.8, arrowhead). When compared with GFP vaccinated mice in which 2 out of 14 
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mice showed these thick structures, a significant difference is observed when a 
Fisher’s exact test is performed (Figure 8.8, P<0.01). Overall there was no 
significant difference between the cap thickness in the different groups (data not 
shown).  
 
FIGURE 8.6: EFFECT OF FOXP3 VACCINATION ON PLAQUE CELLULARITY. After 8 weeks of vaccination and 
Western type diet feeding the LDLr-/- mice were sacrificed and the heart of GFP treated (A) and Foxp3 
treated (B) mice were sectioned and stained with hematoxylin to stain the nucleus of the cells within the 
lesion. The number of nuclei was quantified (C). **P<0.01 
 
FIGURE 8.7: EFFECT OF FOXP3 VACCINATION ON COLLAGEN CONTENT WITHIN THE LESION AT THE AORTIC 
ROOT. After 8 weeks of vaccination and Western-type diet feeding the LDLr-/- mice were sacrificed and 
the heart of GFP treated (A) and Foxp3 treated (B) mice were sectioned and stained with Masson’s 
Trichrome staining which stains collagen blue. The percentage of collagen relative to the lesion size was 
determined (C).  
INCREASED SPLEEN CELL PROLIFERATION IN FOXP3 VACCINATED MICE 
The regulatory function of Tregs is partly mediated by cell-cell contact and surface-
bound TGF-β and CTLA-4.19 Since we observed an increased cellularity within the 
lesions of Foxp3 vaccinated mice, we hypothesized that vaccination against Foxp3 
results in less suppression of T cell proliferation. Therefore we studied the 
proliferation of the spleen cells from the vaccinated mice. We observed a 
significant 1.9-fold increase compared to the GFP vaccinated mice (Figure 8.9: 
4,148.5±941.4 dpm versus 8,230.5±1 542.5 dpm P<0.05). 
 
A B 
%
 C
o
ll
a
g
e
n
  
GFP FoxP3 
C 
  
0 
2 
4 
6 
8 
10 
B 
GFP FoxP3 
C
e
ll
s 
(x
1
0
- 3
 µ
m
2
) ** 
C 
  
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
A 
  Chapter 8    
 
    164 
 
 
FIGURE 8.8: THICKENED CAP STRUCTURE IN FOXP3 VACCINATED MICE. After 8 weeks of vaccination and 
Western type diet feeding the LDLr-/- mice were sacrificed. Within the Foxp3 vaccinated group we 
observed more thickened structures in the fibrous cap (arrow), compared to the control. Frequency of 
thickened structure between control and vaccinated mice is depicted in the table. A Fisher’s exact test 
was used (P<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8.9: EX VIVO SPLEEN CELL PROLIFERATION IN VACCINATED MICE. 8 weeks after vaccination, the 
mice vaccinated with either GFP (N=5, white bar) or Foxp3 (N=5, black bar) were sacrificed. The spleen 
was dissected and cultured ex vivo. Proliferation was assessed by the amount of 3H incorporation in 
dividing cells. The amount of 3H-thymidine incorporation was measured using a liquid scintillation 
analyzer (Tri-Carb 2900R). The proliferation is expressed in disintegrations per minute (dpm). *P<0.05 
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DISCUSSION 
In this study we demonstrate that vaccination against Foxp3+ Tregs aggravates 
atherosclerotic lesion formation, thereby directly establishing the protective role of 
Tregs in atherosclerosis. The beneficial role of Tregs in atherosclerosis is already 
indicated in a number of publications.15, 20 We showed before that induction of 
Foxp3 positive Tregs via oral tolerance induction against HSP60 and oxLDL 
reduces atherosclerotic lesion formation.10, 11 Furthermore, it had been 
demonstrated that a deficiency in co-stimulatory molecules promotes 
atherosclerosis because of a decrease in the number of Tregs15 and Ait-Oufella and 
colleagues showed that a depletion of CD25+ cells using anti-CD25 antibodies 
increased lesion formation.15 However, the final proof for the involvement of 
Foxp3 expressing T cells in atherosclerosis has not been provided since CD25 is not 
exclusive for Tregs. CD25 is for example also expressed on other cell types such as 
activated T cells21, NK cells22 and myeloid DCs.23  
To specifically study the role of Foxp3 positive Tregs in atherosclerosis we 
vaccinated atherosclerosis prone mice against Foxp3 using a DC vaccination 
strategy. DCs are electroporated with mRNA encoding for Foxp3 and this 
approach, described by Nair et al, results in a cytotoxic T lymphocyte (CTL) 
response against Foxp3 and a subsequent depletion of Foxp3+ Tregs.16 As a control, 
mRNA encoding for GFP was used to exclude that mRNA electroporation into 
DCs activates the DCs leading to immune modulatory effects. In all the 
experiments, the treatment with GFP electroporated DCs was compared with PBS 
treatment alone and no differences were observed between both treatments. After 
electroporation of DCs with mRNA, either with GFP or with Foxp3, an activated 
phenotype of DCs was observed. This was not observed when DCs were 
electroporated without mRNA. It is known that single stranded RNA (ssRNA), 
such as mRNA is a natural ligand for Toll like receptors 7 and 8,24,25 which may 
explain the activated phenotype of the DCs after electroporation with mRNA.  
We successfully demonstrated that the DCs were transfected with the 
mRNA coding for Foxp3 via qPCR and a FACS analysis. Foxp3 is a nuclear 
product and is not expressed on the cell surface. However, we use a truncated 
Foxp3 in which the nuclear localization sequence is removed. This results in 
relatively high concentration of cytosolic Foxp3 protein and therefore may results 
in the cross-presentation of Foxp3-peptides on MHC class I. Furthermore, mRNA 
may act as a natural agonist of TLR7/8 and thereby even further enhance cross-
presentation, which is already described by other groups.24-27 This may lead to the 
triggering of CD8+ T cells, which subsequently target Foxp3 expressing cells. 
Our present data show a significant reduction in Foxp3+ Tregs in blood 
five weeks after vaccination. This may be an indication for the induction of Foxp3-
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specific cytotoxic CD8+ T cells. A similar reduction in Foxp3+ Tregs was observed 
within the blood, HLN, MLN and spleen, 8 weeks after vaccination, indicating a 
systemic reduction in Foxp3+ Tregs and a persistent effect of the vaccination. The 
reduction in Foxp3+ Tregs resulted in a 34% increase in initial lesion size and 
additionally 14% increase in advanced lesion size. The increase in atherosclerosis is 
not related to a change in total cholesterol serum levels since there is no significant 
difference in cholesterol levels between the different groups. 
Besides an increase in lesion size, vaccination against Foxp3 also induced a 
30% increase in cellularity of the initial lesions. The increased cellularity may 
indicate an increase in inflammation within the lesion, which may be caused by an 
increase in proliferation of inflammatory cells or by an increase in influx of 
inflammatory cells. Which cells are responsible for this increase needs to be 
determined, but we suggest that at least a part of these cells are T cells, since a 
reduction in Foxp3+ Tregs may result in more proliferation of effector T cells (Th1 
and Th2).28 This is in line with the observed increase in proliferation of spleen cells 
isolated from Foxp3 vaccinated mice as compared with both control groups. This 
may illustrate that a lowered number of Foxp3+ Tregs led to a less suppression of 
Th1 and Th2 cells and thereby led to an increased proliferation of effector T cells. 
In addition to plaque cellularity, we checked plaque stability but the collagen 
content was not changed. In spite of the fact that the fibrous cap thickness was not 
changed between vaccinated and control mice, we observed significant more 
thickened cap structures in the fibrous cap of the Foxp3 vaccinated mice. The 
composition of this thickening and whether this thickened structure results in a 
more stable plaque phenotype remains to be determined. 
The results in this study are in line with the observations that the induction 
of Tregs exert an atheroprotective effect. The increase in lesion size is comparable 
with the decrease of initial lesion size upon the induction of Tregs via oral 
administration of oxLDL (30.0%) or HSP60 (27.5%).10, 11 Oral tolerance induction 
against oxLDL also resulted in a decrease in advanced lesion size, which is 
comparable with the increase in advanced lesion size in this study.10 
In conclusion, we confirmed the protective role of Foxp3+ Tregs in 
atherosclerosis by vaccinating LDLr-/- mice using a DC based Foxp3 vaccination 
strategy. The results illustrate an important role for Foxp3+ Tregs in 
atherosclerosis, thereby providing a potential opportunity for therapeutic 
intervention against atherosclerosis. 
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ABSTRACT 
Atherosclerosis is a chronic inflammatory disease that develops in the context of 
enhanced serum lipid levels. Nowadays, many studies focus on the modulation of 
inflammatory responses to reduce atherosclerosis. The most powerful strategy to 
achieve this is vaccination. In several immune diseases vaccination is shown to be 
very effective, resulting in a drastic decline in the incidence of the disease. But is 
vaccination also realistic in atherosclerosis?  
In this article, several approaches to vaccinate against atherosclerosis are 
described. Vaccination (based on protein or DNA) against bioactive molecules and 
disease-related proteins successfully reduces experimental atherosclerosis. In 
addition, passive immunization with antibodies against atherosclerosis-specific 
antigens and tolerance induction, in which antigen-specific regulatory T cells are 
elicited, are described.  
In the near future, we expect an increased interest in vaccination against 
atherosclerosis and, maybe, the myth may become reality when the first clinical 
trials are performed. 
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INTRODUCTION 
Atherosclerosis, the main underlying pathology of cardiovascular disease, is a 
multifactorial, chronic, autoimmune-like disease initiated by both lipid 
accumulation and inflammatory processes.1–3 Both the innate immune response, 
represented by monocytes and macrophages, and adaptive immune responses, 
represented by T and B cells, are important in the onset and progression of 
atherosclerosis.  
The modification of lipoproteins and the subsequent activation of 
endothelial cells results in an increased expression of chemokines and adhesion 
molecules, leading to the attraction of monocytes and subsequent diapedesis into 
the vessel wall. The monocytes ingest the modified lipoproteins and differentiate 
into foam cells. These foam cells produce chemokines and cytokines that enhance 
the recruitment of more monocytes and also T cells, thereby aggravating 
atherosclerosis.  
Dendritic cells are pivotal in bridging the innate and the adaptive immune 
responses, and the switch towards an adaptive immune response is considered to 
be of utmost importance in the development of autoimmune diseases. Locally 
(within the lesion), but also systemically (periphery), dendritic cells ingest 
autoantigens such as oxidatively modified-LDL (ox-LDL) and heat-shock proteins 
(HSPs), and migrate to secondary lymphoid organs – the spleen and draining 
lymph nodes – where they will activate both naive and antigen-specific T cells.  
Subsequently, the T cells migrate towards the atherosclerotic lesion.  
These effector T cells mainly produce T helper (Th)1-associated cytokines 
such as IL-12, IFN-γ, IL-6 and IL-1β within the lesion, which are pro-atherogenic 
and lead to enhanced activation and recruitment of T cells, macrophages and 
dentric cells in the plaque. A disturbed balance between Th-1 and -2 cytokines has 
long been suggested as the underlying cause of the auto-inflammatory pathology 
in atherosclerosis. Th2 cytokines such as IL-5 and -10 are anti-atherogenic and may 
counteract the Th1 cytokines.1–3 During recent years, this theory has been 
challenged by a new hypothesis in which regulatory T cells (Tregs) play a pivotal 
role, since they can dampen inflammatory responses in several autoimmune 
diseases. Therefore, Tregs may hold promise in the future treatment of 
atherosclerosis.3,4 
 
CURRENT TREATMENT OF ATHEROSCLEROSIS 
Currently, the treatment of atherosclerosis is mainly based on reducing risk factors 
such as high circulating cholesterol levels and hypertension. Statins are currently 
the most prescribed drug and exert their effect largely by lowering plasma 
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cholesterol levels. In addition, statins may improve endothelial function, modulate 
inflammatory responses, maintain plaque stability and prevent thrombus 
formation. Other less frequently prescribed medications to reduce cardiovascular 
diseases are anti-platelet therapies and anti-inflammatory aspirin. Although statins 
produced a decline in the incidence of atherosclerosis, cardiovascular diseases are 
still the leading cause of death in the Western world.  
The role of inflammation in atherosclerosis has been demonstrated 
extensively in experimental studies, but no treatment that directly modulates the 
inflammatory response has reached the clinic as yet. At the moment, a number of 
attractive approaches are available to interfere in the autoimmune reactions. 
Suppressing the function or expression of pro-atherogenic cytokines and/or 
stimulating the function and expression of anti-atherogenic cytokines are the most 
described techniques in atherosclerosis research. However, intervention in 
cytokine pathways may have a disadvantage, since some pro-inflammatory 
cytokines, such as IL-12 and IFN-γ, are crucial for an efficient immune response 
against pathogens. 
 
VACCINATION 
For many diseases, vaccination is used as a preventive therapy. Traditional 
vaccination protocols use weakened or dead pathogens or purified components 
from these pathogens, for example, proteins, to induce immunity. It is an effective, 
relatively easy way to protect against diseases caused by viruses or bacteria such as 
smallpox, polio, measles and rubella. 
 Nowadays, vaccination against nonpathogenic particles such as cytokines 
and immunogenic antigens is also a commonly used strategy to prevent 
autoimmune diseases in animal models. In our opinion, the terminology of 
vaccination and immunization is somewhat unclear. In this perspective review we 
use the term vaccination as a treatment that results in immunization. 
Immunization is the induction of immune resistance to a specific disease in 
humans (or other mammals) by exposing the individual to a disease-related 
antigen in order to raise antibodies and/or other immune reactions towards that 
antigen (e.g., tolerance induction). Although passive immunization is not strictly 
believed to be a vaccination strategy, we include this technique as an 
immunomodulating tool for treatment of autoimmune diseases, such as 
atherosclerosis, in the scope of this review. 
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In different autoimmune diseases, vaccination has already proved to be an 
effective strategy to attenuate disease pathology.5–7 However, the complication in 
atherosclerosis is that it is a multifactorial disease. Many studies suggest that 
several pathogens influence the inflammatory responses towards a more pro-
atherosclerotic condition, probably by cross-reacting with homologous ‘self’ 
proteins in a form of ‘molecular mimicry’. Pathogens such as Chlamydia 
pneumoniae and cytomegalovirus are related to atherosclerosis, but their role is 
still unclear.8–10 As in other autoimmune diseases, autoantigens play an important 
role in the initiation and aggravation of the disease.  
In patients with manifestations of atherosclerosis, several autoantigens can 
be identified, such as modified lipoproteins (ox-LDL, malondialdehyde [MDA]-
modified-LDL), HSPs (HSP60 and HSP70), ApoB100 peptides and β2 glycoprotein 
I. The immunogenecity of these autoantigens is reflected in the levels of 
autoantibody levels against epitopes of ox-LDL and HSPs, since they are 
significantly increased in patients with atherosclerosis. In addition, T cells 
specifically responding to these auto antigens have been detected within 
atherosclerotic plaques.11,12 Considering atherosclerosis as an autoimmune disease, 
vaccination can provide an alternative treatment for atherosclerosis.  
Many of the vaccination strategies mentioned in this article are successfully 
performed in other autoimmune diseases, such as collagen-induced arthritis and 
experimental autoimmune encephalitis (EAE),13,14 but it should be taken into 
account that atherosclerosis is, in some aspects, different from other autoimmune 
diseases. Atherosclerosis is a disease that slowly progresses with age, and the onset 
of lesion formation begins at a very young age (<20 years). Furthermore, 
atherosclerosis is a multifactorial disease in which inflammation and an altered 
lipid metabolism play essential roles, resulting in a more complex pathogenesis. 
Removal or blockade of proatherogenic factors in childhood could be very effective 
in the prevention of lesion formation, and the interesting question is whether 
vaccination is a realistic goal in the treatment of atherosclerosis? We will further 
discuss different ways of vaccination that could become potential treatments for 
atherosclerosis. 
 
PROTEIN VACCINATION: ELIMINATION/BLOCKADE OF BIOACTIVE 
MOLECULES 
Most traditional vaccination strategies use adjuvants to enhance and modulate the 
immune response. Commonly used adjuvants are Freund’s adjuvant and 
aluminium salts adjuvant. The choice of the adjuvant together with the target 
determines the outcome of the vaccination. This approach has been used in other 
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autoimmune diseases, such as vaccination against IL-17A in EAE15 and vaccination 
against TNF-α in experimental arthritis.6 
In a previous study we performed a protein vaccination against IL-12 with 
MPL/QS21 adjuvant. To break tolerance against self-antigens, we coupled IL-12 to 
an immunodominant Th epitope, termed PADRE. Functional antibodies were 
detected and IL-12 was successfully neutralized. In addition, the downstream 
pathway of IL-12 was blocked as was seen in reduced IFN-γ levels. With this 
approach, a 60% smaller sized and more stable plaque was formed.16 Another 
possible target for vaccinating against atherosclerosis is cholesteryl ester transfer 
protein (CETP). CETP transfers cholesteryl esters from anti-atherogenic HDLs to 
pro-atherogenic ApoB-containing lipoproteins, including VLDLs and LDLs. 
Studies show that anti-CETP antibodies can inhibit CETP activity, increase plasma 
HDL-C and attenuate atherosclerosis.17,18 As a next step, a vaccine was developed 
to induce antibodies that continuously inhibit CETP activity for a long time in vivo. 
A chimeric protein containing CETP and a helper T-cell epitope consisting of 
residues of tetanus toxin was constructed. The T-cell epitope from tetanus toxin 
was selected on the basis of its ability to bind many MHC haplotypes. New 
Zealand white rabbits were vaccinated with the chimeric enzyme and CETP-
neutralizing antibodies were formed. There was an increase in plasma HDL-C, a 
decrease in plasma LDL-C and an attenuation in the development of 
atherosclerosis in vivo.18 
Both vaccinations result in the formation of specific antibodies and 
attenuation of atherosclerosis. Despite the successful results in animals, protein 
vaccination has some drawbacks. Large quantities of protein (antigen) have to be 
synthesized or isolated, and its storage and production are rather expensive 
processes. Furthermore, immunomodulatory components need to be added, such 
as adjuvants and immune dominant T-cell epitopes, in order to break tolerance and 
to get an appropriate immune response. The addition of these immunomodulatory 
components might induce a risk for side effects. In our opinion, methods without 
adjuvant addition are, therefore, more favorable in the clinic as very few 
traditional adjuvants are approved by the US FDA for human use.19,20  
Besides these considerations, there is also the risk of side effects related to 
blocking the bioactive molecules. For example, blocking CETP may increase HDL 
levels and a clinical trial demonstrates that this may cause serious problems, 
resulting in high blood pressure and increased deaths and cardiovascular events.21 
Even more riskful is the neutralization of immunoregulatory molecules, such as IL-
12. Blocking IL-12 will impair a proper host defense against several pathogens not 
related to  atherosclerosis. 
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PROTEIN VACCINATION: ELIMINATION/BLOCKADE OF DISEASE-
RELATED PROTEINS 
The most preferred vaccination strategy is to develop a vaccine that induces a 
protective immune response against disease-specific autoantigens. Vaccination 
against a glycosylated collagen type II peptide reduces active arthritis,22 and 
epicutaneous immunization with type II collagen inhibits collagen-induced 
arthritis.23 Furthermore, vaccination against an Alzheimer-specific peptide (Aβ1–
11) protects against Alzheimers disease24 and epicutaneous immunization with 
myelin basic protein protects against EAE.25  
In atherosclerosis, many different antigens and epitopes that induce the 
immune response are known. Interesting candidates are indicated by the presence 
of naturally occurring antibodies against ox-LDL or HSPs in patients with 
cardiovascular diseases or suffering a carotid artery occlusion. 26,27 Vaccination 
against these more disease-specific molecules is often called immunization (active 
immunization).  
Immunization against HSP65 resulted in an enhanced fatty-streak 
formation in C57BL/6 mice and it promoted early atherosclerosis in LDLr-/- mice. 
In both cases, an increase in anti- HSP65 antibodies was found and it was, 
therefore, suggested that these antibodies are pro-atherogenic.28,29 By contrast, 
immunization against modified LDL induced a protective antibody response (both 
IgM and IgG). IgM antibodies are shown to be protective by blocking the uptake of 
ox-LDL via scavenger receptor CD36, thereby reducing foam-cell formation. The 
role of specific IgG antibodies against ox-LDL is, however, still not understood.30 
Lopes-Virella et al. showed a correlation between increased ox-LDL-specific IgG 
levels and the development of coronary artery disease.31 Fredrikson et al., 
however, showed that activation of Th2-specific antibodies (IgG1) as a result of 
immunization with MDA-modified ApoB100 peptide sequences protects against 
atherosclerosis.32,33 Binder et al. showed that active immunization of 
atherosclerosis-prone mice against Streptococcus pneumoniae led to a high level of 
IgM antibodies against phosphorylcholine (PC), owing to molecular mimicry and a 
reduction in the degree of atherosclerosis.34 Subsequently, atherosclerosis-prone 
mice immunized with PC displayed smaller atherosclerotic lesions and an increase 
in serum titers of anti-PC IgG and IgM. In this study, it is again suggested that 
anti-PC antibodies, at least partially, blocked ox-LDL uptake by macrophages. So 
the decline in foam-cell formation may contribute to the reduction in 
atherosclerotic lesion development.35 More research must be performed to 
determine the exact mechanism of action of these autoantibodies.  
Although very effective, immunization against disease-specific antigens 
has a disadvantage owing to the use of adjuvants. Therefore, as stated above, 
strategies without adjuvant addition are more favorable. It would be an 
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improvement when the immunization results in long-term protection. Then you 
would only need one injection, taken once within a certain period, for example 10 
years, as is the case with several general vaccination protocols. This will further 
reduce the incidence of the negative side effects.  
 
DNA VACCINATION  
To overcome the obstacles with protein vaccination, a new approach has been 
used, DNA vaccination. This method uses a eukaryotic expression vector that 
encodes the antigen of interest. In accordance with protein vaccination, an 
immunomodulatory component must be added to enhance the immunogenecity. 
Therefore, the DNA of the antigen is altered or coupled to bacterial motifs, coding 
regions for interleukins, or costimulatory molecules. Furthermore, the plasmid can 
be transfected to an attenuated pathogen and subsequently be administered to the 
patient. This approach induces an enhanced immune response and, thus, functions 
both as an adjuvant and a carrier at the same time.  
The DNA-vaccination technique is already applied in mice models for 
other autoimmune diseases. Vaccination with DNA constructs encoding MOG and 
PLP resulted in a reduction of EAE in mice,36 while vaccination with plasmids 
containing human TNF-α DNA elicits the production of protective antibodies 
against TNF-α  and prevents collagen-induced arthritis in mice.37 We recently used 
a DNA-vaccination strategy in which an attenuated Salmonella typhimurium 
containing a VEGF-receptor (VEGFR) 2-encoding plasmid is administered orally to 
induce a cytotoxic CD8+ T-cell response against this molecule. The specific CD8+ T 
cells target activated endothelial cells within the damaged endothelial lining, 
which results in the subsequent removal of these cells and in a reduction in 
atherosclerotic lesion formation.38 DNA-vaccination techniques are very 
promising, but again, many of the side effects against self antigens seen with 
protein vaccination occurs with DNA vaccination. For example, blocking VEGFRs 
might impair angiogenesis and vasculogenesis, which causes bleedings and 
abnormalities to the vasculature.  
It should be taken into account that with DNA vaccination, some 
posttranslational modifications might be different when compared with the native 
protein expression. In addition, the epitopes may be altered and the specific 
recognition may be ameliorated. However, the main advantage of DNA 
vaccination is that it is relatively fast and easy to develop the vaccine as compared 
with the labor-intensive isolation of proteins and antibodies.  
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PASSIVE IMMUNIZATION 
Another vaccination strategy is passive immunization, in which specific antibodies 
are injected. This approach has already been applied in the clinic as treatment for 
rheumatoid arthritis.39 Treatment with anti-PC IgM antibodies inhibited 
accelerated atherosclerosis in a vein graft in atherosclerosis-prone ApoE-/- mice.40 
A human IgG1 antibody against a MDA-modified ApoB100 peptide is protective 
against atherosclerosis an ApoE-/- mice. Low numbers of the MDA-ApoB100 
peptide were found in plaques of the treated mice and it is suggested that the 
injected IgG antibodies inhibited the uptake of ox-LDL in the lesion and/or 
facilitated the removal of ox-LDL from the circulation or plaques.41  
Passive immunization may be a safer and more controllable treatment 
compared with active immunization (DNA and protein). Furthermore 
immunocompromised patients may benefit from passive immunization. A 
disadvantage is that the treatment is quite expensive and labor-intensive. 
Humanized antibodies are needed before patients can be treated with these 
antibodies.  
 
TOLERANCE INDUCTION  
The last method of vaccination discussed here is tolerance induction. Tolerance 
induction is a relatively new vaccination strategy in which the vaccine is 
administered orally or nasally without the addition of adjuvants or other 
immunomodulatory components. Tolerance can be induced against several 
autoantigens, such as type II collagen peptide 250–270, which protects against 
collagen-induced arthritis via the induction of specific cellular and humoral 
immune responses.42 Low-dose oral tolerance can also be induced against a MOG 
peptide, resulting in decreased EAE in mice.43 Several years ago, oral and nasal 
tolerance against HSP60/65 was shown to successfully suppress early 
atherosclerosis.44,45 Some years later, oral-tolerance induction against β2-
glycoprotein I also proved to be protective against atherosclerosis.46 In all these 
studies, an increased production of anti-atherogenic cytokines was observed, but 
the underlying mechanism remained to be clarified.  
Recently, we performed two studies in which we demonstrated that oral 
administration of HSP60, a small HSP60 peptide (253–268) and ox-LDL resulted in 
a reduction in atherosclerosis.47,48 These are the first studies on oral vaccination that 
demonstrate the suppression of atherosclerosis is due to the induction of Tregs. In 
both cases, we found an initial increase in numbers of Tregs in the Peyer’s patches. 
Subsequently, an increase in Treg numbers is observed in blood, mesenteric lymph 
nodes and spleen 2 weeks after oral vaccination. We now suggest that the Tregs 
migrate from the Peyer’s patches via blood to the secondary lymphoid organs. In 
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addition, an increase in Tregs is observed within the atherosclerotic lesion, and 
mesenteric lymph node cells produced more IL-10 and TGF-β upon restimulation 
with the antigen.  
Oral, but also nasal vaccination in the context of tolerance induction may 
be very effective in reducing atherosclerosis. Recently, it was shown that injections 
with anti-CD25 antibodies, thereby depleting Tregs, resulted in an increased lesion 
size in ApoE-/- mice.49 Depletion of costimulatory molecules such as CD-28, -80 
and -86, also resulted in a reduction in the number and function of Tregs and 
subsequently in higher atherosclerosis susceptibility.49. On the other hand, 
treatment of LDLr-/- mice with anti-CD3 antibodies, stimulating the activation 
and proliferation of Tregs, reduced the development and progression of 
atherosclerotic lesions.50 Furthermore, a transfer of antigen-specific Tr1 cells, a 
subset of Tregs, elevated IL-10 levels in ApoE-/- mice and reduced lesion 
formation.51 In addition, injection of in vitro-generated HSP60-specific Tregs 
prevented atherosclerotic lesion development.52  
However, some important questions remain unanswered. What is the exact 
mechanism involved in Treg suppression of pro-atherogenic immune responses? 
Do Tregs act via cell–cell contact, do they act cytokine-dependently or a 
combination of these two pathways? Do these Tregs suppress the immune 
responses within the lymphoid organs such as lymph nodes and spleen or do they 
act within the lesion? Finally, the opportunity to manipulate Treg responses as a 
treatment for atherosclerosis requires a better characterization of the antigens that 
pro-atherogenic T cells recognize. In addition, the antigens that cause activation 
and proliferation of Tregs that migrate into atherosclerotic lesions or draining 
lymphoid tissues need to be characterized.  
 
CONCLUSION 
In summary, a number of different vaccination strategies have been applied in 
atherosclerosis research during the last 10 years (Table 1). One of the first strategies 
was the targeting of pro-atherogenic interleukins that play an important role in a 
normal host defense, such as IL-12. This strategy can be subdivided into protein 
and DNA vaccinations, and it has been demonstrated to be successful in 
experimental autoimmune encephalomyelitis and may, therefore, also be 
successful in atherosclerosis.5  
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TABLE 9.1: AN OVERVIEW OF THE DIFFERENT VACCINATION STRATEGIES THAT HAVE BEEN APPLIED 
IN ATHEROSCLEROSIS RESEARCH DURING THE LAST 10 YEARS. 
 
Passive immunization uses (humanized) antibodies to block the pro-
inflammatory action of specific cytokines or antigens. However, selection and 
production of these specific humanized antibodies or the production of proteins 
for protein vaccination is very labor intensive and expensive as compared with 
DNA vaccination. It is challenging for the industry to synthesize humanized 
antibodies that are appropriate for administration to patients in, for example, 4-
week intervals that can modulate the function of the pro-inflammatory cytokines 
or antigens.  
We conclude that the optimal approach to introduce a vaccine against 
atherosclerosis is to focus on atherosclerosis-specific components. This can be 
achieved by either immunization, resulting in the production of protective 
antigenspecific antibodies, or by mucosal tolerance induction, resulting in the 
induction of antigenspecific Tregs. Atherosclerosis is a complex disease in which 
several antigens – many of which are not yet characterized – play an important 
role. A vaccination that results in the generation of antibodies that are limited in 
time in their functioning and in which a cocktail of the different antigens is 
administered may be an attractive approach. This cocktail can either be injected 
 
IMMUNOMODULATION 
METHOD 
 
TARGETS 
 
ADJUVANS 
 
 
PHARMA-
CEUTICAL 
APPLICABILITY 
 
PATIENTS 
DISCOMFORT 
 
EXPECTED  
SIDE 
EFFECTS 
 
REF. 
 
Protein vaccination 
Bioactive molecules 
 
Disease related proteins 
 
 
IL-12  
CETP 
Ox-LDL 
MDA-modified 
ApoB100 
Streptococcus 
pneumoniae 
 
 
+ 
+ 
+ 
+ 
 
+ 
 
 
- 
- 
- 
- 
 
- 
 
 
+ 
+ 
+ 
+ 
 
+ 
 
 
+ 
+ 
± 
± 
 
± 
 
 
16 
18 
30 
32,33 
 
34 
 
DNA vaccination 
 
VEGF- 
receptor 2 
 
- 
 
± 
 
+ 
 
+ 
 
38 
 
Passive immunization 
 
PC 
MDA-modified 
ApoB100 
 
- 
- 
 
 
- 
- 
 
± 
± 
 
- 
- 
 
40 
41 
 
Tolerance induction 
 
HSP60/65 
β2-glycoprotein 
I 
HSP60 peptide 
Ox-LDL 
 
- 
- 
- 
- 
 
+ 
+ 
+ 
+ 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
44,45,47 
46 
47 
48 
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intravenously or intraperitoneally to immunize against the antigens, or it can be 
administered orally or nasally to induce protective Tregs against these antigens.  
A major consideration when developing a new therapeutic treatment is the 
inconvenience for the patient. Repeated injections and invasive treatment and, 
thus, repeated visits to the clinic are not favorable, but may not form a major 
problem. A better, more promising approach may be to supplement the vaccine to 
the individual’s diet. This is convenient for the patient and easy to apply every day 
or once a week. The best vaccination strategy will be one that results in plaque 
stabilization in addition to reducing plaque development. Since atherosclerosis 
prevails at a very young age but only manifests itself later in life, the majority of 
patients will not benefit from strategies that focus on early plaque development, 
but will benefit from a vaccination strategy early in life that prevents the 
development of lesions.  
 
FUTURE PERSPECTIVE 
A number of different strategies can be developed to protect people against 
atherosclerosis or to treat patients with clinical symptoms thereof. In our opinion, 
DNA and protein vaccination in experimental models for atherosclerosis will form 
the initial strategy to investigate the possibility of whether vaccination against the 
target protects against atherosclerosis. The studies described in this article 
investigated the effect of vaccination and immunomodulation on the development 
of atherosclerosis. It would be favorable for the clinical application that a 
vaccination against a specific molecule increases the plaque stability, and we 
foresee that this can be achieved by short-term vaccination with proteins or DNA 
or a short-term treatment with humanized antibodies. In the next 5–10 years, we 
expect to see an increase in studies using protein and DNA vaccination as a 
strategy to investigate the blockade of the molecule of interest in experimental 
models for atherosclerosis, with specific interest in pro-atherosclerotic cytokines.  
Treatment with protective antibodies is a very powerful strategy and a 
may form a good achievable alternative for protein or DNA vaccination. This 
technique is nonpermanent, controllable and side effects may be limited. Because 
the antibodies have a defined half-life once injected, one can determine the exact 
administration protocol and the optimal timing for repetitive injections. This 
strategy is, however, very expensive given that it may also be needed to treat the 
majority of the population given the widespread occurrence of cardiovascular 
disease, although this approach is attractive for pharmaceutical companies.  
In our opinion, the strategy with the best future perspective is oral-
tolerance induction. This vaccine is relatively cheap, easy to administer and no 
adjuvants or immunomodulatory components are necessary. The risk for side 
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effects appears minimal and the patient can easily be ‘vaccinated’ by processing 
the tolerant agent in food or drinks. Nowadays, a few antigens – ox-LDL, HSP60 
and β2 glycoprotein I – have been used to induce oral tolerance in atherosclerosis. 
We expect that in the near future a great deal more possible antigens will be tested 
in oral tolerance. The best strategy would be to use a cocktail of different antigens 
as a powerful vaccine. However, a lot of research is still necessary before this 
strategy will be applicable in the clinic, and several questions remain unanswered. 
How to obtain the adequate antigens for tolerance induction? Should we use, for 
example, the ox-LDL from the patients themselves? Which concentration is optimal 
in humans? Although these results look very promising, it should be mentioned 
that all these experiments are performed in mice models for atherosclerosis. In 
order to extrapolate these data, they need to be verified in the human situation.  
Therefore, further research is required and we expect that in the next 
couple of years the first clinical trials will be performed using both antigen-based 
vaccines (oral tolerance induction) and recombinant IgGs targeting epitopes in ox-
LDL. For a lot of people, vaccination against atherosclerosis is still a myth, but it 
may become reality when one of the above described strategies turns out to be 
successful in reducing atherosclerosis without severe side effects. 
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SUMMARY AND PERSPECTIVES 
Atherosclerosis, the predominantly underlying pathology of cardiovascular events, 
is the consequence of lipid deposition in the arterial wall, mostly as consequence of 
high levels of serum cholesterol. Treatment of atherosclerosis is mainly focused at 
the reduction of cholesterol levels by lipid lowering medication, such as statins.  
Despite the use of statins and prophylactic treatments, such as a reduction 
in blood pressure and a reduction in risk factors to prevent atherosclerosis, 
cardiovascular disease is still the major cause of death in the Western world.1-3 As 
the struggle against atherosclerosis continues and its prevalence is increasing in the 
world, it is pivotal to find new targets for implementing new strategies against 
atherosclerosis.  
Inflammation is considered to be a major component in the process of 
atherosclerosis and is involved in initiation, progression and destabilization of the 
atherosclerotic lesion. Although the beneficial effects of statins on atherosclerosis 
may partly be ascribed to their anti-inflammatory properties, relatively little is 
known about the exact mechanism and contribution of different inflammatory cells 
and products in atherosclerosis. The aim of this thesis was to further elucidate the 
contribution of various components of the inflammatory response in 
atherosclerosis and thereby finding new intervention points to reduce the 
incidence and the consequences of atherosclerosis. 
 
INTERLEUKIN 15: BRIDGING THE INNATE AND ADAPTIVE IMMUNE 
SYSTEM 
Macrophages are key inflammatory cells in the process of atherosclerosis and play 
an important role in the development of the atherosclerotic lesions, by taking up 
modified LDL via pattern recognition receptors (PRRs). This results in activation of 
macrophages and subsequently in production of inflammatory mediators, such as 
cytokines.  
One of the cytokines produced by macrophages is IL-15. Expression of IL-
15 is detected in human and murine atherosclerotic lesions.4, 5 IL-15 enhances T cell 
recruitment and activation of peripheral blood T cells within the plaque.6 In 
chapter 2 the role of IL-15 in atherosclerosis is demonstrated by targeting IL-15 
overexpressing cells, using DNA vaccination, in LDL receptor deficient mice. The 
increase in number of IL-15 expressing cells in the circulation and spleen upon 
induction of hypercholesterolemia suggests that IL-15 is involved in atherosclerotic 
plaque formation. To further elucidate the role of IL-15 in atherosclerosis, LDLr-/- 
mice were vaccinated against IL-15 by using an attenuated Salmonella typhimurium 
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carrying an IL-15 encoding plasmid. In mice vaccinated against IL-15 a 75% 
reduction of the atherosclerotic plaque is observed in the carotid artery. 
Interestingly, we observed not only 75 % decrease in plaque size, but also 
an increase in relative macrophage content within the atherosclerotic plaque of 
mice vaccinated against IL-15, indicative for a less advanced state of the lesions in 
the vaccinated mice. IL-15 is, in association with IL-15Rα, also expressed in its 
biologically active form on the surface of monocytes and activated macrophages. 
This surface expressed IL-15 is approximately five times more effective than 
soluble IL-15 in the induction of T cell proliferation.7-9We speculate that the 
macrophages in the lesions of IL-15 vaccinated mice do not, or to a lesser extent, 
express IL-15. This is supported by the observation that the number of IL-15 
expressing cells in the circulation was declined to the same level as before the 
induction of hypercholesterolemia. Blocking the IL-15 pathway may result in an 
impairment of the innate switch towards an adaptive immune response thereby 
attenuating atherosclerosis.  
The vaccination strategy used in this study and described in chapter 2, 
successfully evoked a cytotoxic response targeting IL-15 expressing cells. This 
resulted in a vast reduction in atherosclerosis, thereby providing new insights in 
the process of atherosclerosis and the contribution of IL-15 in this process. These 
new insights may contribute to the future immunomodulating treatment of 
patients with cardiovascular disease.  
 
A NEW PLAYER IN THE FIELD, THE TH17 CELL 
Macrophages exert an important bridge function between the innate and adaptive 
immune response. Activated macrophages are also able to present antigens in 
association with MHC class-II molecules to T cells. Depending on the 
microenvironment, T cells can develop in different subsets and T cells are able to 
either aggravate or attenuate atherosclerosis. Already in 1986 Mosmann et al. 
described two distinct Th subsets, Th1 and Th2 cells, with their own specific 
production of cytokines.10 An imbalance between these cells is often related to 
autoimmune diseases, such as atherosclerosis. An exaggerated pro-inflammatory 
response due to an overexpression of Th1 associated cytokines, like IL-12 and IFN-
γ, enhances atherosclerosis.11 It was speculated that the restoration of the Th1/Th2 
balance may attenuate atherosclerosis. However, a deficiency in IL-4, a typical Th2 
interleukin, reduced atherosclerosis.12 Moreover, IL-4 is associated with increasing 
MMP-1 production by macrophages and may therefore have negative effects on 
plaque stability.13 These data indicate that the Th1/Th2 balance does not 
appropriately describe the immune responses in atherosclerosis. Therefore 
researchers looked for different inflammatory and regulatory pathways. 
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One of these pathways is related to the recently identified T cell subset, the 
Th17 cell. These cells provide more complexity and may provide a better 
understanding in the process of atherosclerosis. Th17 mainly produce IL-17, 
although IL-22 and IL-21 are also produced in large quantities.14,15 Recently, newly 
obtained data and insights resulted in a more complex model where TGF-β and IL-
6 initiate Th17 development.16 This is interesting as TGF-β is also required for Treg 
cell differentiation and partly mediates the suppressive function of Treg cells.17,18 
Furthermore, Tregs and TGF-β are associated with reduced atherosclerosis.19-22 
The role of Th17 cells and its hallmark, IL-17, is not known in the context of 
atherosclerosis. Therefore we studied the role of IL-17 in atherosclerosis as 
described in chapter 3. In this study we observed that IL-17 expression within the 
spleen of LDLr-/- mice does increase under hypercholesterolemic conditions. This 
indicates that IL-17 may be involved in the initiation of atherosclerosis. To unravel 
the role of IL-17 in atherosclerosis we used DNA vaccination to block IL-17. The 
DNA vaccine used, encodes the IL-17 coding sequence, preceded by a specific part 
of the HEL sequence, which binds with high affinity to MHC class II and is able to 
activate T cells, thereby breaking tolerance.23,24 Vaccination against IL-17 results in 
a 90.2% decrease in atherosclerotic lesion formation in the carotid artery, indicates 
that IL-17 has  profound pro-atherosclerotic properties. 
Since IL-17 has also pleiotropic effects on several cell types within the 
atherosclerotic lesion, IL-17 may stimulate a pro-inflammatory environment 
resulting in aggravation of atherosclerosis.25,26 An important matrix 
metalloproteinase (MMP) in atherosclerosis is MMP-9,27 which is upregulated in 
macrophages upon IL-17 stimulation. However, the plaques of the HEL-IL-17 
vaccinated mice were too small to accurately determine plaque stability and MMP-
9 expression. Therefore more research has to be performed to study the effect of IL-
17 on more advanced atherosclerotic lesions. 
We set out to investigate the role of the IL-17 receptor in atherosclerosis, by 
performing a bone marrow transplantation (BMT) with IL-17 receptor deficient (IL-
17R-/-) bone marrow (BM) in LDLr-/- recipient mice. In this study (described in 
chapter 4) we further establish the pro-atherosclerotic role of IL-17, since IL-17R-/- 
BM recipients demonstrated a 46% reduction in plaque size. The reduced lesion 
size relates to a reduced number of IL-17R expressing cells in blood after IL-17R-/- 
BMT. Furthermore, spleen cells from IL-17R-/- BM recipient mice demonstrate a 
decreased IL-6 and an increased IL-10 production. This indicates a shift towards a 
more anti-inflammatory response, which favors a beneficial outcome for 
atherosclerosis. Interestingly, we detected a decrease in IgG auto antibodies against 
modified LDL. This is likely due to an impaired B cell regulation in the germ line 
centre (GC) as a consequence of the disturbed IL-17 pathway.28 
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Based on the obtained results described in chapter 3 and 4, we continued to 
study whether Th17 cells, the prominent IL-17 producing T cell, are involved in 
atherosclerosis. An important interleukin in the development of Th17 cells is IL-23. 
IL-23 is a heterodimeric interleukin consisting of a p40 and a p19 subunit and is 
closely related to its family member IL-12 by both sharing the p40 subunit (Figure 
10.1).29 In our laboratory, we already demonstrated that vaccination against p40 
(IL-12/IL-23) results in a reduction of almost 70% in atherosclerotic lesion 
formation.30 However, p40 is shared by both IL-12 and IL-23 and consequently it 
does not elucidate the individual contribution of IL-12 and IL-23 on atherosclerosis 
(Figure 10.1). 
To unravel the role of IL-23, we performed a BMT using p19-/- mice, which 
do not express functional IL-23 (chapter 5). Although the BMT was successful, 
there was no change in lesion size detected between p19-/- BM recipients and mice 
receiving control BM. Furthermore, BMT with p19-/- BM does not result in a 
decrease of Th17 cells. These results may partially be explained by data form other 
research groups, which state that IL-23 acts more as a stabilizing factor for Th17 
cells in stead of initiating Th17 cells.14 Another possibility is the observation that 
CD3+ T cells are able to express the p19 subunit (Lubberts et al., personal 
communication). Whether p40 is also expressed by these T cells to form functional 
IL-23, remains to be elucidated.  
Interestingly, unpublished reports of S. Pflanz & R.A. Kastelein mention a 
heterodimeric interleukin consisting of p19 and EBI3 in vitro.31 Whether these 
heterodimers may be formed in vivo and what function this new interleukin exerts, 
remains to be elucidated (Figure 10.1).  
Another question which remains is, whether the p19-/- BMT results in an 
increased formation of p40 homodimers (12p80). 12p80 can act as an IL-12 and an 
IL-23 antagonist by binding to the IL-12Rβ1 but it can not mediate a biological 
response.32-34 However, other reports illustrate an agonistic function of 12p80 by 
stimulating the differentiation of CD8+ cytotoxic cells and CD4+ IFN-γ producing 
cells.35 The connection of these new insights with our data has to be elucidated in 
future research. 
 
NEW T CELL SUBSETS, NEW BALANCES 
IL-27 is a recently discovered interleukin that structurally resembles IL-12 and IL-
23. IL-27 is a heterodimeric cytokine composed of Epstein-Barr virus induced gene 
3 (EBI3) and p28 and it is important in the regulation of T cell function and 
cytokine production (Figure 10.1).36 Interestingly, IL-27 was firstly described as a 
pro-inflammatory interleukin by Goldberg et al. in EAE and RA, both autoimmune 
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diseases.37, 38 More recently, IL-27 has been associated with suppression of Th17 cell 
and may thereby attenuate diseases such as EAE.39  
Little is known about IL-27 and to our knowledge the role of IL-27 in 
atherosclerosis is not studied yet. Therefore, we studied the role of IL-27 in relation 
to atherosclerosis, which is described in chapter 6. The expression of both IL-27 
subunits (EBI3 and p28) was upregulated in the atherosclerotic plaques of LDLr-/- 
mice. The fact that both subunits are upregulated suggests the production of 
functional IL-27, since p28 alone cannot be excreted without EBI3.40 After 
vaccination against p28, the lesion size in the vaccinated mice increased, which 
indicates that IL-27 has a protective role in atherogenesis.  
Additionally, we demonstrate that blocking IL-27 was associated with a 
reduced number of Treg cells and with an augmented number of Th17 cells within 
the spleen. These observations are of great interest as they demonstrate a shift in 
the balance between the pro-inflammatory Th17 cells and the anti-inflammatory 
Treg cells, thereby aggravating atherosclerosis. Furthermore, is has been shown by 
other groups that there is a balance between Th17 and Treg cells, thereby adding 
another layer of regulation  in the inflammatory response.16, 41-44  
The results described in chapter 6 demonstrate that blocking IL-27 results 
in aggravated atherosclerosis. Therefore is would be interesting to over-express IL-
27 in LDLr-/- mice to study whether this reduces Th17 cells and induces Treg cells, 
resulting in attenuated atherosclerosis. 
 
ROLE OF TREG CELLS IN ATHEROSCLEROSIS  
Treg cells are important in maintaining immune homeostasis and preventing 
autoimmunity.45 Based on the observations that a disturbed balance between Th17 
and Treg cells aggravates atherosclerosis, further research was performed to 
establish the role of Treg cells in atherosclerosis. Mallat et al. hypothesized that 
there is a balance between pathogenic T cells and Treg cells. Furthermore, 
Puijvelde et al. demonstrated that oral administration of an atherosclerosis 
associated antigen, oxLDL, leads to the induction of Treg cells and subsequently 
ameliorates atherosclerosis.21 Along this line we studied another atherosclerotic 
associated antigen, HSP60, to induce tolerance, which is described in chapter 7.  
Tolerance against HSP60 and a small conserved sequence of HSP60(253-
268) was induced by oral administration with a low dose of the antigen. The 
induction of tolerance upon oral administration of either HSP60 or a HSP60 
derived peptide results in a significant reduction of 80.7 -83.3% in lesion size. 
Furthermore, tolerance induction results in an increased Foxp3+ Treg cell 
population, indicating a systemic effect of the tolerance induction. Upon 
stimulation of spleen cells with HSP60, the production of IL-10 and TGF-β 
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increased in HSP60-treated mice. Moreover, we observed a decreased proliferation 
when spleen cells were stimulated with HSP60. These results indicate that 
tolerance against HSP60 evoked an immune suppression mediated by Treg cells.  
Of great interest is the increased expression of CTLA-4, Foxp3 and CD25 
within the atherosclerotic lesion, which indicates that Treg cells migrated from the 
regional lymph nodes towards the local inflamed tissue and exert their 
immunosuppressive effect, explaining the reduced atherosclerotic lesion size in 
HSP60 treated mice.46 
 
FIGURE 10.1 A SCHEMATIC OVERVIEW OF THE DIFFERENT INTERLEUKINS AND RECEPTORS DESCRIBED IN 
THIS THESIS. IL-12, consisting of p35 and p40, is already established as a pro-atherosclerotic interleukin. 
Its close family member IL-23, which consists of p19 and p40, is less defined in atherosclerosis. 
Although an aggravating role is suspected, based on the role of IL-23 in other autoimmune disease, 
more research on atherosclerosis in relation to IL-23 has to be performed. Although IL-27, consisting of 
p28 and EBI3, is already described in 2002, its pleiotropic effects are not completely understood yet. In 
this thesis we observed a protective role for IL-27 in initial atherosclerosis, however more information is 
needed to elucidate its exact role in atherosclerosis. Recently, a novel interleukin is described consisting 
of p35 (shared with IL-12) and EBI-3 (shared with IL-27). This interleukin is called IL-35 and has been 
associated with immune suppression. Interestingly, IL-35 is probably an exclusive product of Treg cells 
whereas IL-27 and IL-12 are predominantly expressed by APCs. Finally, unpublished results of S. 
Pflanz & R.A. Kastelein describe a novel heterodimeric interleukin, consisting of p19 (shared with IL-23) 
and EBI3 (shared with IL-27). Thus far, this heterodimer has been detected in vitro. Whether this 
interleukin exists in vivo and if it has a biological function, has yet to be determined (More details and 
references see text). 
 
Treg cells which originate from the thymus constitutively express Foxp3 
and Tregs may also acquire foxp3 after oral tolerance. Treg cells play an essential 
role in immune homeostasis.21,22,47-50. To study the effect of the elimination of 
Foxp3+ Tregs in atherosclerosis, we used a novel vaccination strategy directed 
against Foxp3 expressing cells. The effect of Foxp3 elimination on the initial 
atherosclerosis and on advanced atherosclerosis is described in chapter 8. A 
dendritic cell (DC) based vaccine was used to provoke a cytotoxic T cell response 
against Foxp3 expressing cells.  
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During the time course of the experiment we observed significant less 
Foxp3+ Treg cells in the circulation of Foxp3 vaccinated mice. Also within the 
lymphoid tissues the Foxp3+ cells are significantly reduced. Furthermore, 
vaccination against Foxp3 results in an increase of atherosclerotic plaque formation 
in both initial and advanced atherosclerosis and the lesions have an increased 
cellularity. This may suggest that an impaired inhibition of pathogenic T cells 
within the plaque upon depletion of Treg cells. However, more research has to be 
performed to investigate which cells are responsible (e.g. Th1, Th2 or Th17 cells) 
for the increased cellularity and plaque size. The results from this study further 
established the role of Foxp3+ Treg cells in atherosclerosis and are in line with the 
results of Ait-Oufella et al. 51  
 
TH17/TREG BALANCE, A NEW INTERVENTION POINT 
In this thesis, we demonstrate in chapter 6 that blocking of IL-27 results in an 
increased population of Th17 cells and in a decreased number of Treg cells. The 
shift in Treg/Th17 balance favoring Th17 cells, results in an increased lesion size. 
This observation indicates that manipulating the balance between these cells may 
provide a potential therapeutic intervention point. This is further supported by the 
observation that vaccination against Foxp3 aggravates atherosclerosis, which is 
described in chapter 8. On the other hand, when Treg cells are induced via oral 
administration of atherosclerotic specific antigens, this results in ameliorated 
atherosclerosis as is described in chapter 7.  
Therefore, therapeutic approaches must be aimed at inducing Treg cell 
specific for atherosclerosis specific antigens. This possibility is discussed in more 
detail in chapter 9, were vaccination is evaluated as a potential therapy against 
atherosclerosis. Furthermore, based on the results in chapter 6, overexpressing IL-
27 or administration of recombinant IL-27 may also prove to be a new approach to 
shift the balance towards Treg cells favoring a beneficial outcome for 
atherosclerosis.  
 
VACCINATION AGAINST INFLAMMATORY MEDIATORS 
Besides interfering in the T cell balance, vaccination against interleukins involved 
in atherosclerosis may also provide an interesting strategy for therapeutic 
intervention. IL-17, described in chapter 4, and IL-15, described in chapter 2, are 
potential candidates that can be blocked via vaccination. In chapter 9 DNA 
vaccination as a therapeutic approach is discussed. Although vaccination against 
self-antigens may provide a potential therapy to redirect the inflammatory 
response, additional studies have to be performed to establish the long-term effect 
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of these vaccination strategies. Independent of the therapeutical implications, DNA 
vaccination strategy provides an excellent research tool to block endogenous 
proteins with relatively low costs. This can be used to study, for example the role 
of interleukins in different stages of atherosclerotic disease.  
 
CONSIDERATIONS 
Most studies on atherosclerosis in mice are performed on the initial phase of 
atherosclerosis and are thus not necessarily relevant to advanced and complicated 
lesions. Most patients with clinical symptoms do however already posses large and 
complicated atherosclerotic lesions. Therefore treatment should also be focused at 
stabilizing existing plaques, reducing progression of plaques or inducing plaque 
regression. Intervention at Treg cell level, by inducing Treg cells, may fulfill this 
promise. Puijvelde et al. demonstrated that mice, which are tolerized against 
oxLDL display attenuated lesion progression.21 The role of Treg cell depletion in 
advanced atherosclerosis was further demonstrated in chapter 8 of this thesis.  
These data suggests that regulation of the Treg cells may be an attractive 
clinically relevant target to further develop an immunotherapy to treat 
atherosclerosis in the near future.  
To add one final remark, recently a new interleukin is discovered, which 
consists of two subunits and both subunits are, direct or indirect, studied in this 
thesis. This novel interleukin is named IL-35 and consist of p35 (subunit of IL-12) 
and EBI3 (subunit of IL-27) and is thereby another member of the IL-12 family 
(Figure 10.1). In contrast to other known IL-12 family members, IL-35 has anti-
inflammatory properties instead of immunostimulatory or proinflammatory 
features.52-54 IL-35 is produced by Treg cells and contributes to the suppressive 
activity of these cells.52-54 Therefore IL-35 may represents a novel potential future 
target for the therapeutic intervention in atherosclerosis.  
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ADERVERKALKING  
Hart- en vaatziekten zijn de voornaamste doodsoorzaak in de Westerse wereld. 
Het overtreft de aan kanker gerelateerde doodsoorzaken. Patiënten met hart- en 
vaatziekten ervaren pas op latere leeftijd de klinische symptomen zoals angina 
pectoris (drukkend/pijnlijk gevoel op de borst) of een infarct (hartaanval, 
beroerte). Deze symptomen zijn gerelateerd aan een vernauwd of geblokkeerd 
bloedvat, waardoor de bloedtoevoer naar distaal gelegen weefsel geblokkeerd of 
gelimiteerd wordt. De vernauwingen zijn het gevolg van een chronische 
ontsteking in het bloedvat wat resulteert in het ontstaan van een laesie. Deze laesie 
bestaat uit ontstekingscellen en cholesterol deposito’s. Dit proces staat bekend als 
aderverkalking, ook wel atherosclerose genoemd.  
Atherosclerose begint al vroeg in het leven doordat er cholesterol wordt 
afgezet in de vaatwand en dit vormt de zogenoemde “fatty streak”. Dit leidt echter 
niet tot klinische symptomen, omdat deze fatty streaks nog niet tot een obstructie 
van de doorbloeding leidt. Gedurende het leven worden deze laesies groter en dit 
kan uiteindelijk leiden tot klinische symptomen. De leeftijd waarop de symptomen 
optreden is in grote mate afhankelijk van de blootstelling aan risicofactoren. 
Bekende risicofactoren zijn overgewicht, een hoog bloed cholesterolgehalte, roken, 
hoge bloeddruk en te weinig lichaamsbeweging. Daarnaast dragen ziektes zoals 
diabetes en reuma ook bij aan een verhoogd risico voor hart- en vaatziekten. Het is 
dan ook niet verwonderlijk dat hart- en vaatziekten voornamelijk in de “Westerse 
wereld” voorkomen.  
Op dit moment is behandeling van atherosclerose voornamelijk gericht op 
het verminderen van risicofactoren. Een veel voorgeschreven behandeling is de 
toediening van statines. Statines zijn in staat om het cholesterol gehalte te doen 
verlagen en in combinatie met aanbevolen lichaamsbeweging resulteert dit in een 
verbeterde klinische uitkomst. Ondanks deze behandeling blijft het sterftecijfer, dat 
gerelateerd is aan hart- en vaatziekten, erg hoog. Daarom is er ook een grote 
noodzaak om nieuwe behandelmethodes te ontwikkelen.  
 
ONTSTEKING EN ADERVERKALKING 
Recentelijk is geconstateerd dat het immuunsysteem (de cellen en organen die 
betrokken zijn bij een ontstekingsreactie) ook een grote bijdrage levert aan 
atherosclerose. Aangezien statines naast een cholesterol verlagende werking ook 
een ontstekingsremmend effect hebben, zou dit dus deels hun gunstige effect op 
atherosclerose verklaren.  
De ontstekingsreactie tijdens atherosclerose begint wanneer de vaatwand 
beschadigd raakt. Beschadiging gebeurt voornamelijk op plaatsen in het bloedvat 
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waar een turbulente bloedstroom is, bijvoorbeeld bij een aftakking van een 
bloedvat. Door deze beschadiging raakt de vaatwand geactiveerd en wordt deze 
meer doorlaatbaar voor cholesterol vervoerende componenten, ook wel 
lipoproteïnes genoemd. De lipoproteïnes worden in de vaatwand gemodificeerd 
waardoor deze immunogeen worden en dus in staat zijn het immuunsysteem te 
activeren. Vervolgens worden macrofagen aangetrokken door de geactiveerde 
vaatwandcellen (endotheelcellen) en de gemodificeerde lipoproteïnes. Macrofagen 
zijn ontstekingscellen die in staat zijn om ongewenste deeltjes zoals de 
gemodificeerde lipoproteïnes op te nemen, waarna deze geactiveerd raken en 
allerlei signaaleiwitten produceren (cytokines). De cytokines op hun beurt 
rekruteren andere immuuncellen en activeren deze cellen, zodat zij hulp kunnen 
bieden om de ongewenste deeltjes te verwijderen. In de vaatwand nemen de 
macrofagen de lipoproteïnes op en hierdoor veranderen de macrofagen langzaam 
in opgezwollen cellen die gevuld zijn met cholesterol, de “schuimcellen”. Deze 
schuimcellen produceren veel ontstekingsstimulerende cytokines.  
Een belangrijk celtype dat gerekruteerd wordt is de T-cel. Na activatie, 
kunnen T-cellen zich ontwikkelen in verschillende subklassen T-cellen. De 
verschillende typen T-cellen kunnen het immuunsysteem verder activeren of juist 
remmen. Een belangrijke functie van macrofagen is het “presenteren” van de 
opgenomen deeltje (antigenen) aan T-cellen. T-cellen die het antigeen herkennen 
worden geactiveerd en maken vervolgens allerlei cytokines om het 
ontstekingsproces in goede banen te leiden. In het geval van atherosclerose zijn er 
te veel ontstekingstimulerende T-cellen, waardoor er een buitenproportionele 
ontstekingsreactie plaatsvindt. Dit leidt tot het aantrekken van een nieuwe golf 
ontstekingscellen. De laesie zal hierdoor groeien en uiteindelijk kunnen 
“scheuren”. Hierdoor komen de verschillende componenten van de laesie in 
contact met het bloed, waardoor er een bloedstolsel ontstaat. Dit stolsel kan 
terplekke het bloedvat afsluiten, maar als het stolsel los raakt, kan het ook worden 
meegevoerd door de bloedstroom en kan het stolsel verder gelegen bloedvaten 
afsluiten. Door de afsluiting van een bloedvat krijgt het onderliggende weefsel te 
weinig voeding en zuurstof, wat leidt tot het afsterven en functieverlies van het 
weefsel/orgaan. Dit leidt tot de klinische symptomen zoals een hartaanval of een 
beroerte.  
In dit proefschrift is onderzocht hoe verschillende ontstekingscellen 
betrokken zijn bij atherosclerose. Verder is er bestudeerd welke cytokines deze 
cellen maken en welke functie deze cytokines hebben in relatie tot atherosclerose. 
In hoofdstuk 1 is gedetailleerd weergegeven wat er tot nu toe bekend is over de 
ontstekingscellen die zijn betrokken bij atherosclerose. Verder is daar ook ingegaan 
op verschillende belangrijke cytokines. Om ontstekingscellen en cytokines in 
atherosclerose te kunnen bestuderen hebben we gebruik gemaakt van proefdieren. 
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In de studies die zijn beschreven in dit proefschrift wordt gebruik gemaakt van 
muizen die genetisch zijn veranderd zodat ze atherosclerose ontwikkelen. Als deze 
muizen worden gevoed met een vetrijk dieet (Western-type dieet), krijgen ze een 
verhoogde concentratie cholesterol in het bloed, waardoor atherosclerose ontstaat.  
 
“NIEUWE” CELLEN EN CYTOKINES IN ATHEROSCLEROSE 
INTERLEUKINE 15 
In hoofdstuk 2 is een belangrijk ontstekingstimulerend cytokine bestudeerd, 
interleukine-15 (IL-15). IL-15 is een cytokine dat voornamelijk gemaakt wordt door 
macrofagen en vooral effect heeft op T-cellen. Aangezien zowel macrofagen als T-
cellen belangrijk zijn in atherosclerose is het interessant om de rol van IL-15 in 
atherosclerose te bepalen. In dit hoofdstuk demonstreren wij dat het aantal cellen 
dat IL-15 tot expressie brengt sterk toeneemt door de muizen te voeden met een 
vetrijk dieet. Dit kan betekenen dat IL-15 is betrokken bij het ontstaan van 
atherosclerose. 
Om de functie van IL-15 te bestuderen gebruikten we een 
vaccinatietechniek die gebruik maakt van een levende, maar wel verzwakte, 
bacterie. In deze bacterie, de Salmonella typhimurium, hebben we DNA ingebracht 
dat codeert voor IL-15. Wanneer we deze bacterie toedienen wordt er een 
immuunrespons opgewekt die uiteindelijk zorgt voor het doden van cellen die IL-
15 hoog tot expressie brengen. We zien in de tegen IL-15 gevaccineerde muizen een 
sterke afname van atherosclerose. Verder zien we ook dat het aantal cellen dat IL-
15 tot expressie brengt wordt verminderd tot hetzelfde niveau voordat 
atherosclerose werd geïnduceerd. We zien echter wel meer macrofagen in de 
laesie, maar die brengen waarschijnlijk minder of geen IL-15 tot expressie en 
daardoor zal de laesie niet toenemen in grootte. 
 
INTERLEUKINE 17 EN DE TH17 CEL 
Zoals hierboven vermeld zijn er verschillende soorten T-cellen, waaronder de T-
helper 1 (Th1) en T-helper 2 (Th2) cellen. De algemene gedachte is dat tijdens 
atherosclerose  voornamelijk de Th1-cel verantwoordelijk is voor het verergeren 
van atherosclerose en de Th2-cel juist voor het verminderen van atherosclerose. 
Een balans tussen deze twee types T-cellen is van cruciaal belang voor een goede 
uitkomst van de ontsteking. In verschillende auto-immuun ziekten is een 
verstoorde balans richting Th1 verantwoordelijk voor de verergering van de ziekte. 
Echter niet alle resultaten kunnen hiermee verklaard worden. Dit leidde tot de 
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ontdekking van nieuwe T-cellen, de T-helper 17 (Th17) cel en de regulatoire T 
(Treg)-cel.  
De Th17-cel is een T-cel die voornamelijk het ontsteking-stimulerende 
cytokine IL-17 produceert en zijn rol is geïdentificeerd in verschillende ziekte 
modellen, maar de rol van deze nieuwe Th17-cel is nog niet beschreven in 
atherosclerose.  
In hoofdstuk 3 bestuderen we dan ook het effect IL-17, het prominent 
geproduceerde cytokine door Th17-cellen, doormiddel van het blokkeren van de 
functie van IL-17. Als eerste hebben we bestudeerd of de productie van IL-17 
omhoog gaat na het voeden van de muizen met een vetrijk dieet. We hebben 
geconstateerd dat in de milt (een belangrijk orgaan betrokken bij het 
immuunsysteem) een verhoogde productie van IL-17 plaatsvindt, wat inhoudt dat 
IL-17 waarschijnlijk een rol speelt bij atherosclerose. Om dit verder te bevestigen 
vaccineren we de muizen tegen IL-17 door middel van een DNA vaccin, coderend 
voor IL-17. Dit resulteerde in een grote vermindering van 90% in atherosclerose in 
de tegen IL-17 gevaccineerde muizen. 
In hoofdstuk 4 bestuderen we het effect van de receptor voor IL-17, door 
gebruik te maken van een beenmergtransplantatie. We hebben een 
beenmergtransplantatie uitgevoerd met het beenmerg van muizen waarvan de 
receptor van IL-17 (IL-17R) is verwijderd. Deze cellen kunnen dus niet meer 
reageren op IL-17. Op deze manier kunnen we de rol van IL-17 in atherosclerose 
bestuderen in het muismodel. We zien in muizen die het IL-17R deficiënte 
beenmerg hebben gekregen een sterke vermindering van atherosclerose. Verder 
zagen we een afname van IL-6 (dat betrokken is bij een verergering van 
atherosclerose) en een toename van IL-10 (een interleukine dat atherosclerose 
vermindert). Een interessante bevinding is de vermindering van antilichamen 
tegen gemodificeerde lipoproteïnes, welke in sommige gevallen atherosclerose 
kunnen verergeren en dus ook een verklaring kunnen vormen voor verminderde 
atherosclerose.  
De resultaten uit hoofdstuk 3 en 4 bevestigen een rol voor IL-17 in de 
ontwikkeling van atherosclerose. Nu we hebben aangetoond dat IL-17 een 
belangrijke rol speelt in atherosclerose is het waarschijnlijk dat de Th17-cel ook een 
rol speelt in het ziekteproces. 
Onlangs is een nieuw cytokine ontdekt, IL-23, die betrokken is bij het 
ontstaan van Th17-cellen. IL-23 is een interleukine dat uit twee subunits bestaat, 
p40 en p19. Het p40 deel is ook een onderdeel van een ander cytokine, het IL-12. 
IL-12 is een sterk ontstekingstimulerend interleukine en in een eerdere studie is 
gebleken dat na vaccinatie tegen p40 atherosclerose sterk verminderd wordt. 
Omdat p40 zowel een deel van IL-23 als IL-12 is, is het achteraf niet mogelijk vast 
te stellen welk interleukine exact voor de remming van in atherosclerose heeft 
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gezorgd. Om dit verder uit te zoeken hebben we de functie van IL-23 in 
atherosclerose bestudeerd door middel van een beenmergtransplantatie met 
beenmerg waarin het p19 deel van IL-23 is uitgeschakeld. De cellen zonder het p19 
gen kunnen geen functioneel IL-23 meer maken en zodoende kan de rol van dit 
interleukine worden bestudeerd in atherosclerose, zoals is beschreven in  
hoofdstuk 5.  
We vinden echter geen effect van p19 deficiëntie op atherosclerose in het 
beenmerg transplantatie model. We zien ook geen verschil in de Th17-cellen. 
Echter recent onderzoek heeft uitgewezen dat IL-23 waarschijnlijk niet betrokken is 
in de initiatie van de Th17, maar meer betrokken is bij de instandhouding van deze 
cellen. Mogelijk kan dit een verklaring bieden voor het feit dat we geen verschil in 
atherosclerose zien. Er dient echter nog meer onderzoek verricht te worden om de 
rol van IL-23 en p19 te begrijpen. 
 
INTERLEUKINE 27 
Een ander recentelijk ontdekt interleukine is IL-27, dat ook uit 2 subunits bestaat, 
een p28 subunit en een EBI3 deel. Dit interleukine werd in beginsel beschreven als 
ontstekingsstimulerend en betrokken bij een verergering van auto-immuunziekten. 
Door de jaren heen is echter meer onderzoek gedaan en is de aan IL-27 
toegeschreven ontstekingsstimulerende rol herzien. Zo is er aan het licht gekomen 
dat IL-27 de potentie heeft om de Th17-cel te remmen en dit zou kunnen resulteren 
in een verminderd ziektebeeld.  
IL-27 is echter nog niet bestudeerd in atherosclerose en gezien de rol van 
IL-17 en waarschijnlijk ook de Th17 cel in atherosclerose, is IL-27 een interessant 
interleukine om te bestuderen in de context van atherosclerose. In hoofdstuk 6 
wordt een studie beschreven waarin muizen gevaccineerd worden tegen p28. Uit 
dit onderzoek blijkt dat de 2 delen van IL-27 (p28 en EBI3) sterk tot expressie 
komen in de atherosclerotische laesie, wat aangeeft dat IL-27 mogelijk betrokken is 
bij atherosclerose. Vervolgens zijn enkele muizen gevaccineerd met DNA, 
coderend voor het interleukine p28, en is atherosclerose geïnduceerd.  
Uit de resultaten van dit onderzoek blijkt dat atherosclerose was verergerd 
in de muizen die gevaccineerd waren tegen p28. Dit betekent dat IL-27 
beschermend werkt in atherosclerose. De verergering van atherosclerose zou 
verklaard kunnen worden door de gevonden toename van Th17-cellen. Daarnaast 
hadden de gevaccineerde muizen ook minder Treg-cellen. Treg-cellen zijn 
betrokken bij vermindering van atherosclerose. Het lijkt er dus op dat de balans 
tussen de Th17-cellen en Treg-cellen is omgeslagen naar Th17-cellen in de 
gevaccineerde muizen tegen p28, met verergerde atherosclerose tot gevolg. 
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REGULATOIRE T-CELLEN  
Treg-cellen verminderen ontsteking en kunnen daardoor beschermend zijn in auto-
immuunziekten, wellicht ook in atherosclerose. Een manier om Treg cellen te 
stimuleren is door een antigeen oraal toe te dienen. Door dit via het 
spijsverteringskanaal toe te dienen, ontstaat er in de darmen een immuunreactie 
die ervoor zorgt dat er tolerantie ontstaat tegen dit antigeen. Bij het ontstaan van 
tolerantie wordt het antigeen herkend en vindt er activering van Treg-cellen plaats. 
Hierdoor wordt vervolgens de immuunrespons afgeremd. Dit is bijvoorbeeld van 
belang bij tolerantie opwekking tegen voedingsmiddelen. Deze methode is al 
eerder uitgeprobeerd tegen gemodificeerde lipoproteïnes, wat resulteerde in meer 
Treg-cellen en minder atherosclerose.  
In hoofdstuk 7 zijn door middel van orale toediening van HSP60 Treg 
cellen geïnduceerd. HSP60 is een antigeen dat is geïdentificeerd in atherosclerose. 
In atherosclerose is er een immuunreactie tegen HSP60 die niet wenselijk is. Door 
Treg-cellen te induceren kunnen we deze immuunreactie remmen om 
atherosclerose te verminderen. We zien in deze studie dat atherosclerose 
inderdaad afneemt en dat dit komt door meer Treg cellen. 
Vervolgens willen wij ook het effect bestuderen van de blokkering van 
Treg cellen om de rol van Treg cellen in atherosclerose verder te bevestigen. Dit is 
beschreven in hoofdstuk 8. In dit hoofdstuk wordt een vaccinatiemethode 
beschreven waarbij dendritische cellen de “opdracht” hebben gekregen om een 
immuunrespons op te wekken tegen een antigeen. Dendritische cellen zijn speciale 
cellen van het immuunsysteem die zeer goed in staat zijn een bepaald antigeen te 
presenteren aan andere immuuncellen om zo een imuunrespons op te wekken. In 
deze studie hebben we de dendritische cellen speciaal gericht tegen cellen die 
Foxp3 tot expressie brengen. Foxp3 is een eiwit dat voornamelijk gemaakt wordt 
door Treg cellen. Door cellen die Foxp3 tot expressie brengen te vernietigen kan de 
bijdrage van Treg cellen in atherosclerose bestudeerd worden. We zien in deze 
studie dat de vaccinatie leidt tot minder Treg cellen in de muis. Dit heeft tot gevolg 
dat door de Foxp3 vaccinatie, de atherosclerotische laesie toeneemt in grootte. 
Hetzelfde is ook waargenomen in muizen met een vergevorderde 
atherosclerotische laesie. Dit geeft aan dat Treg cellen zowel bij beginnende als 
gevorderde atherosclerose betrokken zijn. Verder zien we dat de laesie van 
gevaccineerde muizen veel meer cellen bevat. Mogelijk duidt dit op meer 
ontsteking in de laesie, waardoor deze in grootte toeneemt. Welke cellen dit precies 
zijn moet nog worden uitgezocht in een toekomstig onderzoek. Kortom, in de 
hoofdstukken 7 en 8 hebben we aangetoond dat Treg cellen een belangrijk celtype 
is in de regulatie van atherosclerose en mogelijk kan dit leiden tot een 
therapeutische toepassing. 
                                                                                                                                     Nederlandse samenvatting 
 
207 
CONCLUSIE  
Het onderzoek beschreven in dit proefschrift is er op gericht meer inzicht te 
verkrijgen in de rol van ontstekingscomponenten in atherosclerose. De nieuwe 
bevindingen kunnen leiden tot nieuwe inzichten en idealiter resulteren in een 
klinische toepassing zodat patiënten met atherosclerose in de toekomst beter 
behandeld kunnen worden. In dit proefschrift wordt veel gebruik gemaakt van 
vaccinatietechnieken om de functie van bepaalde cellen en interleukines te 
bestuderen. In hoofdstuk 9 staat beschreven hoe deze inzichten, die zijn verkregen 
door onder andere een bijdrage uit dit proefschrift, kunnen leiden tot 
therapeutisch haalbare toepassingen.  
Vooralsnog is de beste remedie om atherosclerose te verminderen het 
voorkomen van blootstelling aan risico factoren. Helaas is dit niet altijd mogelijk, 
door bijvoorbeeld erfelijke factoren, en zal de zoektocht naar een behandelmethode 
tegen atherosclerose voort blijven gaan. Een veel belovende toepassing kan het 
induceren van tolerantie tegen atherosclerose gerelateerde eiwitten kunnen zijn. 
Deze non-invasieve behandeling die tolerantie opwekt tegen ziekte specifieke 
antigenen kan een uitkomst bieden in veel auto-immuunziekten en dus ook in 
atherosclerose. Echter, er dient nog veel onderzoek te worden verricht naar de 
haalbaarheid en effectiviteit in patiënten. 
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LIST OF ABBREVIATIONS 
-/-   homozygous knock out 
36B4   acidic ribosomal phosphoproteinP0 
β2GPI   β2-glycoprotein I 
Ab   antibody 
ACS   acute coronary syndromes 
APC   antigen presenting cell 
apoE/apoB   apolipoprotein E/apolipoprotein B 
BM   Bone marrow 
BMT   Bone marrow transplantation 
CC/CXC   chemokine 
CCL/CXCL   chemokine ligand 
CD    cluster of differentiation 
CETP    cholesteryl ester transfer protein 
CIA   collagen induced arthritis 
CMV    Cytomegalovirus 
conA    concanavalin A 
CTL   cytotoxic T lymphocyte 
CTLA    cytotoxic T-lymphocyte antigen 
CTX-I   cardiotoxin I 
CVD    cardiovascular disease 
DC    dendritic cell 
EAE    experimental acquired encephalomyelitis 
EBI3   Epstein-Barr virus induced gene 3 
ECM   Extracellular matrix 
ELISA   enzyme-linked immunosorbent assay 
FACS    fluorescent-activated cell sorting 
Foxp3    forkhead box p3 
GC   germinal center 
(e)GFP    (enhanced) green-fluorescent protein 
GTC   guandium isothiocyanate 
HDL    high-density lipoprotein 
HEL   hen egg-white lysozyme 
HPRT   hypoxanthine phosphoribosyl transferase 
HSP    heat shock protein 
imDC   immature dendritic cell 
i.m.   intra muscular 
i.p.    intra peritoneal 
iTreg   inducible regulatory T cell 
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i.v.    intravenous 
ICAM-1   intercellular adhesion molecule-1 
IFN    interferon 
Ig    immunoglobulin 
IL    interleukin 
IL-.R   interleukin . receptor 
imDC    immature dendritic cell 
JAM-1   junctional adhesion molecule-1 
LDL    low-density lipoprotein 
LDLr    low-density lipoprotein receptor 
LFA-1   lymphocyte function associated antigen-1 
LPS    lipopolysaccharide 
MCP-1    monocyte chemotactic protein 
M-CSF    macrophage colony stimulating factor 
MDA-LDL   malondialdehyde modified LDL 
mDC    mature dendritic cell 
MHC   major histocompatibility complex 
MMP    matrix metalloproteinase 
NF-κB    nuclear factor κB 
NK cell   natural killer cell 
NKT cell   natural killer T cell 
oxLDL    oxidized low-density lipoprotein 
PAMP   pathogen-associated molecular pattern 
PBS    phophate buffered saline 
PBMC   peripheral blood mononuclear cell 
PCR   polymerase chain reaction 
PC    phosphatidyl choline 
PE    phosphatidyl ethanolamine 
PECAM  platelet endothelial cell adhesion molecule 
PGE2   prostaglandin E2 
PRR   pattern recognition receptor 
qPCR   quantative polymerase chain reaction(also RT-PCR) 
RA   rheumatoid arthritis 
RAG   recombination activating gene 
SCID   severe combined immunodeficient 
s.i.    Stimulation index 
SMC    smooth muscle cell 
SNP   single nucleotide polymorphism 
SOCS   suppressor of cytokine signaling 
ScR    scavenger receptor 
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STAT   signal transducers and activators of transcription  
TβRII    transforming growth factor β receptor II 
TCR    T cell receptor 
TGF    transforming growth factor 
Th1/Th2/Th3/Th17  T helper 1/T helper 2/T helper 3/T helper 17  
TLR    Toll-like receptor 
TNF    tumor necrosis factor 
Tr1    regulatory T cell type 1 
Treg    regulatory T cell 
VCAM-1   vascular cell adhesion molecule-1 
VEGF (R)  vascular endothelial growth factor (receptor) 
VLA-4   very late antigen-4 
VLDL    very low-density lipoprotein 
vSMC   vascular smooth cell 
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